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ABBREVIATIONS    
 
ADC: apparent diffusion coefficient (MRI)  
ADL:  activities of daily living 
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ATP: adenosine triphosphate 
CBF: cerebral blood flow 
CBS: cystathionine beta-synthase 
CBV: cerebral blood volume  
CSE: cystathionine gamma-lyase 
cm: centimeter 
CNS: central nervous system  
CO: carbon monoxide 
CO2: carbon dioxide 
CVA: cerebrovascular accident 
ºC : degree centigrade 
d: day/ days 
DAPI: 4', 6-Diamidino-2-Phenylindole 
DSC MRI: Dynamic susceptibility contrast – Magnetic Resonance Imaging 
DNA: Deoxyribonucleic acid 
DWI: Diffusion-weighted imaging (MRI)  
EU: European Union 
EPI: echo planar imaging 
Fe-Cu: Iron-Cupper redox center (in cytochrome oxidase) 
FMUL: Faculdade de Medicina da Universidade de Lisboa 
G : giga 
Gd: gadolinium 
GFAP: glial fibrillary acid protein 
h: hour 
1
H: chemical compound with one hydrogen atom 
HSP-27: heat shock protein 27 
H2S: hydrogen sulfide 
HO1: heme oxygenase-1 
16 |  
 
H&E: hematoxylin and eosin stain 
.JPG/JPEG: Joint Photographic Experts Group 
K (ATP) channel: ATP-sensitive potassium channel  
LTP: long term potentiation  
MCA: middle cerebral artery 
MCAO: middle cerebral artery occlusion 
 
microM:  micro molar (µM) 
min: minutes 
ml: milliliter 
MMP: matrix metalloproteinase 
MRI:  magnetic resonance imaging  
MTT: mean transient time 
mv: millivolt 
n: number 
NADPH: nicotinamide adenine dinucleotide phosphate 
NeuN: neuronal nuclei 
NIH: National Institutes of Health  
NINDS: National Institute of Neurological Diseases and Stroke 
NMDA: N-methyl D-aspartate 
NO: nitric oxide 
NOS: nitric oxide synthetase 
NOX-4: NADPH oxidase 4 
O2: Oxygen 
PET: positron emission tomography 
pMCAO: permanent middle cerebral artery occlusion 
ppm: parts per million 
rADC: relative apparent diffusion coefficient 
RARE: rapid acquisition with relaxation enhancement sequence  
rCBF: relative CBF 
ROI: region of interest 
ROS: reactive oxygen species 




SD: standard deviation 
SEM: standard error of the mean 
SOD-2: superoxide dismutase 2 
SPECT: single photon emission computed tomography  
rtPA: recombinant tissue plasminogen activator 
T2 : T2-weighted image sequence (MRI) 
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling 
US: United States 
UAM: Universidad Autónoma de Madrid 
6-0: size of suture material  
∆ CBF: differential CBF between ipsilateral and contralateral side 
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In the present study, we explored the effect of short-term exposure to hydrogen 
sulfide (H2S) after acute ischemia in an animal model of pMCAO. We hypothesized that 
H2S exposure after acute ischemic stroke modulates ischemic lesion either by an early 
protective effect or by promoting post-ischemic repair. To address our hypothesis we 
exposed rats to H2S after pMCAO and measured functional outcome and infarct size in 
vivo and post-mortem. We identified underlying markers of cytoprotection and repair. 
Finally, we compared brain imaging with immunohistochemical data to look for early 
imaging features of ischemic tissue damage that may relate to functional outcome.  
H2S exposure after pMCAO improved functional outcome and decreased infarct size 
and the expression of cell death. H2S may act very early in the ischemic process, since 
there were lower levels of acute injury-related markers at 24h without enhancement 
of repair-associated markers for vasculogenesis, angiogenesis or synaptogenesis at day 
14. Significant benefit is likely to occur before major tissue damage develop and 
includes modulation of NOX-4, a major enzyme generator of reactive oxygen species 
(ROS) and endothelial dysfunction, as well as by vasomodulation of intralesional 
microcirculation, since intralesional CBF assessed by PWI MRI improved in rats exposed 
to H2S. Given that H2S limits brain damage after experimental ischemic stroke, 
























1. INTRODUÇÃO E CONTEXTO 
Nas últimas décadas obtiveram-se resultados promissores com várias substâncias 
neuroprotectoras, em estudos pré-clínicos em modelos de isquémia cerebral. No 
entanto nenhuma comprovou eficácia e segurança em contexto de ensaio clínico em 
doentes com acidente vascular cerebral (AVC) isquémico agudo. Entre os factores que 
contribuíram para as dificuldades na extrapolação dos resultados, realça-se a ausência 
de homogeneidade nos instrumentos de medida funcional e no modo de aquisição dos 
exames de imagem, nomeadamente quanto à definição de penumbra. Existe evidência 
de que, na ausência de reperfusão, a área de penumbra isquémica se transforma de 
modo célere em área de necrose, aumentando assim o volume da lesão e agravando o 
prognóstico funcional. 
A hibernação e a hipotermia grave são duas situações metabólicas extremas onde, 
apesar da ausência ou de diminuto fluxo sanguíneo cerebral (CBF), é possível não 
ocorrer isquémia cerebral nem defeito neurológico permanente. O conhecimento dos 
processos através dos quais estes estados de hipometabolismo protegem no contexto 
de oligemia e isquémia, pode contribuir para a compreensão da complexa 
fisiopatologia da isquémia aguda cerebral. A possibilidade de induzir um estado de 
hipometabolismo onde as necessidades energéticas estejam mais adequadas à oferta 
energética, após isquémia aguda, diminuindo o consumo de oxigénio, pode contribuir 
para alargar a janela de oportunidade terapêutica para trombólise.  
Foi possível induzir um estado semelhante à hibernação em mamíferos que não 
hibernam, pela inalação de uma mistura do gaz sulfeto de hidrogénio (H2S) com 
atmosfera. Durante o período de inalação, observou-se significativa diminuição das 
suas taxas metabólicas (nomeadamente do consumo de O2 e da eliminação de CO2) e 
da sua temperatura corporal. Após 6 h, e ao serem de novo colocados a respirar 
atmosfera voltavam, de modo espontâneo, às suas taxas metabólicas e temperatura 
basais, sem interferência no seu estado de saúde a curto ou longo prazo.  
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Os efeitos biológicos do H2S parecem depender, em particular, da sua capacidade de 
inibição da fosforilação oxidativa mitocondrial, competindo com o O2 na ligação à 
enzima citocromo C oxidase, a nível da cadeia de transporte de eletrões mitocondrial. 
No entanto, os efeitos biológicos do H2S dependem entre outros fatores da dose de 
exposição e da sua duração. Em concentrações da ordem dos microMolar, o H2S 
parece ter um efeito neuroprotector no stress oxidativo, e modelador da morte 
celular, interferindo nas vias das capases e kinases. No contexto da isquémia aguda 
cerebral, o papel do H2S parece relacionar-se ainda com o seu papel de sensor de 
oxigénio, de regulador da comunicação glial e neuronal e do controlo do tónus 
vascular local, e não apenas da sua capacidade em induzir hipotermia. Neste contexto, 
a hipotermia pode ser consequência e não causa do hipometabolismo induzido. As 
propriedades de sensor de O2 permitem a monitorização do O2 do meio, contribuindo 
assim para uma libertação adequada de O2 aos tecidos, tanto em contexto de isquémia 
como em basal.  
Os dados existentes sobre o uso de H2S em contexto de isquémia cerebral eram 
escassos e discordantes, quando desenhamos este projeto. O primeiro trabalho de 
exposição ao H2S após isquémia cerebral focal permanente não demonstrou benefício 
funcional. Os trabalhos seguintes, que incluíram animais mais idosos, modelos de 
reperfusão e tempos de exposição prolongados, demonstraram benefício funcional e 
uma diminuição do volume da lesão final após isquémia do território da artéria 
cerebral média (ACM). Estes resultados estão de acordo com a literatura existente 
relativamente a isquémia noutros órgãos como o rim ou coração onde a exposição ao 
H2S ou a dadores de H2S também melhora a função e diminui o volume final da lesão 
isquémica. Deste modo, o potencial benefício da exposição a H2S ou dadores de H2S no 





Neste estudo avaliámos a hipótese de que após isquémia aguda cerebral, o H2S actue 
como protector cerebral por modular o stress oxidativo pós isquémico e a expressão 
de espécies reactivas de oxigénio, ou por promover a reparação tecidular ulterior.  
Para analisar esta hipótese estudámos os efeitos da exposição ao H2S num modelo 
animal de oclusão permanente da artéria cerebral média (pMCAO) em ratazana 
Sprague-Dawley, medindo o resultado funcional, o tamanho do enfarte in vivo e post-
mortem, analisando ainda marcadores de protecção celular, morte celular e reparação 




Comparámos 3 grupos de ratos macho adulto Sprague-Dawley,randomizados: Sham 
(n= 14), pMCAO (n=22) e pMCAO seguido de exposição durante 24 min a atmosfera 
com 40ppm de H2S em caixa acrílica fechada, 3h após a indução da isquémia (n= 23). A 
amostra foi sacrificada às 24h e ao 14º dia. Usamos codificação para manter a alocação 
ao grupo sempre cega ao observador, excepto durante o procedimento cirúgico. 
Medimos o tamanho do enfarte com a sequência T2 de ressonância magnética nuclear 
(MRI) e com hematoxilina/eosina (H&E). Avaliamos a funcionalidade antes dos 
procedimentos, às 24h e aos 14 dias com a escala de Rogers modificada e o teste de 
Rotarod. Avaliámos a morte celular usando a técnica TUNEL. Para o estudo de 
protecção e reparação celular, utilizámos marcadores da oxidase do NADPH 4 (NOX-4), 
de proteína acídica fibrilhar glial (GFAP), de fator de crescimento endotelial vascular 
(VEGF), de sinaptofisina, de superóxido dismutase 2 (SOD2) e de proteína de choque 
térmico 27 (HSP-27). Usamos beta-actina como controlo de carga (1:400, Sigma-
Aldrich™). Para a técnica de Western-Blot fizeram-se 3 réplicas experimentais de cada 
experiência (n= 4 animais por grupo). Uma vez que os dados não seguiam uma 
distribuição normal, o teste de Mann-Whitney foi usado para comparar 2 amostras e o 
teste de Kruskal-Wallis para comparar mais de 2 amostras do mesmo grupo ou mais de 
2 grupos.   
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4. RESULTADOS 
A temperatura corporal foi significativamente mais baixa após indução da anestesia 
em todos os grupos. Após exposição ao H2S durante 24 minutos, a temperatura 
corporal diminuiu 1,85ºC (média), começando a normalizar logo que os animais 
reiniciavam a respiração com atmosfera normal. Duas horas após a exposição, 
nenhuma alteração na temperatura corporal basal era mensurável.  
Observámos um melhor resultado funcional às 24h após pMCAO nos animais expostos 
ao H2S quando comparado com o grupo controlo tanto com a escala modificada de 
Rogers como com o teste de Rotarod. Esse benefício manteve-se até ao 14º dia, data 
de sacrifício desse grupo. Relativamente às dimensões do enfarte, aos 14 dias tanto na 
sequência T2 de MRI como em post-mortem com H&E, os animais expostos ao H2S 
apresentavam enfartes de menores dimensões comparativamente aos do grupo 
controlo. Às 24h após pMCAO não encontrámos diferenças significativas nas 
dimensões dos enfartes medidos com a sequência T2 MRI entre os animais tratados 
(expostos ao H2S) e os controlos. O grupo tratado apresentava, no entanto, nas 
sequências de difusão (DWI) nos mapas de Coeficiente de difusão aparente (ADC) um 
padrão de heterogeneidade intralesional. Esta heterogeneidade dentro da área 
isquémica inclui áreas centrais e periféricas da lesão, existindo áreas centrais com 
coeficientes de difusão superiores a áreas periféricas da lesão. Quando avaliamos a 
perfusão cerebral na área de isquémia com MRI de perfusão, verificamos que a 
diferença entre o fluxo sanguíneo cerebral no lado contralateral e o isquémico era 
menor nos animais expostos ao H2S, que tinham assim melhor perfusão relativa na 
área de isquémia.  
Relativamente à expressão de morte celular, os animais tratados apresentaram 
significativamente menor expressão de células TUNEL positivo, tanto às 24h como aos 
14d. Ao 14º dia, não se verificou diferença nos níveis de expressão dos marcadores 
VEGF ou sinaptofisina entre tratados e controlos. Os níveis de expressão de GFAP 
estavam diminuídos aos 14d em animais tratados. Os níveis de SOD-2 aos 14 dias 
estavam diminuídos relativamente ao grupo controlo, mas não às 24h. Os níveis de 
expressão de NOX-4 eram significativamente menores em animais expostos ao H2S, 
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tanto às 24h como no 14ºdia. A expressão do marcador HSP-27 foi significativamente 
menor em animais tratados às 24h mas não ao 14ºdia. 
 
5. DISCUSSÃO 
Os nossos resultados demonstram que a exposição a H2S após isquémia cerebral aguda 
em modelo animal de pMCAO melhora o resultado funcional e diminui a dimensão do 
enfarte cerebral aos 14 dias. A melhoria no resultado funcional foi observada nos dois 
instrumentos de medida e manteve-se até ao dia de sacrifício.  
A sequência T2 de MRI às 24h não demonstrou diferença significativa no tamanho do 
enfarte, para o que pode contribuir a presença de edema cerebral com consequente 
aumento de volume. No entanto aos 14 dias e na avaliação post-mortem usando a 
coloração H&E às 24h, os animais tratados apresentavam lesões de menor dimensão. 
Curiosamente, os animais expostos ao H2S apresentavam ainda nos mapas de ADC 
áreas de heterogeneidade intralesional que correspondiam a coeficientes de ADC mais 
elevados e mais diversos, tanto em áreas centrais como periféricas da lesão isquémica. 
Este facto pode contribuir para explicar a discrepância entre a dimensão da lesão in 
vivo e a melhoria funcional às 24h. No entanto, o tamanho da lesão parece ser 
insuficiente como medida isolada de evidência de efeito protector. 
Estudos de genómica demonstraram evidência da expressão de genes associados ao 
desenvolvimento do SNC e a factores tróficos na área central da lesão isquémica. Às 
24h, os mapas de ADC do grupo tratado mostraram coeficientes de ADC heterogéneos 
dentro da lesão isquémica que corresponderão a áreas de diferente difusão de água e 
portanto de integridade tissular diversa, dentro da área de isquémia. Estas 
heterogeneidades podem representar o que foi previamente descrito como "mini 
cores" e "mini penumbras".  
Quando comparamos com estudos de perfusão o CBF em ambos os hemisférios nos 
grupos expostos a H2S e em controlos, verificamos menor diferença nos animais 
expostos ao H2S. Para esta melhor perfusão da lesão isquémica em animais expostos 
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ao H2S após pMCAO, podem contribuir mecanismos de microvasoregulação, uma 
característica da acção biológica do H2S. No presente estudo, a presença de 
heterogeneidades dentro da lesão isquémica corresponde a um melhor prognóstico 
funcional, a uma menor dimensão do enfarte e a uma melhor preservação do tecido 
cerebral em risco de isquémia definitiva. 
A hipotermia, quando não induzida por factores externos, pode ser consequência de 
hipometabolismo e não a causa das alterações metabólicas. A modelação pelo H2S, no 
contexto de isquémia aguda cerebral, tem sido associada à indução de hipotermia 
especialmente em protocolos que incluem tempos de exposição prolongados ao H2S. 
No presente estudo, após exposição durante apenas 24 min, observamos uma 
diminuição de 1.85ºC que os animais recuperam em menos de 2 horas. Assim, a 
hipotermia parece ser um efeito fugaz do hipometabolismo induzido pelo H2S, e outros 
mecanismos parecem estar envolvidos, pois o seu efeito protector se mantem pelo 
menos até ao 14ºdia. Será ainda de realçar que, contrariamente aos protocolos prévios 
com tempos de exposição muito prolongados, a exposição durante 24 min foi 
igualmente eficaz. A pequena diminuição de temperatura observada com a exposição 
breve ao H2S permitirá, em contexto translacional, antever a ausência de necessidade 
de internamento em unidades de cuidados intensivos, que os riscos da hipotermia 
moderada a grave não permitem dispensar. As limitações do presente estudo incluem 
o uso de apenas uma dose de H2S, pois doses diferentes poderão ter efeitos distintos 
no resultado final. Devido a limitações orçamentais e à característica exploratória da 
investigação, não incluímos animais idosos, fêmeas ou animais com co-morbilidades 
associadas a doença cerebrovascular. Também, apenas avaliámos o resultado clínico 
funcional com testes de funções motoras. No entanto, em todos os casos a MRI 
permitiu excluir os animais em que por falha cirúrgica, o território da MCA não se 
encontrava enfartado. Os efeitos a longo prazo da exposição ao H2S, após oclusão 
permanente da MCA não foram investigados, pois o estudo incluía comparação de 






No presente estudo, a exposição precoce ao H2S após pMCAO melhora o prognóstico 
funcional e diminui a dimensão da lesão isquémica final. A perfusão cerebral foi 
superior nas lesões isquémicas dos animais expostos ao H2S e os estudos de difusão 
revelaram um padrão de heterogeneidade nos coeficientes de ADC de áreas centrais e 
periféricas da lesão. A heterogeneidade intralesional, observada como um padrão 
mosqueado nos mapas de ADC em animais expostos ao H2S, corresponde a animais 
com melhores resultados funcionais e menor dimensão final da lesão isquémica e com 
melhor preservação tecidular nos animais tratados. Assim, este padrão poderá revelar-
se de interesse do ponto de vista translacional, visto que as decisões de reperfusão 
dependem também da imagem cerebral, onde o padrão de heterogeneidade nos 
mapas de ADC parece distinguir e prever um melhor prognóstico funcional tanto em 
ratos tratados como em ratos não tratados. 
O H2S poderá actuar muito precocemente no processo isquémico pois encontramos 
uma expressão diminuída de marcadores de lesão aguda às 24h, sem aumento da 
expressão de marcadores de reparação de vasculogénese, angiogénese ou 
sinaptogénese ao 14º dia. O benefício mais marcante parece ocorrer antes que o 
tecido se deteriore, e inclui a modelação de NOX-4, uma enzima geradora de espécies 
























INTRODUCTION   
1. CEREBROVASCULAR DISEASE  
Stroke is a rapidly developing focal brain dysfunction of vascular origin lasting more 
than 24h, including ischemic stroke, intracerebral hemorrhage, subarachnoid 
hemorrhage and cerebral venous thrombosis  (WHO MONICA Project Principal 
Investigators, 1988). 
Ischemic stroke occurs after a sudden interruption of a brain artery by thrombosis or 
embolism and is the most common type of stroke, representing more than three 
quarters of all strokes (Feigin et al., 2003). Once considered a disease of the artery 
itself, current data support a broader view, including a model where all brain cells and 
structures participate in the mechanisms of both tissue damage and repair. Structures 
involved include glia, neurons, matrix components, and vascular cells that act together 
in specialized frameworks like the neurovascular unit.   
In the last decades, stroke research was centered on the neuron itself, trying to 
achieve "neuroprotection” or avoid neuronal death. Lately, attention focused on death 
or recovery of all cells or groups of cells involved , as well as their matrix structure, and 
ischemic stroke is no more just considered a matter of neuronal death (Caplan et al., 
2011; Moskowitz et al., 2010). 
 
1.1. STROKE BURDEN 
Stroke is a devastating disease and the second leading cause of death worldwide 
(Moskowitz et al., 2010). The burden of stroke estimated from stroke incidence and 
prevalence studies in Europe showed regional differences, although variations in 
methodology should also be taken into account when interpreting the numbers. A 
recent review including 44 incidence and 12 prevalence studies emphasized that in 
Western Europe incidence will rise from 1.1 million per year in 2000 to as much as 1.5 
million per year in 2025, merely because of expected changes in demographic factors 
and ageing of populations (Truelsen et al., 2006). In Europe, projections consider an 
increase in the ratio of people aged over 65, at highest risk for acute stroke, from 20% 
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in 2000 of the total population to 35% in 2015. In Portugal, epidemiological data 
showed an estimated incidence of 187/100 000 inhabitants, being the first cause of 
dependency and death after the age of 65 (Correia et al., 2013, 2004).   
However, stroke mortality in Europe shows significant differences between Western 
and Eastern European countries. While Western European countries have lower and 
declining stroke mortality rates, in Eastern Europe, mortality rates are not only higher 
but also increasing if compared using age-standardized mortality rates from death 
certificates (Sarti et al., 2000). 
 
1.2. BOTTLE-NECKS IN ISCHEMIC STROKE RESEARCH 
In the clinical setting, we witnessed relevant changes in the attention paid to the 
disease. Diagnosis and treatment sustained a remarkable advance, including new and 
better imaging methods and a redesigned organization of stroke care. The advent of 
acute stroke units and publication of guidelines for stroke management and for the 
prevention of major complications, alongside with the generalization of pharmacologic 
reperfusion with recombinant tissue plasminogen activator (rtPA) improved patient 
care and outcome after an acute event. Nevertheless, there are still several 
bottlenecks not yet resolved in both primary and secondary prevention, as well as in 
acute stroke care. Obstacles include the lack of a biological marker of ischemia in the 
acute clinical setting that would allow confirming ischemia, even when clinical signs 
had already faded. Additionally, there is no approved alternative for reperfusion 
therapy in the majority of patients with ischemic stroke that are not eligible for rtPA 
treatment.  
In the large group of patients that do not qualify for reperfusion after acute ischemic 
stroke, many present with an unknown interval since onset of symptoms. However, 
this interval is crucial for the decision to start reperfusion therapy since it has been 
shown that there is a threshold after which reperfusion is futile and even potentially 
harmful (Ferro, 1997; Hacke et al., 2008; Hussein et al., 2010; Lees et al., 2010). 
Consequently, reperfusion should not be used if cell death in ischemic areas has 
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already occurred due to higher risk of hemorrhagic transformation. Yet, a therapeutic 
window might still exist in patients whose brain tissue in the infarct area is still 
potentially salvable in MRI image signaling (Cheng et al., 2013). Since time is a major 
variable of tissue integrity and potential reversibility of ischemic lesions, image 
markers for ischemia time that correlate with histological status are considered a 
highly desirable target for investigation. 
Unfortunately, in the field of pharmacological neuroprotection,  no drug investigated 
to date showed both clinical benefit and an adequate safety profile despite several 
new therapeutic approaches that were tested in stroke models and clinical trials during 
decades of both basic and clinical research (Dirnagl, 2006). Therefore, new 
pharmacological targets have still to be established in order to improve treatment of 
acute ischemic stroke and ultimately diminish individual and global burden of stroke. 
 
2. PATHOPHISIOLOGY OF ISCHEMIC STROKE AND CELL DEATH  
2.1. RISK FACTORS AND REGULATION OF CEREBRAL BLOOD FLOW 
Major cerebrovascular risk factors cannot be modified like age, male sex, Afro-
American or Hispanic origin (in the US population), or family history of cerebrovascular 
disease. Other risk factors like hypertension, diabetes, smoking habits, dyslipidemia, or 
cardiac embolism due to atrial fibrillation can be controlled by lifestyle modifications 
or medical interventions, reducing significantly the chance of ischemic stroke.  
Risk factors for stroke act by damaging physiological adaptive mechanisms that 
guarantee an adequate brain perfusion under different circumstances. They promote a 
change of both structure and function of the arterial wall, including the interface with 
the circulating blood, through pathophysiological mechanisms like atherosclerosis with 
subsequent narrowing and stiffness of the arteries, arterioles, and capillaries. This 
process is associated with loss of regulation of local cerebral blood flow (CBF). At the 
microvascular level, adaptative mechanisms of the endothelium are no longer perfect,  
leading to an inadequate oxygen and energy supply with loss of adaptive increase in 
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blood flow usually evoked by neuronal activity (Arrick et al., 2007; Iadecola and 
Davisson, 2008). Additionally,  the impairment of cerebrovascular autoregulation that 
keeps CBF stable during variations in systemic blood pressure, compromises the 
development of collateral circulation and increases the probability of ischemia 
(Moskowitz et al., 2010).  
The presence of risk factors also promotes changes in cerebral arteries by mechanisms 
that include production of reactive oxygen species (ROS). Major vascular sources of 
ROS are superoxide-producing enzyme nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, mitochondrial enzymes, uncoupling of nitric oxide synthetase (NOS), 
and xanthine oxidase. Under physiological circumstances, ROS participate in regulation 
of cellular metabolism. However, when ROS increase to toxic levels mainly by excessive 
production or insufficient neutralization by antioxidant enzymes, cell injury occurs 
through mechanisms that include lipid peroxidation, protein oxidation and DNA 
damage (Olmez and Ozyurt, 2012). Endothelial dysfunction involves increased levels of 
ROS and decreased levels of nitric oxide (NO). Major vascular damage due to oxidative 
stress is related to the inactivation of NO by free superoxide radicals, reducing the 
availability of NO and consequently its protective role (Pacher et al., 2007). Thus, the 
regulation of microvascular flow is affected by the loss of the regulatory effect of 
endothelial NO, leading to vasoconstriction and inadequate NO-related vascular 
responses (Schulz et al., 2008). 
 
2.2 THE ISCHEMIC CASCADE    
When a cerebral artery is obstructed and no adequate blood supply is provided despite 
response from collateral circulation and microcirculation, brain cells start a process 
that will end up in cell death either by apoptosis or necrosis (Kulik et al., 2008; Shuaib 
et al., 2011). The ischemic cascade begins with an inadequate production of energy 
resources, mainly adenosine triphosphate (ATP). The resulting anaerobic metabolism 
that develops in the ischemic lesion unbalances the normal acid-base homeostasis. 
ATP-dependent ion pump transport fails and causes depolarization of cell membranes, 
thus leading to imbalanced ion flux including enlarged calcium influx and potassium 
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efflux. High intracellular calcium levels trigger the release of excitatory amino acids 
(mainly glutamate) that stimulate calcium-permeable-N-methyl D-aspartate (NMDA) 
and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, leading 
to even more calcium influx. Subsequently, cells become overexcited by excessive 
calcium levels triggering an activation of proteases, lipases, and reactive oxygen 
species (ROS). This pathophysiological process, also referred to as excitotoxicity, 
represents a series of events that ultimately leads to cell death during the ischemic 
cascade. 
 
Ischemic cascade: 1. Lack of energy production 
Failure of ATP 
production 
Anaerobic metabolism 
& unbalanced acid-basis 
homeostasis 
Failure of ATP 
transport  pump
Ischemic cascade: 2. Depolarization, overexcitation and cell death
Intense membrane 





& activation of lipases, 
proteases & ROS 
Excitatory aminoacids & more Ca++ in





Figure 1. Ischemic cascade   
 
When the cell membrane integrity is lost, mainly due to the intervention of 
phospholipases, the control of ion influx or efflux becomes impossible. As a result, 
mitochondrial integrity can no longer be maintained and apoptotic factors and toxins 
are liberated promoting cell death through mechanisms that include apoptosis and 
necrosis. As cells die through necrotic processes, they further liberate glutamate and 
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other cytotoxic products that provoke severe damage in the cells of the peri-infarct 
zone. Finally, vascular integrity is lost leading to the disruption of the protective blood-
brain barrier. In consequence, brain edema is intensified and triggers further 
secondary brain injury.   
Cell death is a particular aspect of cerebral ischemia, not only referring to neuronal 
death but also to other cell types and components of the blood-brain barrier. The 
twilight zone between cell death and recovery to normal homeostasis through 
reperfusion is the focus of current research in acute stroke.  
 
3. ACUTE TREATMENT: NEUROPROTECTORS AND THE NEED FOR THERAPEUTIC 
WINDOW ENLARGEMENT  
In the recent past, the development of new and better brain imaging techniques and 
the progress in the knowledge of stroke pathophysiology due to biomolecular research 
contributed to an increased interest in cerebrovascular diseases. Since the 1990’s, 
treatment options for acute ischemic stroke include arterial reperfusion using 
thrombolytic agents. However, functional benefit from reperfusion could only be 
shown if used during a short time window after stroke (Bluhmki et al., 2009). Initial 
clinical studies demonstrated that vessel recanalization was effective in selected 
patients if intravenous thrombolysis with recombinant tissue plasminogen activator 
was used within 3h after onset of acute symptoms (Hacke et al., 1995; “Tissue 
plasminogen activator for acute ischemic stroke. The National Institute of Neurological 
Disorders and Stroke rt-PA Stroke Study Group.,” 1995). As the reduced time window 
excluded the majority of stroke patients, new trials were carried out to investigate the 
safety and effectiveness of an enlarged time window that would permit to extend the 
established time frame for reperfusion treatment up to 4.5h after symptom onset in 
clinical protocols in Europe (Bluhmki et al., 2009). Yet, the small time window 
contributes to the fact that less than 15% of the patients with acute ischemic stroke 
are eligible for thrombolysis. In consequence, research on factors that would permit an 
enlargement of the time window is highly desirable and may focus on modulation of 
the ischemic cascade to delay apoptotic processes and cell death. In this context, 
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neuroprotectors can be useful in pre-hospital acute stroke medication, wake-up 
stroke, and patients excluded from thrombolysis including delayed arrival. Moreover, 
neuroprotective treatment may be beneficial in a synergic approach in addition to 
thrombolysis and may enlarge the therapeutic window.  
 
3.1. TIME IS BRAIN 
The concept of "time is brain", emerging from the need to start thrombolysis as early 
as possible after ischemic stroke, has contributed to the development of updated 
organizational models in acute stroke care, regarding the structure and procedures of 
emergency medical services. The need to understand the reasons for delay that 
ultimately excludes patients from access to thrombolysis has led research on pre-
hospital and in-hospital therapeutic delay (Gomez et al., 1994). Despite different 
methodologies, overall results showed that in-hospital times from hospital door to 
acute image interpretation and clinical evaluation by a neurologist were too long. 
However, pre-hospital delay accounted for the largest contribution if considering the 
total interval from symptom onset to thrombolysis (Díez-Tejedor and Fuentes, 2012; 
Evenson et al., 2001; Hill et al., 2000).  
Furthermore, studies that attempted to obtain a quantitative estimate of the pace of 
neural circuitry loss during ischemic stroke highlighted the urgency of acute stroke 
care. In untreated patients, the approximate rate of neuron loss reached up to 1.9 
million neurons per minute, alongside with destruction of synapses and myelinated 
fibers (Saver, 2006). More recently, evaluation of the benefit of early thrombolytic 
treatment in the United States showed that intervention was associated with reduced 
mortality and better functional outcome at discharge. These findings support efforts to 
improve emergency management of stroke patients, but also highlight the need for a 
better pharmacological management of pre-hospital acute stroke care. In the context 
of brain ischemia, it would be desirable to find the equivalent of nitrates for acute 
coronary disease that delay irreversible ischemia and save many cardiac patients 
before reaching the hospital. 
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In the light of above-mentioned evidence, strategies that include public campaigns on 
the recognition of common stroke symptoms and reinforcement of the importance of 
early admission after symptom onset were widely employed in order to promote early 
arrival after symptom onset at hospital emergency rooms. Yet, the best strategy to 
maintain population awareness after media campaigns has still to be established. 
Isolated interventions resorting on popular mass media like TV are unlikely to 
guarantee extended effects on population behavior and lack a positive cost-benefit 
analysis (Goldstein, 2003; Silver et al., 2003; Tadros et al., 2009). However, the attitude 
towards the problem has shifted and health care workers and the public in general 
nowadays look at acute stroke as a clinical emergency, requiring specific care as 
promptly as possible. 
Advances in the treatment of acute ischemic stroke and the advent of thrombolysis led 
to the development and implementation of dedicated wards and specific care for this 
group of patients. In so-called "stroke units", teams with special training in 
cerebrovascular disease began to attend acute stroke patients. This new type of 
organization of acute stroke care in specialized units proved to provide benefit in the 
short and long-term follow-up. Mortality decreased and patient functional 
independency improved, with a higher chance of returning to live at home, one year 
after the acute event (“Organised inpatient (stroke unit) care for stroke.,” 2013). The 
improvement in functional outcome could still be observed at 5 and 10 years of follow-
up, when compared to patients treated in non-dedicated wards (Alberts et al., 2005; 
Drummond et al., 2005; Indredavik et al., 1999; Langhorne and Dennis, 2004). 
 
3.2. NEUROPROTECTION VS. BRAIN PROTECTION 
Since the majority of patients do not meet criteria for thrombolysis, neuroprotective 
strategies are needed to prevent definitive ischemia and cell death after stroke. 
However, and despite a huge amount of research, none of the more than 1000 
neuroprotective drugs proposed in the setting of acute stroke that were promising in 
pre-clinical research proved to have clinical benefit (Ferro and Dávalos, 2006; 
Radermacher et al., 2012). Reasons for translation failure of experimental data into 
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clinical context include pleomorphic ischemic pathophysiology, double-sword effect of 
drugs and confounding immunobiochemical markers in different times after ischemia. 
Furthermore, publication bias leads under-reported negative results and inadequate 
replication of primary results. Other quality issues in basic research include outdated 
estimations of sample size, lack of randomization, failure in validation of scales, lack of 
control for relevant physiological parameters, and missing representation of female 
and older animals as well as models that include animals with common associated risk 
factors for stroke. Thus, most experimental models fail to express the multifaceted 
features of stroke patients and suffer from methodological issues. Additionally, as 
stroke does not comprise just a single mechanism, focusing on a unique 
pharmacological target is probably inadequate (Dirnagl, 2006). Furthermore, acute 
stroke involves all brain cells and structures. Consequently, strategies must not only 
target the protection of neuronal cells ("neuroprotection") but also other cells and 
structures (Endres and Dirnagl, 2002; Fukuda and del Zoppo, 2003; Gutiérrez et al., 
2013; Liang et al., 2004; Mergenthaler et al., 2004; Traystman, 2003). 
In response to the failure to tackle the step from bench to bedside, researchers tried to 
establish criteria and guidelines for quality control in preclinical stroke research 
(Lapchak et al., 2013; Saver et al., 2009). Some topics were already dealt with in the 
Stroke Therapy Academic Industry Roundtable (STAIR) that tried to understand the 
lack of success of translational research in stroke and edited recommendations for 
standards in preclinical neuroprotective and restorative drug development 
(“Recommendations for standards regarding preclinical neuroprotective and 
restorative drug development.,” 1999), as well as for clinical trials evaluating acute 
stroke therapies (“Recommendations for clinical trial evaluation of acute stroke 
therapies.,” 2001).   
An additional critical issue is the interpretation of experimental data given that many 
stroke targets and markers can be biphasic and act differently in the ischemic 
sequence of events (Caplan et al., 2011). 
Nonetheless, complete understanding of cell death after brain ischemia is missing so 
far, with consequences concerning new acute treatment strategies. Research on 
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protection of all brain cells (and not only the neuron "neuroprotection") after focal 
brain ischemia is needed, in order to develop new therapeutic targets. The ideal 
protector would include the possibility of being given blindly after symptom onset, in 
order to avoid brain tissue deterioration and ultimately cell death. Additionally, it 
would be safe enough not to harm patients that eventually suffer from other types of 
stroke.  
On the other hand, besides rushing after symptoms onset, another possibility could 
include the reduction of metabolic needs in order to improve the balance between 
energy needs and production inside the ischemic tissue. In nature, this equilibrium is 
sometimes obtained in conditions like extreme external cold or hibernation, where 
despite lack of total or severely reduced cerebral blood flow, reversibility to normal 
homeostasis is possible without permanent ischemic damage.  
 
4. PENUMBRA AND CORE   
4.1. THE PENUMBRA CONCEPT 
After acute stroke, the ischemic injury shows areas with a different potential for 
recovery, depending mainly on residual perfusion threshold, collateral circulation and 
capacity of microcirculation response. The classical description of penumbra after focal 
brain ischemia in primates (Astrup et al., 1981) includes the demonstration through 
measurements of electrical activity that inside the ischemic injury subsist regions that 
are dysfunctional but not yet dead. Neurons would not fire action potentials but could 
still sustain their resting membrane potentials (-70 mV), and, provided that blood flow 
was improved, these areas recovered with restoration of action potentials. However, if 
ischemia was prolonged, neurons died after anoxic depolarization, as described before 
(Astrup et al., 1977).  
Consequently, the destiny of cells and matrix after acute stroke depends on the area 
where they are located inside the ischemic region: the region with a lower degree of 
hypoperfusion where no reversibility could be expected, the so called "ischemic core", 
| 47 
 
or the remaining hypoperfusion region, not to be recruited directly into ischemic 
tissue, the "penumbra",  where potentially salvageable tissue depends on the access to 
reperfusion (Baron, 2001). As such, the penumbra represents the part of ischemic 
brain tissue that is damaged but not yet dead and whose recovery ability decreases 
over time. 
From the perspective of therapeutic rescue of ischemic tissue, the "ischemic core" 
represents an area beyond possible rescue, electrically silent and irreversibly damaged, 
with energy and ion homeostasis failure. From the hemodynamic point of view, the 
ischemic core is perfused below the threshold of brain tissue survival (5-8 ml/100g/min 
in the first hours after ischemic onset) (Baron, 1999). Penumbra can also be defined as 
hypoperfused tissue at risk of infarction that contributes to clinical deficit and whose 
early reperfusion permits a better functional outcome (Lo, 2008; Moustafa and Baron, 
2008).  
Research on penumbra focused initial into ischemic regulation of electrophysiology, 
cerebral blood flow, and metabolism. Lately, on molecular mechanisms mediating cell 
death in the penumbral spot and imaging tools that allow to differentiate brain tissue 
compromise after acute ischemia (Lo, 2008). The possibility to "visualize" the 
penumbra both in MRI and in PET studies is considered of high translational interest 
since it permits individualized information regarding the existence and size of 
penumbra regions in each patient and the evaluation of the potential interest of 
reperfusion, avoiding futile reperfusion in cases where the brain tissue is irreversibly 
damaged.   
Interestingly, the progression from injury to infarct in the penumbra metabolism may 
not be linear. Some penumbra areas that seem to be dying can also be, at the same 
time, starting endogenous repair and remodeling. Since the observation that some 
"dreadful" mediators linked with cell death pathways are upregulated in the acute 
phase of stroke and may actually promote repair, many mediators started to be seen 
as having a "double-edged sword" behavior, modulating both injury and repair. 
Furthermore, some molecular targets are thought of as having a biphasic role, 
mediating injury during acute phase, but contributing to remodeling and repair in the 
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recovery phase. Examples of this "double behavior" include NMDA antagonists or 
extracellular proteases of matrix metalloproteinase (MMP) that were promising in 
experimental research but of no proven clinical benefit after clinical trials. This double 
behavior, dependent on the interval after the onset of the acute event,  contributed to 
the comprehension of how and why some neuroprotective drugs failed in the clinical 
context (Caplan et al., 2011). 
Future research on penumbra should focus on further clarifying not only how but 
when and where normal brain tissue switches to a deleterious sequence of events and 
then back from damage to repair (Lo, 2008). 
 
4.2. ISCHEMIA IS ABOUT CELL DEATH 
All brain cell types and structures are potentially involved in the pathophysiology of 
ischemic stroke, and ischemia is about death of different cell types at different time 
points in different regions of the ischemic lesion. Lesion progression to cell death 
include other factors than lack of blood supply, such as  inflammation. However, 
defining correctly the moment of irreversible cell death can be difficult and depends 
on the techniques employed (Zille et al., 2012). 
Mechanisms involved in cell death after a sudden lack of arterial blood flow, include 
necrosis with disintegration of the cell membrane and release of cell content, and 
apoptosis with nuclear dissolution and chromatin condensation without loss of 
membrane integrity. Other mechanisms include autophagic cell death and phagoptosis 
being one cell devoured by another (Ferrer and Planas, 2003; Linnik et al., 1993; Puyal 
et al., 2013). Nevertheless, and although major interest exist in distinguish different 
types of cell death, so far no methodology can accurately distinguish between 
apoptosis and necrosis. Methodological problems may lead to misuse of terms or 
ambiguous concepts regarding cell death in stroke literature (Ferrer and Planas, 2003; 
Galluzzi et al., 2012).  
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Before neuroimaging and modern molecular biology, visualization of cell death was 
only possible in histological postmortem samples where morphological characteristics 
were associated with cell death. In the beginning of the 20th Century, many histological 
descriptions of different types of necrosis like "selective neuronal necrosis" or 
"incomplete necrosis" were described; later, necrotic cell death included also swelling 
of the organelles and disruption of the cell membrane. Only in the early seventies, Kerr 
and collaboraters described apoptosis, characterized by cells that show nuclear 
fragmentation with chromatin condensation without cell membrane rupture (Kerr et 
al., 1972). Years later, the morphological aspects of apoptosis after cerebral ischemia 
were confirmed by electron microscopy (Li et al., 1995). Finally, molecular and 
biochemical markers of cell dead were identified and assigned to either apoptosis or 
necrosis. However, the distinction is not yet as accurately as expected, despite current 
guidelines on definitions and nomenclature for cell death (Galluzzi et al., 2012; Zille et 
al., 2012).  
Both histological and biomolecular markers identify cell death at a definite time point 
but not always coincidently. Additionally, in vivo imaging shows regions of interest 
(ROI) that will progress either to cell death or back towards normal tissue homeostasis. 
While it would be desirable that acute imaging tools in the context of acute brain focal 
ischemia would match perfectly with immunohistochemical data and relate ultimately 
to visualization of cell death, current descriptions of brain lesions in acute stroke 
imaging still represent only a surrogate for diagnosis of tissue fate.  
Imaging techniques used in acute stroke include magnetic resonance imaging (MRI) 
and nuclear imaging techniques like positron emission tomography (PET) and single 
photon emission computed tomography (SPECT) (Zille et al., 2012). MRI uses very 
strong magnetic fields and radio waves inducing different states of excitation in the 
nuclei or protons of hydrogen atoms. Resulting images represent specific pathological 
changes in tissue water content. In the acute ischemic setting, the ability of calculating 
infarct volume has been used as a correlate of cell death, namely using T2-weighted 
image sequence and diffusion-weighted imaging (DWI).  
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DWI is a sequence very sensitive to Brownian water motion. Regions of restricted 
diffusion appear very intense and present a very low diffusion coefficient. In the 
setting of acute ischemia, the hyperintensity signal in DWI is attributed to 
disintegration of ion homeostasis and intracellular accumulation of water associated 
with cytotoxic edema (Fisher et al., 1992). Furthermore, the sequence of apparent 
diffusion coefficient (ADC) allows obtaining a quantitative measure of the level of 
water restriction. This quantification permits comparisons in permanent models of 
focal ischemia of imaging and biomolecular pathophysiological events in acute 
ischemia. So far, DWI can still be considered the best imaging method to diagnose 
acute cerebral ischemia, although it represents an indirect measure of damage without 
resolution at the cellular level.  
MRI can also measure cerebral brain flow (CBF), cerebral blood volume (CBV) and 
mean transient time (MTT), using perfusion weighted imaging MRI (PWI). The 
"mismatch" between areas of blood perfusion and water diffusion in the ischemic 
territory represents the gold standard in brain image of the classical concept of 
"penumbra", a region at risk of definitive infarct but still potentially salvable, in 
opposition to "core" that has been described as one where tissue is irremediably lost. 
Limitations of the mismatch concept include the lack of penumbra threshold within the 
oligoemia region, the overestimation of the final infarct volume and the possible 
reversibility of PWI images if blood flow is restored. As such, initial PWI may not fully 
predict the final core (Kidwell et al., 2000).  
Biomolecular correlates of penumbra include preserved ATP synthesis, synthesis of 
heat-shock proteins, general decrease of protein synthesis, and the capacity to elicit an 
unfolded protein response (Sharp et al., 2000).   
The switch from “penumbra” to "core" follows an injury progression if reperfusion is 
not reestablished. PET studies suggested that injury progression occurs in three 
different stages. Initial acute ischemic injury begins within minutes after stroke onset, 
with a CBF below the threshold needed for energy metabolism; then it is followed by a 
subacute phase where "core" expands into "penumbra". Oxygen extraction fraction is 
still maintained despite decreased CBF and O2 metabolism. Finally, a delayed injury 
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phase lasts from days to weeks. However, about half of the “penumbra” area expands 
to “core” within the first 3 hours, and after 6 – 8 hours, almost all ischemic area will 
appear as core if perfusion is not restored, both in animal models and in humans (del 
Zoppo et al., 2011; Heiss, 2000; Ramos-Cabrer et al., 2011).  
 
4.3. "MICRO CORES AND MICRO PENUMBRAS"      
An advance in the concept of penumbra that better expresses the variability within the 
ischemic injury is the theory of multiple micro penumbras and micro cores inside the 
ischemic territory (del Zoppo et al., 2011). Contrary to the original conception of 
penumbra as a concentric model of flow-related changes in evoked potentials within 
the ischemic injury around a core of permanent injury (Astrup et al., 1977), new data 
suggest that the central "core" is not dead since it can express genes that do not relate 
to the ischemic cascade (Ramos-Cejudo et al., 2012). Consequently, “core” may 
develop heterogeneously and only with time will coalesce into a homogeneous area 
when not reperfused in due time (and if electrical silence will not recover). 
 An important factor that influences differences in ischemic tissue fate consists in the 
variability in response of local microcirculation. Although it is generally accepted that 
the regulation of microvasculature plays an important role in acute ischemia, its role is 
not yet completely understood. In brain arteries, the blood conductance is operated by 
the macrocirculation, whereas the regulation of blood flow depends more on the 
microcirculation, including pial and penetrating arterioles, capillaries, and venules. 
During ischemia and after changes in endothelial cells and the breakdown of the BBB, 
capillaries and venules maximally dilate until no further response is obtained, and 
represent, in ischemic conditions, a major component of vascular resistance. Previous 
studies suggest a dynamic response of the microvasculature to acute focal ischemia 
suggestive of the presence of multiple cores. These changes support the concept that 
microvascular integrity is modified in a heterogeneous but consistent pattern (Tagaya 
et al., 2001). In consequence, a temporal relationship seems to exist between brain 
tissue integrity, regional CBF and electrical failure that define regions of reversible or 
permanent injury after acute brain ischemia (Kulik et al., 2008). 
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5. ISCHEMIC TOLERANCE: HYPOTHERMIA AND HIBERNATION  
5.1 LACK OF CEREBRAL BLOOD FLOW WITHOUT PERMANENT NEUROLOGICAL DEFICIT 
In nature, there are exceptions to the rule that lack of cerebral blood flow during a 
prolonged period inexorably leads to ischemia and irreversible brain damage. 
Examples include cardiac arrest from extreme cold (Dobson and Burgess, 1996) and 
hibernation (Rouble et al., 2013) where, despite very severe brain oligoemia or no 
cerebral blood flow at all, survival without permanent neurological deficit is possible 
(Dave et al., 2012; Schwartz et al., 2013; Storey and Storey, 2010). The prevention of 
severe brain damage in these cases, characterized by a markedly reduced cerebral 
blood flow during long periods, may serve as a model that can contribute to our 
understanding of new pharmacological targets in acute ischemic stroke treatment and 
to preserve brain tissue before reperfusion is achieved.  
 
5.1.1. HYPOTHERMIA 
Extreme cold is a condition where despite severe cerebral hypoperfusion or no 
perfusion at all, irreversible neurological damage can be avoided. Patients rescued 
from cardiac arrest in iced mountains or induced cold cardioplegia in the context of 
cardiac surgery illustrate that brain (and other tissues) can be preserved despite lack of 
blood flow. Consequently, there is a rational for the induction of hypothermia in acute 
stroke, since it may reduce deterioration if induced early enough after the onset of 
symptoms and maintained for an adequate period.  
Two levels of externally induced decrease in body temperature are considered of 
therapeutic significance for translational studies: mild hypothermia (33ºC – 35ºC) and 
moderate hypothermia (30ºC – 33ºC). Mild hypothermia is safer, technically easier to 
perform (Buchan and Pulsinelli, 1990) and can be achieved in humans without sedation 
or mechanical ventilation. However, the neuroprotective effect varies with 
temperature and the time from symptom onset to hypothermia induction. A maximal 
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efficacy was observed with moderate cooling, maintained during a prolonged period 
(12h to 48h) (Corbett et al., 2000). Nonetheless, even a small decrease of basal body 
temperature of around 2ºC or less has a protective effect and its histological and 
behavioral evidence could be shown. However, external hypothermia was only 
effective if applied 5 min after hypoperfusion begun and not when it was delayed 
more than 30 min (Busto et al., 1989). Therefore, the extent of decrease in body 
temperature, the time from stroke onset, and the duration of hypothermia exposure 
contribute to outcome.  
In animal models of acute ischemia, induced hypothermia showed benefit by reducing 
infarct size and ameliorating functional outcome (Campos et al.,2012). A meta-analysis 
of experimental data, including more than 100 experiments, confirmed that induced 
hypothermia after focal brain ischemia diminished infarct size and improved functional 
outcome. Yet, a very wide array of temperatures, duration of exposure and intervals 
between stroke onset and the initiation of hypothermia was tested, making it difficult 
to conclude for the most adequate subset of conditions. Overall, the hypothermia 
effect was more pronounced with lower temperatures, although still present in mild 
hypothermia as long as temperature was decreased below 35ºC (van der Worp et al., 
2007). In the translational context, the induction of lower temperatures requires 
intensive care support, not universally available for the treatment of a highly prevalent 
disease like ischemic stroke.       
The mechanisms by which hypothermia may protect brain tissue from ischemia are not 
yet entirely understood. In regard to mild hypothermia, protection was not only 
associated with the induced metabolic changes and reduction in metabolic needs, but 
also with inhibition of presumably protective biological processes, such as 
detoxification and repair, and the final balance between protective and non-protective 
mechanisms is difficult to establish. Nevertheless, some mechanisms are already 
acknowledged for their contribution to hypothermia brain protection. These include 
the decline of cerebral metabolic rate creating a more favorable balance between 
oxygen demand and supply, which represents a critical issue in acute ischemia. 
Furthermore, hypothermia promotes the decrease in arteriole permeability with 
development of less cerebral edema and a reduced brain-blood-barrier disruption with 
54 |  
 
less formation of free radicals and excitatory neurotransmitters (including glutamate), 
as well as a milder inflammatory response with reduced release of pro-inflammatory 
cytokines and leukocyte adhesion (Sinclair and Andrews, 2010). Thus, hypothermia 
induces changes in the CBF regulation, cell membrane stability, energetic metabolism 
and intracellular signaling, as well as modulation of excitotoxicity and acid-base 
balance, with  interference in apoptotic mechanisms (Schaller and Graf, 2003). 
In the clinical context, physical or pharmacological induction of hypothermia after 
acute stroke can trigger complications like bradycardia, shivering, and an increase in 
pneumonia occurrence, with controversial benefit in death rate. A  Cochrane meta-
analysis showed no evidence supporting the routine use of reducing temperature after 
acute ischemic stroke (Den Hertog et al., 2009). However, recent clinical trials showed 
benefit reducing unfavorable functional outcome at 3 months (Piironen et al., 2014). A 
large multicenter randomized phase III trial is under way to further clarify this issue  
(van der Worp et al., 2014). 
  
5.1.2. DORMANCY AND HIBERNATION  
Hibernation is a molecular, physiological, and behavioral adaptation of some 
mammalian species in periods of unpredictable or shortage of food availability. During 
states of dormancy and hibernation, mammals are able to survive with metabolic rates 
as low as 2% of their usual needs, without irreversible brain lesions. During these 
periods, animals need to carry out adaptive transformations, including mechanisms of 
metabolic suppression by actively decreasing body temperature and depressing 
immune functions, but also increased oxidative resistance (Drew et al., 2007; Zhou et 
al., 2001).  
CNS regulation of hibernation is poorly understood but comprises a "circannually 
regulated hibernating protein complex". This protein complex allows metabolic 
flexibility regulated via neuronal pathways. Central sites for regulation include the 
hippocampus, hypothalamus, and nuclei of the autonomic nervous system. Wide-
ranging sympathetic activation is suppressed and parasympathetic inhibition of 
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metabolic pathways promoted. The decreased demands in CNS metabolism cause a 
decrease in body temperature that assists further cooling by temperature-dependent 
mechanism. The mechanisms of metabolic suppression in hibernation include a 
reversible reduction in cellular needs for oxygen and other nutrients, better fitting the 
metabolic demand with the supply (Drew et al., 2007). Knowledge about the 
mechanisms used by hibernating animals to decrease metabolic demand may have 
translation potential for stroke therapy (Drew et al., 2007; Storey and Storey, 2010).  
 
5.2 NITRIC OXIDE, CARBON MONOXIDE, AND HYDROGEN SULFIDE 
Nitric oxide (NO) and carbon monoxide (CO) are signaling gaseous molecules of the 
central nervous and cardiovascular system with cytoprotective properties in the 
context of brain and heart ischemia (Elrod et al., 2006). Lately, particular attention has 
been paid to the potential biological significance of hydrogen sulfide (H2S), initially 
known for its toxic environmental properties (Abe and Kimura, 1996; Beauchamp et 
al., 1984). These 3 labile biological mediators (NO, CO e H2S) have common 
characteristics like being able to cross cell membranes without the need of membrane 
transporters, thus having easy and prompt access to intracellular pathways.  
Interestingly, Blackstone and coworkers induced a condition similar to hibernation in 
mammals that normally do not hibernate by H2S inhalation in their study published in 
2005. They called this condition the “suspended animation-like state”. Mice exposed 
to a H2S enriched atmosphere showed a significant decrease in their metabolic rates 
(measured through O2 consumption and CO2 elimination) and body temperature. After 
6 hours of exposure to H2S, animals started to breathe normal atmosphere and 
returned spontaneously to normal metabolic rates and body temperature, with no 
changes in health condition in short and long-term follow-up (Blackstone et al., 2005). 
Hydrogen sulfide is a gas that results from bacterial breakdown of organic matter in 
anaerobic conditions. Small amounts are produced in the human body and used as 
signaling molecule. H2S is present in the central nervous system at relatively 
concentrations (50 to 160 microM) in comparison to other organs which suggests that 
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it may have a localized physiological function (Abe and Kimura, 1996; Kimura and 
Kimura, 2004). Nevertheless, controversy still exists about measuring methods (Olson 
et al., 2014). H2S is a vasodilator of the cerebral arterioles via activation of K(ATP) 
channels (Leffler et al., 2011), but its biological functions extent far beyond its direct 
effects on vasotonus. 
H2S is synthesized in mammals in different organs through two major L-cysteine 
metabolic pathways that depend on pyridoxal-5'-phosphate enzymes: cystathionine 
beta-synthase (CBS) and cystathionine gamma-lyase (CSE). L-cysteine can originate 
from food sources (like yogurt, oat flakes, and eggs), or be synthesized from L-
methionine through the transsulfuration pathway, with homocysteine acting as 
intermediary in the process. The biological effects of exposure to H2S seem to depend 
largely on its capacity to inhibit mitochondrial oxidative phosphorylation. H2S is a 
potent inhibitor of brain cytochrome oxidase activity and suppresses metabolism since 
it is an inhibitor of cellular oxidative phosphorylation (Wallace and Starkov, 2000). 
Consequently, metabolic suppression precedes the decrease in body temperature that 
is observed after H2S inhalation (Blackstone et al., 2005). This characteristically 
differentiates H2S from other methods to induce hypothermia where the decrease in 
temperature precedes the hypometabolic effect.  
Regarding temperature regulation in hibernation, the decrease in CNS activation and 
metabolic demand facilitates the drop in body temperature. Cooling can then boost 
further metabolic suppression by down-regulating temperature-dependent 
mechanisms including neuronal activity (Drew et al., 2007). Thus, the biologic effect of 
H2S can be compared to the mechanisms described in the torpor phases of hibernation 
where reduced metabolism also seems to be accomplished by synergistic effects of 
both passive (temperature-dependent) and active (temperature-independent) 
mechanisms that provide a decrease in oxygen demand.  
H2S is endogenously produced in different organs including the brain (Mani et al., 
2013) and regulates oxygen consumption by competing with O2 in binding to 
cytochrome C oxydase at the mitochondrial electron transport chain (Wagner et al., 
2009). A suggested mechanism for the regulation of H2S refers to the observation that 
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the concentration of biologically active H2S is regulated by the simple balance between 
constitutive H2S production and its oxidation by the mitochondria (Olson, 2013; Olson 
et al., 2014). The potential of H2S as a pharmacological tool in acute brain ischemia 
may also relate to its role as an oxygen sensor (Olson et al., 2013) and its properties 
concerning the regulation of neuronal and glial communication (Mikami et al., 2011) 
and of local vasotone (Leffler et al., 2011). Being an oxygen sensor H2S may contribute 
to monitoring environmental oxygen and ensuring adequate delivery to tissues.  
However, the biological effects of H2S are still controversial and depend, among other 
factors, on the dosage and duration of the exposure. At micromolecular 
concentrations, H2S appears to have a neuroprotective role, not only by interference 
with oxidative stress and cell death pathways but by modulation of the activity of the 
N-metil-d-aspartate (NMDA) receptors in physiological concentrations (Kimura and 
Kimura, 2004). Furthermore, induction and upregulation of cytoprotective and anti-
inflammatory genes, including heme oxygenase-1 (HO1) which allows the production of 
CO with renowned cytoprotective and anti-inflammatory properties, was attributed to 
H2S (Nagai et al., 2004). Thus, exogenous administration of H2S may also be 
cytoprotective in the context of acute experimental ischemia.  
 
5.3. PREVIOUS WORKS WITH H2S AFTER EXPERIMENTAL STROKE 
Since the publication of an article in Science in 2005, showing that the inhalation of a 
mixture of atmosphere and H2S induced a dramatic reduction in oxygen consumption 
to less than 15% of normal metabolic rates without irreversible neurological deficits 
(Blackstone et al., 2005), the potential benefit of H2S in the context of acute ischemia 
started to be investigated. 
Despite multiple potentially protective mechanisms of H2S, data regarding the benefit 
of H2S in the context of acute ischemic stroke were few and conflicting when we 
designed the present research project. A first report on H2S in acute ischemic stroke in 
a rodent model showed no benefit in functional outcome (Qu et al., 2006). Later, other 
studies including older rats or permanent and reperfusion models and prolonged 
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exposure to H2S, demonstrated a clear benefit, both in functional outcome and in 
lesion size (Florian et al., 2008; Gheibi et al., 2014; Joseph et al., 2012). These results 
were in concordance with the data from experimental ischemic models of other organs 
like the heart and the kidney where similar benefits were observed using H2S gas or 
liquid vials with H2S donors (Bannenberg and Vieira, 2009; Hosgood and Nicholson, 
2010; Simon et al., 2008; Sodha et al., 2009). Consequently, a rational for the potential 
translational interest of H2S or H2S donors in the context of acute stroke was 
established.  
Nevertheless, the controversy about the cytoprotective role of H2S in the context of 
acute ischemia persists and neurotoxic effects have been described in rodents. These 
discrepancies in the action of H2S have been observed within the same specie
 (Qu et 
al., 2006) , between distinct species (mouse and piglets) (Li et al., 2008), and between 
distinct organs (heart and brain) (Hayashida et al., 2008). The reasons for this 
discrepancy in existing data include the fact that H2S protective effects are dose–
dependent, probably even at micro doses (ppM), as suggested by studies in myocardial 
ischemia (Johansen et al., 2006). Furthermore, results of H2S administration also 
depend on exposure time for the purpose of hypometabolic effects, particularly in 
mammals with large body size.  
The induction of hypometabolic conditions after the onset of acute cerebral ischemia 
by reducing metabolic needs and diminishing the difference between energy 
production and demand may theoretically contribute to prevention of ischemic injury, 
enlarging the time window until spontaneous reperfusion occurs or therapeutic 
reperfusion is available. If confirmed in experimental and clinical setting, the induction 
of hypometabolism may represent an option to increase the therapeutic window and a 
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AIMS AND SCOPE OF INVESTIGATION 
We studied the hypothesis that exposure to hydrogen sulfide after acute cerebral 
ischemia has a protective effect regarding brain damage and functional outcome in an 
animal model of focal cerebral ischemia, addressing in particular the following 
questions:  
1. Does current literature support further research concerning the role of oxidative 
phosphorylation inhibitors in the context of acute stroke treatment?  
2. Does exposure to H2S after acute ischemic stroke diminish infarct size and enhance 
recovery?  
3. Does the effect of H2S relate to brain protection or repair mechanisms, involving 
either modulation of post-ischemic oxidative stress and the expression of reactive 
oxygen species or promotion of post-ischemic repair? 
4. Is it possible to use in vivo brain imaging to predict outcome in experimental stroke?   
 
We analyzed the effects of H2S exposure in a permanent middle cerebral artery 
occlusion (pMCAO) model in rodents and measured functional outcome and infarct 
size in vivo and post-mortem. Furthermore, we investigated mechanisms of 
cytoprotection and repair and compared data from in vivo brain imaging with post-
mortem immunohistochemical evidence.  
Our research shall contribute to the understanding of the potential role of H2S in the 
context of acute ischemic stroke and clarify underlying processes involved in presumed 
ischemic tissue preservation. In the future, we shall expect a major translational 
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1. ACUTE BRAIN ISCHEMIA, HYPOTHERMIA AND HIBERNATION: THE ROLE OF 
OXIDATIVE PHOSPHORYLATION INHIBITORS  
INTRODUCTION 
Current treatment of acute ischemic cerebrovascular accidents (CVA) includes arterial 
reperfusion using rt-PA (recombinant tissue-plasminogen activator) and treatment at 
CVA Units. During the last decades, numerous neuroprotective substances have been 
promising in pre-clinical studies, both in terms of ischemic volume and functional 
outcome. Regrettably, none has demonstrated unequivocal clinical benefit.  
Reasons for the difficulties of extrapolation to humans include the need for very quick 
administration of drugs which presents difficulties within a clinical context, the 
disparity of measurement instruments including functional scales (Richard Green et al., 
2003), or the differences in the acquisition of imaging techniques during the acute 
stage and the definition of  penumbra (Fisher et al., 2007; Weinstein et al., 2004). 
There is evidence that, if untreated, the penumbra area bordering the ischemic lesion 
will soon become part of the infarct zone (core), increasing the volume of the initial 
lesion and worsening functional prognosis.   
The rational for the recommendation to treat stroke as an emergency is that early 
reperfusion is associated with functional improvement by preventing irreversible brain  
damage. Unfortunately, the therapeutic window between symptoms onset and useful 
reperfusion is short, and measures that permit the widening of the therapeutically 
window may allow to include an important number of patients that arrive too late to 
benefit from brain reperfusion therapies. Procedures aiming to slow down or interrupt 
the metabolic processes involved in the so-called “ischemic cascade” have potential of 
extending the time available to perform arterial reperfusion.      
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HYPOTHERMIA 
Inducing a drop in body temperature may reduce deterioration following the acute 
ischemic lesion if induced early enough after the beginning of ischemic symptoms and 
if the duration is also appropriate. The use of moderate external hypothermia in the 
context of the acute stage of stroke is currently under research in Phase II clinical trials.   
In animal models of acute ischemia, induced hypothermia has proved benefit, both in 
terms of reducing infarct size and improving functional outcome.   
There are two different levels of decrease in body temperature that have therapeutic 
interest for translational studies: mild hypothermia (33ºC – 35ºC) and moderate 
hypothermia (30ºC - 33ºC). Mild hypothermia is safer and technically easier to perform 
(Buchan and Pulsinelli, 1990). In humans, it is possible to reach the desired 
temperature without the need of sedation or mechanical ventilation which is an 
advantage for translation into clinical context. Nonetheless, the neuroprotective effect 
is different for different temperatures and for different intervals between ischemia 
and hypothermia induction; it was noted that maximum efficacy occurs when cooling 
is moderate (≤31ºC) and exposition is long (12 to 48h) (Corbett et al., 2000).  
However, even small reductions of basal body temperature of around 2ºC or less seem 
to have a neuroprotective effect with histological and behavioural evidence (Busto et 
al., 1989). 
The mechanisms by which hypothermia is neuroprotective are not entirely 
understood. With regard to mild hypothermia, neuroprotection was exclusively 
associated with the induced metabolic changes (the drop in temperature reduces 
metabolic needs). However, protective biological processes, such as detoxification and 
repair, would also be inhibited, which makes the final balance difficult to establish. 
Currently, there seems to be evidence that the pathophysiology of hypothermia  
includes also changes in cerebral blood flow, cell membrane stability, energetic and 
calcium metabolism, intracellular signalling, excitotoxicity mechanisms, acid-base 
balance,  formation of free radicals, and in apoptotic mechanisms (Schaller and Graf, 
2003). Therefore, hypothermia is considered a tissue protector due to the fact that it 
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boosts resistance to deleterious effects including interfering with glucose metabolism 
diverging it from the glycolysis pathway to the pentose phosphate pathway which is 
potentially a neuroprotective pathway and reducing the levels of tissular lactate and 
intracellular acidosis. It frees excitatory amino acids, the formation of free radicals, the 
mitochondrial release of cytochrome C and kinase C, the activation of microglia, and 
improves the behaviour of the hematoencephalic barrier by reducing its deterioration 
and rupture. Hypothermia induces also the inhibition of at least one cell death 
pathway, covering several lesion mechanisms and contributing to the preservation of 
both cell function and structure, thus improving tissue preservation (Minard and 
Grant, 1982). 
 
NITRIC OXIDE, CARBON MONOXIDE AND HYDROGEN SULFIDE  
Nitric Oxide (NO) and Carbon Monoxide (CO) are signalling gaseous molecules of the 
central nervous and cardiovascular system, which have proved cytoprotective benefits 
in the context of brain and heart ischemia (Elrod et al., 2006). Lately, particular 
attention has been paid to the potential biological significance of hydrogen sulphide 
(H2S) (Abe and Kimura, 1996), first known for its environmental toxic properties 
(Beauchamp et al., 1984). These three gaseous labile biological mediators (NO, CO e 
H2S) are able to cross cell membranes without the need of specific transporters, what 
facilitates their quick interference in the regulation of intracelular mechanisms.  
H2S is synthesized in mammals in several tissues through two main metabolic 
pathways of the L-Cysteine, that depend on pyridoxal-5'-phosphate enzymes: 
cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CSE). L-Cysteine 
can originate from food sources or be synthesized from L-Methionine through a 
transsulfuration pathway, homocysteine acting as the intermediary in the process. 
The biological effects of exposure to H2S seem to depend, in particular, on its capacity 
to inhibit mitochondrial oxidative phosphorylation and hypothermia induction. 
Nonetheless, they are controversial and depend, among other factors, on the dosage 
and duration of the exposure. In micro molecular concentrations, hydrogen sulphide 
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appears to have a neuronal protective role in oxidative stress (Kimura and Kimura, 
2004), with modulation of the intracellular caspase and kinase pathways, influencing 
the activity of the N-metil-d-aspartate (NMDA) receptors in physiological 
concentrations and modifying the induction of long term potentiation (LTP) (Nagai et 
al., 2004). It can also induces an upregulation of cytoprotective and anti-inflammatory 
genes, including Heme oxygenase-1 (HO1), which promotes the production of CO, that 
has cytoprotective and anti-inflammatory behaviour. 
H2S is present in the central nervous system in relatively high concentration levels (50 
to 160 microM), by comparison with other organs, which suggest it may have a 
localized physiological function (Abe and Kimura, 1996) . 
 
OXIDATIVE PHOSPHORYLATION INHIBITORS AND HYBERNATION  
During states of dormancy such as hibernation, mammals are able to survive with 
metabolism rates as low as 2% of their usual needs, without suffering irreversible brain 
lesions, despite very low CBF. During these periods, animals need to carry out adaptive 
transformations at brain level. These adaptations include not only mechanisms of 
metabolic suppression, but also of increased oxidative defence, in addition to lowering 
body temperature and immune functions (Drew et al., 2007). Knowledge on the 
regulation mechanisms and reversible adaptative induction in case of extreme 
hypometabolic conditions can contribute to a better understanding of some crucial 
aspects of ischemic lesion, namely how brain cells can sustain homeostasis despite 
very low CBF. .  
Remarkably, it was exactly with H2S that it was possible, in 2005, to induce a condition 
similar to hibernation in mammals that normally do not hibernate. This condition was 
called “suspended animation-like state” (Blackstone et al., 2005). After inhalation of an 
H2S enriched atmosphere mixture, mice had a significant drop in body temperature 
and in metabolic rates (measured through O2 consumption and CO2 elimination). After 
6 hours of exposure, rats returned to breathe normal atmosphere, with quick and 
spontaneous recovery of their normal metabolic rates and body temperature, without 
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changes in their health condition in the short or medium follow-up. Therefore, the 
potential role of H2S, as a neuroprotective agent and hypometabolic inductor was 
enhanced. Mechanisms involved included H2S tamponading effect in oxygen 
consumption, changes the intracellular redox environment, and prevention of further 
imbalance between energy sources and needs (Blackstone and Roth, 2007). The 
proposed mechanism, that may regulated the consumption of cell O2 by H2S, appears 
to be centred on inhibiting cytochrome C oxidase, which, at the level of the brain, 
reduces oxygen consumption and inhibits the recapture of the L-glutamate, an 
excitatory neurotransmitter.  
Concerning the cytoprotective role of hypothermia, its potential benefit has been 
demonstrated in animal models of acute brain ischemia, not just for outcomes 
regarding infarct size, but also at functional recovery.  
Regarding the cytoprotective role of H2S, controversy persists, with some studies 
showing neurotoxic effects. These discrepancies in the action of H2S have been 
observed within the same species (Qu et al., 2006), between distinct species (small 
mouse and piglets) (Li et al., 2008) and between distinct organs (brain ischemia and 
cardiac ischemia) (Hayashida et al., 2008). The explanation for these differences 
concerning the expression of hypometabolic effects may relate to dose and exposition 
time differences (Johansen et al., 2006), and body mass effect, especially for ischemic 
models using larger mammals., 
Severe hypothermia and hibernation are two extreme metabolic conditions where, 
despite the presence of much reduced metabolic rates, it is possible to recover 
without irreversible cerebral lesion.  
The possibility of inducing hypometabolic states following acute cerebral ischemia by 
lowering body temperature as well as oxygen consumption and other metabolic needs, 
may help increase the window of therapeutic opportunity of thrombolysis, thus 
helping to make it accessible to an increased number of patients with ischemic CVA.  
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CONCLUSION 
Severe hypothermia and hibernation are two extreme metabolic conditions where, 
despite the presence of severely reduced metabolic rates, it is possible to recover 
without irreversible cerebral lesion. The possibility of inducing hypometabolic states 
following acute cerebral ischemia by lowering body temperature as well as oxygen 
consumption may help increase the window of therapeutic opportunity of 
thrombolysis, thus contributing to making it accessible to a larger number of patients 
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2. EXPOSURE TO HYDROGEN SULFIDE DIMINISHES INFARCT SIZE AND ENHANCES 
RECOVERY:  EXPERIMENTAL DATA IN A pMCAO MODEL IN RODENTS 
INTRODUCTION  
There are exceptions in nature to the rule that lack of cerebral blood flow during a 
prolonged period of time inexorably leads to ischemia and irreversible brain damage. 
Two examples are cardiac arrest from extreme cold (Dobson and Burgess, 1996) and 
hibernation (Rouble et al., 2013) where, despite very low or no cerebral blood flow at 
all, survival is possible without permanent neurological damage (Schwartz et al., 2013; 
Storey and Storey, 2010). These examples show that severe brain damage may be 
prevented even in the absence of cerebral blood flow during long periods. This 
observation may contribute to new strategies in acute stroke therapy.  
The induction of a “hibernation-like” state in mice using the inorganic gas hydrogen 
sulfide (H2S) suggested its potential in the context of acute ischemia (Szabó, 2007), 
promoting a dramatic reduction in oxygen consumption to less than 15% of normal 
metabolic rates, without subsequent irreversible neurological deficits (Blackstone et 
al., 2005). 
H2S regulates oxygen consumption by competing with O2 in binding to cytochrome C 
oxidase at the mitochondrial electron transport chain level, inhibiting the electron 
transport chain by binding stronger than O2 to the Fe-Cu center in cytochrome C 
oxidase. H2S is also involved in neuronal and glial communication (Mikami et al., 2011) 
and local vasotone regulation.  
Despite of these potential beneficial effects, data about the benefit of H2S in the 
context of acute ischemic stroke was modest and conflicting when we designed this 
study. First reports showed no functional benefit (Qu et al., 2006), whereas others 
demonstrated improvement in functional outcome and lesion size (Joseph et al., 
2012). Data from experimental models in the context of acute ischemia in other organs 
like heart and kidney showed clear benefits of H2S exposure (both with the gas itself or 
with liquid vials with H2S donors) (Hosgood and Nicholson, 2010; Snijder et al., 2013).  
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We here hypothesized that inducing a reversible hypometabolic state after acute 
cerebral ischemia through exposure to H2S could limit acute ischemic brain damage. 
In the present section, we investigated the effects of short-term H2S exposure after 
permanent middle cerebral artery occlusion (pMCAO) by analyzing the functional 
outcome and infarct size.  
 
MATERIALS AND METHODS  
All experiments were designed to minimize animal suffering in compliance with the 
ARRIVE criteria and our medical school’s Ethical Committee for the Care and Use of 
Animals in Research (EU directives 86/609/CEE and 2003/65/CE). Regarding all 
procedures, researchers were blinded to group allocation after randomization. Male 8 
- 12 weeks old Sprague-Dawley rats (250 to 320g) (Charles River©, Spain) were 
randomly assigned to three groups:  sham (craniotomy, n=13), control (craniotomy + 
pMCAO, n=23) and treated (craniotomy + pMCAO + exposure to 40 ppm H2S, n=28). 
Rats were anesthetized with the halogenated general inhalation anesthetic drug 
Sevoflurane {[fluoromethyl 2, 2, 2,-trifluoro-1-(trifluoromethyl) ethyl ether] [1, 1, 1, 3, 
3, 3-hexafluoro-2-(fluoromethoxy) propane]}. Its median alveolar concentration (the 
concentration at which half of the subjects do not move in response to a skin incision) 
is 2.5 (+/-0.3) volumen %. We performed pMCAO after a small craniotomy above the 
rhinal fissure over the branch of the right middle cerebral artery (MCA), exposing MCA 
and permanently ligated with a 9-0 silk suture before its bifurcation, in order to 
enhance reproducibility. After MCAO, both common carotid arteries were temporarily 
occluded for 60 min with a lace of a 6-0 silk suture. Scar size and location were equal 
for all groups, animal cages had no information about group allocation, and codes 
were used in post mortem samples, in order to maintain blinded data collection and 
analysis. Body temperature and glycemia were measured throughout procedures. Rats 






Treated animals were exposed to H2S, 3 hours after acute ischemia and breathed a 
mixture of atmosphere with hydrogen sulfide [Gasin medical bottles, 40 ppm H2S in 
nitrogen (N2: 99, 9%)] during 24 min inside a Plexiglas® chamber (9.5 x 20 x 10 cm = 
Volume 1,900 cm3). Pressure output of hydrogen sulfide was 1 bar/30s. Control and 
sham animals breathed normal atmosphere in the same temperature and humidity 
conditions.  
When this study was designed, no data was available regarding time and dosage of H2S 
exposure and its efficacy in pMCAO. Thus, we established an effective dose by 
exposing healthy rats to progressive doses of H2S. Our variables were H2S 
concentration (40 and 80 ppm), time of exposure (from 1 to 90 min), and output 
pressure (1 or 2 bar). We used rectal temperature before and after exposure as an 
indirect measure of change into lower metabolism. Finally, we established an exposure 
time of 24 minutes under a concentration of 40ppm with an output pressure of 1 
bar/30s as standard dosage.  
 
Ischemic lesion size          
Lesion size was evaluated in vivo at 24h and 14d with T2-weighted sequence MRI and 
post mortem by hematoxylin and eosin (H&E) stains, as previously described 
(Gutiérrez-Fernández et al., 2011). 
 
Magnetic Resonance Imaging  
The extension of ischemic lesions was analyzed in vivo at 24h (group sacrificed at 24h) 
and twice, at 24h and 14d (group sacrificed at 14d), using T2-weighted images. The 
observer was blinded to allocation of animals in all cases. After contrast adjustment, 
the contours of the hemispheres were traced manually on each slice. Data analysis was 
performed using Image J software from NIH Image, slice-by-slice contouring at lesion 
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site and in the contralateral hemisphere in the same location. Only lesions larger than 
2mm x 2mm x 2mm were analyzed to minimize partial volume effects. We used JPG® 
region of interest (ROI) to measure infarct size. To correct for brain edema effect, 
lesion size was determined by an indirect method: (infarct area) = (area of the intact 
contralateral hemisphere) – (area of the intact ipsilateral hemisphere). Lesion size was 
expressed as percentage of total size of the ipsilateral hemisphere. Exclusion criteria 
were no measurable lesion on MRI except for the sham group. These animals were 
sacrificed and excluded from the sample (n=3). We therefore used T2 MRI at 24h as 
confirmation tool for successful ischemic lesion induction.  
MRI images were acquired on a 7 Tesla/16 cm Bruker Avance III system (Bruker 
Medical Gmbh, Ettlingen, Germany) at the MR Imaging Facility (SIERMAC, 
http://www.siermac.es) from the Institute for Biomedical Research “Alberto Sols” 
CSIC/UAM, Madrid, Spain. The magnet was equipped with a 1H selective birdcage 
resonator for rat head (38mm) and a gradient coil insert (90 mm, maximum intensity 
36 G/cm). Anesthesia was induced in a plexiglass chamber with 2%-3% isoflurane 
mixed with oxygen and maintained during the experiment through a nose mask. The 
physiological state of the rats was monitored during MRI acquisitions with a Biotrig 
physiological monitor (Bruker) depicting on-line the respiratory rate.  
Axial T2-weighted spin echo images were obtained using a rapid acquisition with 
relaxation enhancement (RARE) sequence in axial and coronal orientations using the 
following parameters: Number of echo images 2 (TE: 29.54ms and 88.61ms), TR = 3000 
ms, RARE factor = 4, Av = 3, FOV = 3.5 cm, acquisition matrix = 256 × 256 
corresponding to an in-plane resolution of 136 × 136 μm2, slice thickness = 1.00 mm 
without gap.  
Diffusion-weighted magnetic resonance images (DWI) were obtained in three 
ortoghonal orientations as defined by the read, phase and slice encoding gradients 
using a multishot spin-echo echo planar imaging (EPI) sequence. Acquisition conditions 
-echo echo planar imaging (EPI) sequence. TR: 
3000ms; TE: 50ms, FOV: 3.8cm; axial slices (1.5mm thickness) and three b values: 100, 
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400 and 1000 s/mm2; acquisition matrix = 128 × 128 corresponding to an in-plane 
resolution of 296 × 296 μm2.  
Dynamic susceptibility contrast – Magnetic Resonance Imaging (DSC MRI) was 
performed using a bolus injection of paramagnetic contrast agent (Gd-DTPA; 
Magnevist, Bayer Schering Pharma AG, Leverkusen, Germany; 0.3mmol/Kg i.v.). 
Dynamic changes in signal intensity were used to calculate CBF (cerebral blood flow), 
CBV (cerebral blood volume, the fraction of tissue volume occupied by blood) and MTT 
(mean transit time: MTT=CBF/CBV, the time it takes for blood to pass through the 
vasculature within the tissue of interest). Dynamic T2* Weighted images were 
acquired using a spin-echo single shot echo planar imaging (EPI) sequence with the 
following scan parameters: TR/TE of 250/7ms; Flip angle: 30º; Number of repetitions: 
150; slice thickness and interslice gap: 1.5mm and 0.1mm; number of slices: 6; FOV: 
3.8cm and matrix size: 86x8. After an initial baseline period of 10s, a rapid bolus 
injection of Gd-DTPA was administered intravenously in the tail vein.  
ADC, CBF, CBV and MTT pixel by pixel maps were generated with a homemade 
software application (MatLab ®, 2007a). ADC value was computed for each voxel using 
the exponential model according to the expression: Sb = S0 e
−b*ADC, where Sb is signal 
intensity with the different b weightings and So the signal intensity for b=0. Perfusion 
parameters were calculated based on the premise that ΔR* is proportional to the 
contrast agent concentration according to the curve equation: ΔR*= -K. ln [ S(t) / So 
(t)], where S(t) is de signal intensity at time t, So baseline signal intensity and, K a 
constant. The transit curve was then fitted to a gamma variant function.  
The mean and standard deviation of ADC of the central and peripheral lesion area 
were determined, and the same measurement performed in the same anatomic 
location as the lesion but in the normal contralateral hemisphere. These three regions 
of interests (ROIs) are easy to identify on color coded ADC maps and drawn manually 
over the maps. The ROIs were applied on all affected ADC slices from each rat with a 
maximum number of five slices. The mean ADC values of central and peripheral lesion 
areas were divided by the value in the contralateral normal hemisphere and expressed 
as a relative ADC (rADC).  
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Perfusion weighted MR imaging was performed using bolus tracking and resulting data 
used to generate CBF, CBV and MTT maps. In these maps, only two ROIs were 
investigated: ischemic lesion and contralateral normal hemisphere, because of the 
smaller matrix size (86*86) than in ADC maps, hindering the selection of central and 
peripheral lesion areas. The mean CBF values of the ischemic region were divided by 
the value of the contralateral normal hemisphere used as reference region and 
expressed as relative CBF (rCBF).  
 
Functional evaluation scales  
Functional evaluation was performed using Rotarod and Rogers tests by a blinded 
observer at baseline, 24h and at 14d after surgery. The latency to fall from a rotator 
cylinder (accelerating at 4-40 rpm) was measured and recorded. Motor function by 
Rogers test was scored: 0, no deficit; 1, failure to extend contralateral forepaw fully; 2, 
decreased grip of the contralateral forelimb while tail gently pulled; 3, spontaneous 
movement in all directions, contralateral circling only if pulled by the tail; 4, circling or 
walking to the right; 5, walks only when stimulated; 6, unresponsive to stimulation; 
and 7, dead (Gutiérrez-Fernández et al., 2011). 
 
Statistical analysis  
Quantitative data is shown as mean ± standard error of the mean (SEM) and presented 
as box and whiskers plots. As data followed a non-normal distribution, the Mann–
Whitney test was used to compare two samples and the Kruskal–Wallis test to 
compare more than two samples in the same group or more than two groups (SPSS 16 






Functional outcome after exposure to hydrogen sulfide  
We measured functional outcome before procedure, at 24h and 14d. At baseline, 
Rogers Modified Scale was zero for all animals and the latency to fall in the Rotarod 
test was >120 seconds. The sham-operated group showed no functional deficit. A 
better functional outcome was observed at 24h in animals exposed to H2S compared 
to control group regarding Rogers Modified Scale (1.73 ± 0.23, vs. 3.29 ± 0.18, p= 
0.001) and Rotarod test (65 ± 5.97, vs. 37 ± 7.14, p=0.03). At 14d, the functional 
benefit observed in treated animals was sustained in both tests: Rogers Modified Scale 
(1.18±0.17 vs. 1.82± 0.20, p=0.03), and Rotarod (55.25±5.17 vs. 31.5±7.79, p=0.04) 
(Figure 2.1A). 
 
Infarct size after exposure to hydrogen sulfide  
At 24 hours after pMCAO, lesion size measured by T2-weighted MRI did not differ 
significantly between treated and control groups (9.69±1.67 vs. 15.45±1.06, p= 0.054). 
However, H&E stains showed a reduced infarct size in the treated group (6.69±1.38 vs. 
23.20±3.05, p= 0.008). At day 14, both T2-weighted MRI and H&E showed smaller 
infarct size in treated compared to control rats (6.13±0.62 vs. 11.56±0.4, p=0.0004, and 
4.94±0.92 vs. 11.63±1.99, p=0.002). Sham operated rats showed no cerebral lesion and 
the maximum lesion size was observed in the control group (Figure 2.1B). 
 
MRI heterogeneities in ischemic territory after exposure to hydrogen sulfide 
In treated rats, we observed heterogeneities inside the ischemic lesions on MRI ADC 
maps at 24h (Figure 2.2, upper right image and graph). These heterogeneities were 
observed inside the ischemic area, including central and peripheral areas, presenting 
central areas with a higher diffusion coefficient than peripheral ones. In animals 
treated with H2S, the relative ADC (rADC) coefficients were similar in central and 
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peripheral areas (Figure 2.2, lower left images and graph). Finally, using perfusion MRI, 
the differential CBF (∆ CBF) between the lesion side and contralateral hemisphere was 
lower in treated rats (Figure 2.2, lower right image and graph). 
 
Physiological parameters 
Glycemia was assessed immediately after starting the procedure and during surgery 
and was similar in all groups. Body temperature was significantly lower after induction 
of anesthesia in all groups (p<0.05). After an exposure time to H2S of 24 minutes, body 
temperature decreased by 1.85 ºC (mean) but quickly recovered after animals started 
to inhale normal atmosphere; no difference in body temperature was observed at 2 
hours after exposure (Figure 2.3).  
 
DISCUSSION  
We report on the role of short-term exposure to H2S in acute ischemic brain damage. 
Our results show that exposure to hydrogen sulfide after pMCAO improves functional 
outcome and decreases infarct size. DWI MRI ADC maps revealed intralesional 
heterogeneity compared to controls and PWI MRI showed higher intralesional cerebral 
blood flow. Significant benefit is likely to occur before major tissue damage develops. 
 
H2S exposure improved functional outcome after pMCAO  
A main goal of acute stroke treatment is the improvement of functional outcome. In 
the present study, a better functional outcome in animals exposed to H2S was 
observed at 24h and 14 days. A similar benefit in functional outcome has been 
reported in studies that used H2S in the context of ischemia reperfusion (Lin et al., 
2012), in global brain ischemia (Yin et al., 2013), and in cardiac and kidney ischemia 
(Shibuya et al., 2013; Szabó et al., 2011). In our model, functional benefit from H2S 
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exposure was not limited to short term, but sustained until day 14. This observation is 
supported by our in vivo imaging data that showed improved brain tissue preservation 
and smaller lesion size.  
 
H2S exposure decreased lesion size after pMCAO 
Concerning infarct size, a previous publication using a H2S donor (NaHS) in an ischemic 
electrocauterization model did not show reduction in lesion size (Qu et al., 2006). 
However, others reported smaller infarcts using longer H2S exposure times, higher 
doses (Joseph et al., 2012) or reversible MCAO models (Lin et al., 2012). Our data 
showed that lower dose and shorter exposure (40 ppm, during 24 min) were able to 
decrease infarct size after pMCAO. 
Despite of finding smaller infarcts at day 14, differences between infarct sizes assessed 
by T2-weighted MRI at 24h were not significant, possibly due to acute post ischemic 
brain edema that increases brain volume. However, H&E staining at 24h showed 
significant reduction in lesion size in treated rats. This discrepancy may be related to 
the process of H&E staining that includes tissue exsiccation steps. Interestingly, MRI 
ADC maps at 24h in treated rats revealed heterogeneity, with spotty areas inside 
ischemic lesion with higher ADC coefficients, both in central and peripheral areas that 
may reflect partial brain tissue preservation within the ischemic area. This may 
contribute to better understand the discrepancy between in vivo lesion size and better 
functional outcome at 24h. Nevertheless, infarct size as single outcome measure 
seems to be insufficient to serve as evidence for protection, and demonstration of 
ischemic size should not be interpreted independently from other endpoints (Balkaya 
et al., 2013).  
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H2S exposure induces heterogeneities within the ischemic lesion in brain MRI  
Previous studies from our group showed that gene expression exists inside the 
ischemic lesion, including CNS development and trophic factors within the lesion core, 
until at least 24h after pMCAO, suggesting the presence of surviving areas within the 
ischemic core (Ramos-Cejudo et al., 2012). At 24h, ADC maps showed heterogeneities 
in the central part of the ischemic lesion, revealing different rates of water diffusion 
and underlying brain tissue integrity. These heterogeneities may represent previously 
described "mini-cores and mini-penumbras" (del Zoppo et al., 2011). Finally, when we 
compared CBF in both hemispheres in treated and control groups, less difference 
between CBF in affected and non-affected hemispheres was observed in treated rats. 
This suggests that better perfusion may be achieved by mechanisms that include 
microvasoregulation, a known property of H2S (Zhao et al., 2001). In our study, 
heterogeneity in ADC maps corresponded to better functional outcome as well as 
smaller lesions and better ischemic tissue preservation in treated rats. Consequently, 
in a translational context where acute imaging is crucial for acute therapeutic 
decisions, prognostic relevance of ADC heterogeneities may be assumed and merits 
further research.   
 
H2S exposure during 24 min is effective with minor interference with body 
temperature  
Hypothermia, when not induced from external sources, is a result of hypometabolism 
and not the cause of metabolic changes. H2S modulation in the context of acute stroke 
has been associated with induction of hypothermia, especially in protocols that 
included prolonged exposure times (Joseph et al., 2012). In our study, after an 
exposure time of 24 minutes, a mean decrease of 1.85ºC in body temperature was 
observed. Body temperature fully recovered in less than 120 min (Figure 2.3). 
Consequently, hypothermia appears to be a side effect of hypometabolism induced by 
H2S and other mechanisms must be involved since the effects of H2S administration 
were observed until day 14. In the present study, a shorter exposure time than 
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previously reported was effective and the reduced effect on body temperature 
represents an important finding in a translational context since minor changes in body 
temperature will not require patient management in intensive care units. 
 
Study limitations 
We designed this study to fulfill the most recent recommendations for research in 
translational stroke. Animals were randomized and all procedures except surgery were 
performed in a blinded manner to avoid observational bias regarding functional 
outcome, MRI image evaluation, and in-bench procedures, by using codes not known 
to observers. Detailed data is shown to facilitate reproducibility. 
Unfortunately, dosage of H2S in the present study was the same in all animals and 
different dosages might produce distinct effects on outcome. Due to a limited budget 
and the preliminary nature of our study, we were not able to include female or older 
animals or animals with co-morbidities in this study. In the setting of an experimental 
study using rodents, clinical outcome was only assessed by evaluation of motor skills. 
However, we used MRI at 24h as a confirmation tool of successful pMCAO. As such, no 
bias in results can be attributable to surgical failure. The long-term results of H2S 
exposure were not investigated, as study design included comparison of in vivo and 
post mortem data in the acute setting at 24h and after 14d only.  
 
CONCLUSIONS 
In our pMCAO model of ischemic stroke, early exposure to hydrogen sulfide after focal 
brain ischemia improved functional outcome and decreased infarct size. Regarding 
brain imaging, perfusion MRI in rats exposed to H2S revealed improved cerebral blood 
flow, while diffusion MRI showed spots of heterogeneity inside ischemic lesions in ADC 
maps, including central regions. Heterogeneity in ADC maps corresponded to better 
functional outcome as well as smaller lesions and better ischemic tissue preservation 
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in treated rats. Consequently, in a translational context where acute imaging is crucial 
for acute therapeutic decisions, prognostic relevance of ADC heterogeneities may be 









                                                                        
 
Figure 2.1. RATS EXPOSED TO H2S SHOW BETTER FUNCTIONAL OUTCOME AND 
SMALLER LESION SIZE. A. Rats exposed to H2S (black bars) had significantly lower score 
in Rogers scale (left graph)) at 24h (***P<0.001) and at 14d (*P<0.05) and more 
latency to fall from Rotarod (right graph) at 24h (*P<0.05) and at 14d (*P<0.05). B. At 
14d rats exposed to H2S ( black bars) had significantly smaller ischemic lesion size, both 
in MRI (T2 weighted sequence) (left graph) (***P<0.001) and H&E stain (right graph) 
(**P<0.01). At 24h, MRI showed a lower but non-significant difference in lesion size 
(left graph), whereas H&E showed a significantly smaller ischemic lesion after H2S 
exposure (**P<0.01)(right graph).    
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Figure 2.2. RATS EXPOSED TO H2S SHOW BETTER INTRALESIONAL CBF AT 24H. Upper 
and lower left: Diffusion-weighted imaging MRI (ADC maps). Rats exposed to H2S 
showed heterogeneities in ADC maps (upper right) whereas control rats showed 
homogeneous ischemic lesions (upper left). ADC maps in rats exposed to H2S showed 
islands of ADC diffusion coefficient in central lesion area, similar to ADC observed in 
peripheral areas (lower left big image). For quantification, three manually designed 
Region of Interest (ROIs) were considered on ADC maps: ROI 1, ischemic central lesion 
area; ROI 2, peripheral lesion area; ROI 3, contralateral hemisphere (lower left small 
image). Animals exposed to H2S showed similar differential ADC coefficients (rADC) in 
central and peripheral lesion areas. In controls, rADC was lower in central lesion area 
(lower left graph).Lower right: Perfusion-weighted imaging MRI (CBF). CBF showed  
improved intralesional perfusion in rats exposed to H2S (lower right image), being the 
difference between intralesional and contralateral hemisphere CBF (ΔCBF) significantly 








Figure 2.3. BODY TEMPERATURE DURING EXPERIMENTS IN RATS EXPOSED TO H2S 
(LOWER GRAPH) AND CONTROLS (UPPER GRAPH). No difference in body temperature 
2h after exposure to hydrogen sulfide was observed.  AXIS LEGEND: Before: rectal 
temperature in awake rats before starting surgery; After surgery: rectal temperature 
after surgery, before entering the box with atmosphere enriched with 40 ppm H2S 
(please see Methods for exposure to H2S conditions). Out of Box: Rectal temperature 
after getting out of the box, 24 minutes later. 1h after and 2h after: rectal temperature 
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3. HYDROGEN SULPHIDE PROTECTION AFTER ACUTE ISCHEMIC STROKE INCLUDES 
REACTIVE OXYGEN SPECIES (ROS) MODULATION WITH DECREASED EXPRESSION OF 
NOX-4 
INTRODUCTION  
H2S is endogenously produced in different organs including the brain (Mani et al., 
2013) and regulates oxygen consumption by competing with O2 in binding to 
cytochrome C oxidase at the mitochondrial electron transport chain (Szabó, 2007). H2S 
is also involved in neuronal and glial communication (Mikami et al., 2011) and in local 
vasotone regulation (Leffler et al., 2011). Being a gas, it can diffuse and cross 
membranes, allowing quick interaction with intracellular mechanisms. Its role as an 
oxygen sensor further enhances its potential as a pharmacological tool in ischemic 
stroke (Olson et al., 2013). Yet, data about the potential benefit of H2S in the context 
of acute ischemic stroke is scarce and conflicting.  
We hypothesized that inducing a reversible hypometabolic state after acute cerebral 
ischemia through exposure of H2S after pMCAO, could limit acute ischemic brain 
damage. We showed that short-term exposure to H2S after pMCAO improves 
functional outcome and decreases infarct size. Interestingly, DWI MRI ADC maps 
revealed a different intralesional pattern compared to controls and PWI MRI showed 
higher intralesional cerebral blood flow. To better understand if, and when, H2S can be 
protective in the context of acute ischemic stroke, it is needed to dissecate the 
mechanisms by which H2S modulates brain ischemia. 
In the current study, we investigated the effects of short-term H2S exposure after 
permanent middle cerebral artery occlusion (pMCAO) by analyzing markers of 
cytoprotection and repair. We completed the study with in vivo brain imaging (MRI) 
and compared it to post-mortem immunohistochemical analysis.  
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MATERIALS AND METHODS  
All experiments were designed to minimize animal suffering in compliance with the 
ARRIVE criteria and our medical school’s Ethical Committee for the Care and Use of 
Animals in Research (EU directives 86/609/CEE and 2003/65/CE). Regarding all 
procedures, researchers were blinded to group allocation after randomization. Male 8 
- 12 weeks old Sprague-Dawley rats (250 to 320g) (Charles River©, Spain) were 
randomly assigned to three groups:  sham (craniotomy, n=13), control (craniotomy + 
pMCAO, n=23) and treated (craniotomy + pMCAO + exposure to 40 ppm H2S, n=28). 
Rats were anesthetized with the halogenated general inhalation anesthetic drug 
Sevoflurane {[fluoromethyl 2, 2, 2,-trifluoro-1-(trifluoromethyl) ethyl ether] [1, 1, 1, 3, 
3, 3-hexafluoro-2-(fluoromethoxy) propane]}. Its median alveolar concentration (the 
concentration at which half of the subjects do not move in response to a skin incision) 
is 2.5 (+/-0.3) volumen %. We performed  pMCAO after a small craniotomy above the 
rhinal fissure over the branch of the right middle cerebral artery (MCA), exposing MCA 
and permanently ligated with a 9-0 silk suture before its bifurcation, in order to 
enhance reproducibility. After MCAO, both common carotid arteries are temporarily 
occluded for 60 min with a lace of a 6-0 silk suture. Scar size and location were equal 
for all groups, animal cages had no information about group allocation, and codes 
were used in post mortem samples, in order to maintain blinded data collection and 
analysis. Body temperature and glycemia were measured throughout procedures. Rats 
were sacrificed at 24h and 14d after surgery. 
 
Gas mixtures 
Treated animals were exposed to H2S 3 hours after acute ischemia and breathed a 
mixture of atmosphere with hydrogen sulfide [Gasin medical bottles, 40 ppm H2S in 
nitrogen (N2: 99, 9%)] during 24 min inside a closed box (9.5 x 20 x 10 cm = Volume 
1,900 cm3). Pressure output of hydrogen sulfide was 1 bar/30s. Control and sham 
animals breathed normal atmosphere in the same temperature and humidity 
conditions. When this study was designed, no data was available regarding time and 
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dosage of H2S exposure and its efficacy in pMCAO. Thus, we established an effective 
dose by exposing healthy rats to progressive doses of H2S. Our variables were H2S 
concentration (40 and 80 ppm), time of exposure (from 1 to 90 min), and output 
pressure (1 to 2 bar). We used rectal temperature before and after exposure as an 
indirect measure of change into hypometabolism and established an exposure time of 
24 minutes under a concentration of 40ppm with an output pressure of 1 bar/30s as 
standard dosage.  
 
Ischemic lesion size          
Lesion size was evaluated in vivo at 24h and 14d using T2-weighted sequence MRI and 
post mortem by hematoxylin and eosin (H&E) stains, as previously described 
(Gutiérrez-Fernández et al., 2011). 
 
Magnetic Resonance Imaging  
The extension of ischemic lesions was analyzed non-invasively after 24h (group 
sacrificed at 24h) and twice, after 24h and 14d (group sacrificed at 14d), using T2-
weighted images. The observer was blinded to allocation of animals in all cases. After 
contrast adjustment, the contours of the hemispheres were traced manually on each 
slice. Data analysis was performed using Image J software from NIH Image, slice-by-
slice contouring at lesion site and in the contralateral hemisphere in the same location. 
Only lesions larger than 2mm x 2mm x 2mm were analyzed to minimize partial volume 
effects. We used JPG® region of interest (ROI) to measure infarct size. To correct for 
brain edema effect, lesion size was determined by an indirect method: (infarct area) = 
(area of the intact contralateral hemisphere) – (area of the intact ipsilateral 
hemisphere). Lesion size was expressed as percentage of total size of the ipsilateral 
hemisphere. Exclusion criteria were no measurable lesion on MRI except for the sham 
group, and animals were sacrificed and excluded from the sample (n=3). We therefore 
114 |  
 
used T2-weighted MRI at 24h as confirmation tool for successful ischemic lesion 
induction.  
MRI images were acquired on a 7 Tesla/16 cm Bruker Avance III system (Bruker 
Medical Gmbh, Ettlingen, Germany) at the MR Imaging Facility (SIERMAC, 
http://www.siermac.es) from the Institute for Biomedical Research “Alberto Sols” 
CSIC/UAM, Madrid, Spain. The magnet was equipped with a 1H selective birdcage 
resonator for rat head (38mm) and a gradient coil insert (90 mm, maximum intensity 
36 G/cm). Anestesia was induced in a plexiglass chamber with 2%-3% isoflurane mixed 
with oxygen and maintained during the experiment through a nose mask. The 
physiological state of the rats was monitored during MRI acquisitions with a Biotrig 
physiological monitor (Bruker)   depicting on-line the respiratory rate.  
Axial T2-weighted spin echo images were obtained using a rapid acquisition with 
relaxation enhancement (RARE) sequence in axial and coronal orientations using the 
following parameters: Number of echo images 2 (TE: 29.54ms and 88.61ms), TR = 3000 
ms, RARE factor = 4, Av = 3, FOV = 3.5 cm, acquisition matrix = 256 × 256 
corresponding to an in-plane resolution of 136 × 136 μm2, slice thickness = 1.00 mm 
without gap.  
Diffusion-weighted magnetic resonance images (DWI) were obtained in three 
ortoghonal orientations as defined by the read, phase and slice encoding gradients 
using a multishot spin-echo echo planar imaging (EPI) sequence. Acquisition conditions 
were; diffus
3000ms; TE: 50ms, FOV: 3.8cm; axial slices (1.5mm thickness) and 3 b values: 100, 400 
and 1000 s/mm2; acquisition matrix = 128 × 128 corresponding to an in-plane 
resolution of 296 × 296 μm2.  
Dynamic susceptibility contrast – Magnetic Resonance Imaging (DSC MRI) was 
performed using a bolus injection of paramagnetic contrast agent (Gd-DTPA; 
Magnevist, Bayer Schering Pharma AG, Leverkusen, Germany; 0.3mmol/Kg i.v.). 
Dynamic changes in signal intensity were used to calculate CBF (cerebral blood flow), 
CBV (cerebral blood volume, the fraction of tissue volume occupied by blood) and MTT 
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(mean transit time: MTT=CBF/CBV, the time it takes for blood to pass through the 
vasculature within the tissue of interest). Dynamic T2-weighted images were acquired 
using a spin-echo single shot echo planar imaging (EPI) sequence with the following 
scan parameters: TR/TE of 250/7ms; Flip angle: 30º; Number of repetitions: 150; slice 
thickness and interslice gap: 1.5mm and 0.1mm; number of slices: 6; FOV: 3.8cm and 
matrix size: 86x8. After an initial baseline period of 10s, a rapid bolus injection of Gd-
DTPA was administered intravenously in the tail vein.  
ADC, CBF, CBV and MTT pixel by pixel maps were generated with a homemade 
software application (MatLab®, 2007a). ADC value was computed for each voxel using 
the exponential model according to the expression: Sb = S0 e
−b*ADC, where Sb is signal 
intensity with the different b weightings and So the signal intensity for b=0. Perfusion 
parameters were calculated based on the premise that ΔR* is proportional to the 
contrast agent concentration according to the curve equation: ΔR*= -K. ln [ S(t) / So 
(t)], where S(t) is de signal intensity at time t, So baseline signal intensity and, K a 
constant. The transit curve was then fitted to a gamma variant function.  
The mean and standard deviation of ADC of the central and peripheral lesion area 
were determined, and the same measurement performed in the same anatomic 
location as the lesion but in the normal contralateral hemisphere. These three regions 
of interests (ROIs) are easy to identify on color coded ADC maps and drawn manually 
over the maps. The ROIs were applied on all affected ADC slices from each rat with a 
maximum number of five slices. The mean ADC values of central and peripheral lesion 
areas were divided by the value of the contralateral normal hemisphere and expressed 
as a relative ADC (rADC).  
Perfusion-weighted MR imaging was performed using bolus tracking and resulting data 
used to generate CBF, CBV and MTT maps. In these maps only two ROIs were 
investigated: ischemic lesion and contralateral normal hemisphere, because of the 
smaller matrix size (86*86) than in ADC maps, hindering the selection of central and 
peripheral lesion areas. The mean CBF values of the ischemic region were divided by 
the value of the contralateral normal hemisphere used as reference region and 
expressed as relative CBF (rCBF).  
116 |  
 
Cell death 
Cell death was assessed by TUNEL staining (biotin-dUTP nick end-labeling mediated by 
terminal deoxynucleotidyl transferase; TdT-FragEL DNA Fragmentation Detection Kit, 
Oncogene Research Products) following manufacturer’s instructions. The number of 
positive cells was counted using a 40× objective and image analysis software (Image-
Pro Plus 4.1®, Media Cybernetics) in the ischemic lesion. Blind access to group code 
was done in all microscopic observations and all samples were independently counted 
by at least two of the authors. 
 
Immunohistochemistry, immunofluorescence and western blot 
We used markers for NADPH oxidase 4 (NOX-4), neuronal nuclei (NeuN), astrocytes 
[glial fibrillary acid protein (GFAP)], vascular endothelial growth factor (VEGF), 
synaptophysin, superoxide dismutase 2 (SOD-2) and heat shock protein 27 (HSP-27). Β-
actine loading (1:400, Sigma-Aldrich) was used as control. 
 
NOX-4 
Pro-oxidant enzyme, NADPH oxidase 4 (NOX-4) primary polyclonal antibody anti-Nox-4 
(1:1000, Abnova) was incubated for1 hour at room temperature. 
 
Immunofluorescence 
Serial coronal sections were cut at 10μm in a cryostat (Leica CM1950) and studied by 
immunofluorescence neuronal markers. Markers for neuronal nuclei (NeuN) 
(monoclonal antibody diluted 1:100, Millipore), astrocytes [glial fibrillary acid protein 
(GFAP) (monoclonal antibody diluted 1:400, Chemicon)], vascular growth [vascular 
endothelial growth factor (VEGF) marker (polyclonal antibody diluted 1:500, 
Millipore)], synaptogenesis [synaptophysin (monoclonal antibody diluted 1:200, Sigma 
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- Aldrich)], Superoxide dismutase 2 (SOD-2) (polyclonal antibody diluted 1:150, 
Abcam®), and Heat shock protein 27 (HSP-27) (monoclonal antibody diluted 1:200, 
Abcam®), followed by goat anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 594 
(1: 750, Molecular Probes, Invitrogen) were used.  
Sections were mounted with a H-1200 VectaShield® mounting medium for 
fluorescence with DAPI (ATOM). Samples were examined using a spectral confocal 
microscope Leica TCS SPE (Leica Microsystems®, Heidelberg, Germany) and the 
confocal images were analyzed using Leica software LAS AF, version 2.0.1, build 2043. 
The images were acquired at maximum confocal projection. 
 
Western Blot  
Animals (n=4 per group) were decapitated and the proteins of the peri-infarct tissue 
and their concentrations were determined using a BCA protein assay kit (Pierce). 
Western-Blot for β-actin (monoclonal antibody diluted 1:400, Sigma Aldrich), NADPH 
oxidase 4 (NOX-4)(polyclonal antibody 1:2000, Abnova), SOD-2 (polyclonal antibody 
diluted 1:5000, Abcam), HSP27 (monoclonal antibody diluted 1:1000, Abcam), GFAP 
(monoclonal antibody diluted 1:500, Chemicon), VEGF (polyclonal antibody diluted 
1:500, Millipore) and synaptophysin (monoclonal antibody diluted 1:400, Sigma)  were 
measured in all groups. To reduce differences between animals, at least three Western 
blots were performed for each animal. In addition, at least three repeated samples 
were always included in every set of experimental samples as internal standards. 
 
Statistical analysis  
Quantitative data are shown as mean ± standard error of the mean (SEM) and 
presented as box and whiskers plots. As data followed a non-normal distribution, the 
Mann–Whitney test was used to compare two samples and the Kruskal–Wallis test to 
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compare more than two samples of the same group or more than 2 groups (SPSS 16 
for Windows®). Values of p<0.05 were considered significant at a 95% confidence level.  
 
RESULTS  
Cell death after exposure to hydrogen sulfide  
Treated rats showed significantly less TUNEL positive cells, both at 24h (367.5 ± 78.03 
vs. 901.25 ± 217.45 p=0.047) and 14d (42.7 ± 7.76 vs. 53.71 ± 6.75 p=0.04) (Figure 
3.1A, Figure 3.2A) in comparison to controls. No sham operated rats showed TUNEL 
positive cells.  
 
Exposure to hydrogen sulfide does not increase brain repair but enhances markers 
associated with brain protection  
At day 14, the group treated with H2S showed no increase in expression of VEGF (0.75 
± 0.22 vs. 0.79 ± 0.18 p= 0.88) or synaptophysin (1.40 ± 0.39 vs.1.29 ± 0.30 p=0.50) 
compared to control group (Figure 3.2B). GFAP showed significantly lower levels at day 
14 in treated animals compared to control (0.36 ± 0.16 vs. 0.77 ± 0.43, p=0.027) (Figure 
3.2B and C).  The levels of SOD2 at day 14 were lower than in the control group (0.66 ± 
0.06 vs. 1.07 ± 0.14, p= 0.05) (Figure 3.2C), but not at 24h (0.788±0.13 vs. 0.90±0.3 
p=0.11) (Figure 3.1B). The levels of NOX-4 were lower in treated rats compared to the 
control group at 24h (0.50 ± 0.12 vs. 1.11 ± 0.28 p=0.03) (Figure 3.1A) and day 14 (0.47 
± 0.21 vs. 1.40 ± 0.46 p=0.049) (Figure 3.2A). HSP-27 levels were lower at 24h in 
treated rats compared to control animals (0.41 ± 0.12 vs. 0.81 ± 0.11 p=0.49) but not at 





Glycemia was assessed immediately after starting the procedure and during surgery 
and was similar in all groups. Body temperature was significantly lower after induction 
of anesthesia in all groups (p<0.05). After an exposure time to H2S of 24 minutes, body 
temperature decreased by 1.85 ºC (mean) but quickly recovered after animals started 
to breathe normal atmosphere; no difference in body temperature was observed at 2 
hours after exposure (Figure 3.3).  
 
DISCUSSION  
We report on the role of short-term exposure to H2S in acute ischemic brain damage. 
Our previous results have shown that exposure to hydrogen sulfide after pMCAO 
improves functional outcome and decreases infarct size and cell death. Now, we 
conclude for that H2S may act very early in the ischemic process, since there were 
lower levels of acute injury-related markers at 24h without enhancement of repair-
associated markers for vasculogenesis, angiogenesis or synaptogenesis at day 14. 
Significant benefit is likely to occur then before major tissue damage develops, 
including modulation of NOX-4, a major generator of reactive oxygen species (ROS) 
and mediator of endothelial dysfunction. 
 
H2S exposure during 24 min is effective with minor interference with body 
temperature  
Hypothermia, when not induced from external sources, is a result of hypometabolism 
and not the cause of metabolic changes. H2S modulation in the context of acute stroke 
has been associated with induction of hypothermia, especially in protocols that 
included prolonged exposure times (Joseph et al., 2012). In our study, after an 
exposure time of 24 minutes, a mean decrease of 1.85ºC in body temperature was 
observed. Body temperature fully recovered in less than 120 min (Figure 3.3). 
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Consequently, hypothermia appears to be a side effect of hypometabolism induced by 
H2S and other mechanisms must be involved since hypothermia during 2 hours may 
not explain all the effects of H2S administration observed at least until day 14. In the 
present study, a shorter exposure time than previously reported was effective and the 
reduced effect on body temperature represents an important finding in a translational 
context since minor changes (less than 2º Celsius) in body temperature will not require 
stroke patient management in intensive care units. 
 
H2S exposure protects brain tissue and does not enhance repair markers after 
pMCAO  
Previous in vitro studies have shown that the use of D-cysteine (a biosynthetic pathway 
for H2S production) was associated with attenuation of ischemia-reperfusion injury in 
the kidney (Shibuya et al., 2013). Also in a murine primary cortical neuron preparation 
ischemic neuronal death was prevented using a H2S-releasing NMDA receptor 
antagonist (Marutani et al., 2012). Additionally, rats pre-treated with diallyl sulfide 
showed a significant decrease in TUNEL positive cell count (Lin et al., 2012). Our study 
confirmed that markers for cell death depict significantly less expression in treated 
animals.  
HSP27 is a stress-related protein known to be differentially expressed after stroke 
(Stetler et al., 2012). Genomic studies have already highlighted that several 
chaperones including HSP27 were upregulated at 24h, both in the core and peri-infarct 
areas (Ramos-Cejudo et al., 2012). Others reported that neuronal expression of 
another HSP (HSP 70) was associated with ischemic penumbra and core, using a 
reporter mice model (de la Rosa et al., 2013). Also a study with reperfusion in cardiac 
ischemia showed that HSP27 expression was lower in H2S-treated pigs (Osipov et al., 
2009). In the present study, we observed less expression of HSP27 at 24h after pMCAO 
in rats exposed to H2S, associated with markers of tissue preservation, reflecting an 
additional indication of a possible protective role for H2S. 
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It is known that oxidative stress causes tissue damage in the context of acute brain 
ischemia with ROS expressed above physiological levels (Kleinschnitz et al., 2010; 
Moskowitz et al., 2010). ROS downregulation after exposure to H2S was reported in 
ischemia-reperfusion models, after hemorrhagic shock (Ganster et al., 2010), and 
during lung transplantation (George et al., 2012). NOX-4 is a major source of oxidative 
stress in ischemic stroke (Kleinschnitz et al., 2010). In our study, NOX-4 levels were 
lower at 24h and day 14 in treated rats. Thus, the protective effect of H2S after acute 
brain ischemia is maintained in time and may modulate early ROS expression. 
Interestingly, also less expression of SOD2 was observed at day 14, which could be 
related to reduced ROS production during the acute phase of ischemic stroke.  
Finally, GFAP levels were  lower in rats exposed to H2S, suggesting that early protection 
may be related to preservation of tissue structure and less glial scar, since we did not 
find increased levels of repair-associated markers implicated in synaptogenesis, 
vasculogenesis or angiogenesis at day 14.  
 
CONCLUSIONS 
In our pMCAO model of ischemic stroke, early exposure to hydrogen sulfide after focal 
brain ischemia decreased cell death expression through processes that involve 
modulation of NOX-4, a major enzyme generator of reactive oxygen species. H2S 
probably acts very early after administration, since lower levels of acute injury-related 
markers were present at 24h, without increase of repair-associated markers for 
vasculogenesis, angiogenesis or synaptogenesis at day 14. Significant benefit is likely to 
occur before major tissue damage has taken place. Since H2S donors exist already for 









Figure 3.1. RATS EXPOSED TO H2S AFTER pMCAO SHOW LOWER EXPRESSION 
OF CELL DEATH, NOX-4 AND HSP27 AT 24H. A. Decreased expression of cell 
death (*P<0.05) and of NOX-4 in rats exposed to H2S. B. Decreased 
expression of heat shock protein 27 (HSP 27) in treated rats (*P<0.05). No 
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Figure 3.2. DECREASED EXPRESSION OF CELL DEATH AND ROS GENERATING ENZYME 
NOX-4 AT 14D IN RATS EXPOSED TO H2S A. At 14d, cell death (*P<0.05) and NOX-4 
expression levels (*P<0.05) were significantly lower in rats exposed to H2S B. 
Significant lower levels of NOX-4 (*P<0.05), SOD2 (*P<0.05) and GFAP (*P<0.05) were 
present at day14 in rats exposed to H2S. No significant  differences were observed in 











Figure 3.3. BODY TEMPERATURE DURING EXPERIMENTS IN RATS EXPOSED TO H2S 
(RIGHT GRAPH) AND CONTROLS (LEFT GRAPH). No difference in body temperature 2h 
after exposure to hydrogen sulfide was observed.  GRAPH LEGEND: Before: rectal 
temperature in awake rats before starting surgery; After surgery: rectal temperature 
after surgery, before entering the box with atmosphere enriched with 40 ppm H2S 
(please see Methods for exposure to H2S conditions). Out of Box: Rectal temperature 
after getting out of the box, 24 minutes later. 1h after and 2h after: rectal temperature 
one and two hours after exposure to H2S. All rats showed significant differences before 
and after surgery (***p<0.0001). Rats exposed to H2S showed a significant decrease in 
body temperature after surgery (***p<0.0001) until one hour (*p<0.05). No difference 
in rectal temperature was observed 2h after exposure. 
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4. INTRALESIONAL PATTERN OF MRI ADC MAPS PREDICT OUTCOME IN 
EXPERIMENTAL STROKE  
INTRODUCTION 
After acute ischemia, viable tissue at risk of infarction can be detected by perfusion 
weighted imaging/diffusion weighted imaging (PWI/DWI) mismatch but the time 
needed to process PWI limits its use in the acute clinical setting. However, acute 
ischemic stroke can produce different types of intralesional patterns in DWI (Rivers et 
al., 2006). In ADC maps, those patterns can be either homogeneous or patchy and 
heterogeneous. Since DWI is highly sensitive to tissue damage, we hypothesized that 
these two patterns in ADC maps represent ischemic areas with a different potential for 
recovery after acute ischemia and consequently predict functional outcome after 
acute ischemia.  
In the present study, we evaluated the correlation between different patterns in MRI 
ADC maps, functional outcome, and immunohistochemical markers of tissue damage 
to further confirm that different patterns relate to a distinct potential for brain tissue 
recovery despite the same infarct size and interval after permanent middle cerebral 
artery occlusion (pMCAO).  
 
MATERIAL AND METHODS  
Ethical committee, animal rights 
All procedures were carried out at our Cerebrovascular and Neuroscience Research 
Laboratory at La Paz University Hospital, Universidad Autónoma de Madrid, Spain, and 
at the Animal Imaging Department (SIERMAC®, Consejo Superior de Investigación 
Científica), Madrid, Spain. All experiments were performed in compliance with the 
Ethical Committee for the Care and Use of Animals in Research rules following the 
International Guidelines for the Care and Use of Laboratory Animals (Royal Decree 
(R.D.)1201/2005 and European Directive 2010/ 63/UE). The experiments were 
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designed to use the smallest number of animals possible and to minimize their 
suffering in accordance with the ethical standards of the Helsinki Declaration of 1975. 
We included post-surgery analgesia for all groups until sacrifice at 24h. All operated 
rats (sham and pMCAO) had a cranial suture of the same dimension and on the same 
side (right craniotomy), and we used group allocation codes in order to keep 
observation blinded to group allocation while collecting functional data and 
performing molecular and histological procedures.  
 
EXPERIMENTAL PROCEDURES  
Surgical model of pMCAO  
Rats were anesthetized using halogenated general inhalation anesthesia with 
Sevoflurane® {[fluoromethyl 2, 2, 2,-trifluoro-1-(trifluoromethyl) ethyl ether] [1, 1, 1, 3, 
3, 3-hexafluoro-2-(fluoromethoxy) propane]}. We performed pMCAO after a small 
craniotomy above the rhinal fissure over the branch of the right middle cerebral artery 
(MCA). We exposed the homolateral MCA and permanently ligated it with a 9-0 silk 
suture immediately before its bifurcation, in order to enhance reproducibility including 
similar lesion size. After MCAO, both common carotid arteries were temporarily 
occluded during 60 min with a lace of a 6-0 silk suture.  
 
Subject selection criteria & data collection tools 
Animals 
Adult male Sprague-Dawley rats, 10 to 12 weeks old, with an average body weight of 
250 to 320 g (Charles River® S.L., Barcelona, Spain) were housed with free access to 
standard rat chow and water. Room temperature was maintained at 21±2°C, with a 
relative humidity of 45±15%  and a light/dark cycle of 12/12 h (7:00h to 19:00h/19:00h 
to 7:00h). Rats were randomly assigned to the following groups: sham surgery 
(craniotomy) and permanent middle cerebral artery occlusion (pMCAO). At 24h, T2-
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weighted MRI was performed in order to confirm complete MCAO infarct and evaluate 
infarct size in animals submitted to pMCAO. Rats submitted to pMCAO were then 
further divided into 2 groups according to the result of the DWI MRI ADC maps: group 
1 if heterogeneities were present inside the ischemic lesion at least in more than 2/3 
of the lesion in ADC maps (subgroup "heterogeneous"), and group 2 if DWI showed a 
homogenous lesion in ADC maps (subgroup "homogeneous"). The number of rats 
submitted to surgery was progressively increased until a minimum of 12 animals was 
reached in both groups.  
 
Functional evaluation scales  
Functional evaluation scales were performed before procedures at baseline and at 
24h. All rats were evaluated using a variant of the Rogers’ scale and the Rotarod 
performance test™ (accelerating course of 4- 40 rpm). We used previously validated 
functional scales to minimize observational bias in semi-quantitative scales by 
maintaining blindness to allocation group in all observations. We performed similar 
size cranial and neck scars for all groups and used cage codes regarding group 
allocation. 
 
Ischemic lesion size measurements                            
Lesion size was measured at 24h, in vivo by T2-weighted magnetic resonance imaging 
(MRI) and post-mortem by hematoxylin and eosin (H&E) stain after processing of tissue 
samples. We used Image J® software to analyze and measure the Regions of Interest 
(ROI), employing an 8-bit grayscale or indexed color, 16-bit unsigned integers, 32-bit 
floating-points and RGB color.  
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Measurement of ischemic size by hematoxylin & eosin (H&E) staining 
Post-mortem lesion size was estimated by H&E stain of brain sections at 24h. Brains 
were sectioned at the optic chiasm and at the infundibular stalk. A digitalized image 
was obtained from these slices (Epson® Perfection 1260 scanner) to automatically 
measure the ischemic area (Image Pro plus 4.0, Media Cybernetics, USA), as previously 
described (Gutiérrez-Fernández et al., 2011). 
 
Magnetic resonance imaging 
We used T2 sequence diffusion-weighted imaging (DWI) including apparent diffusion 
coefficiency (ADC) maps and tractography, as well as perfusion-weighted imaging 
(PWI) with determination of cerebral blood flow (CBF), cerebral blood volume (CBV), 
and mean transient time (MTT). 
The extension of the ischemic lesions was analyzed at 24h using T2-weighted images. 
After contrast adjustment, the contours of the hemispheres were traced manually on 
each slice. Analysis of the data was performed using Image J® software from NIH 
Image, slice- by-slice lesion contouring of the lesion and the contralateral hemisphere 
in the same location as the lesion. Only lesions larger than 2mm x 2mm x 2mm were 
analyzed to minimize partial volume effects. We used JPG Region of Interest (ROI) to 
measure infarct size. To correct for the brain edema effect, lesion size was determined 
by an indirect method: infarct area = area of the intact contralateral hemisphere – area 
of the intact ipsilateral hemisphere (Swanson et al., 1990; van der Worp et al., 2001). 
Lesion size was expressed as a percentage of the ipsilateral hemisphere. Exclusion 
criteria was no lesion on the 24h MRI except for the sham group. When complete 
MCAO was not confirmed on T2-weighted MRI at 24h, animals were sacrificed and 
excluded from the sample (n=3). We therefore used MRI at 24h as a confirmation tool 
of successful ischemic lesion induction.  
The MRI images were acquired on a 7 Tesla Bruker Pharmascan system (Bruker 
Medical GmbH, Ettlingen, Germany) in the local High Field Magnetic Resonance 
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Spectroscopy and Imaging Facility (SIERMAC®) of the Institute of Biomedical Research 
“Alberto Sols” CSIC/UAM, Madrid, Spain. The system is equipped with a 1H selective 
birdcage resonator of 38mm and a 90mm Bruker gradient coil insert (maximum 
intensity 36 G/cm). Rats were anesthetized with 2% - 3% Isoflurane® mixed with 
oxygen and anesthesia was maintained during the experiment employing a mask. The 
physiological state of the rats was monitored using a Biotrig physiological monitor 
(Bruker) that controlled the respiratory rate. 
T2-weighted spin echo images were generated using rapid acquisition with relaxation 
enhancement (RARE) sequence in axial and coronal orientations and the following 
parameters: Number of echo images 2 (TE: 29.54ms and 88.61ms), TR = 3000 ms, RARE 
factor = 4, Av = 3, FOV = 3.5 cm, acquisition matrix = 256 × 256, corresponding to an in-
plane resolution of 136 × 136 μm2, slice thickness = 1.00 mm, without gap. 
Diffusion-weighted (DW) magnetic resonance images were obtained with three 
different directions defined by the read, phase and slice encoding gradients using a 
multishot spin-echo echo planar imaging (EPI) sequence. Acquisition conditions were 
diffusion gradient duration: 3ms; diffusion gradient separation: 18ms; TR: 3000ms;   
TE: 50ms, FOV: 3.8cm; axial slices (1.5mm thickness) and 3 b values: 100, 400 and 
1000 s/mm2; acquisition matrix = 128 × 128. 
 
Tractography 
Diffusion tensor imaging and fiber tractography were constructed from DTI datasets 
acquired with 30 noncollinear directions for diffusion weighted gradient scheme. At 
24h after pMCAO, data were acquired with a spin echo single shot echo planar imaging 
(EPI) pulse sequence. The receiver bandwith was 300KHz; b factor of 1000 sec/mm2; 
repetition time 8s; echo time: 35ms; 18 contiguous slices with a slice thickness of 
1.5mm; field of view of 3.5 cm x 3.5cm; 128x128 image matrix and a total acquisition 
time was 56 min.  
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We employed DSC (Dynamic susceptibility contrast) MRI with a bolus injection of 
paramagnetic contrast agent (Gd-DTPA; Magnevist, Bayer Schering Pharma AG, 
Leverkusen, Germany; 0.3mmol/Kg i.v.). Changes in signal intensity for dynamic data 
were used to calculate CBF (cerebral blood flow), CBV (cerebral blood volume: as 
fraction of tissue volume occupied by blood) and MTT (mean transit time; 
MTT=CBF/CBV, as time that it takes for blood to pass through the vasculature within 
the tissue of interest). Dynamic T2-weighted images were acquired using a spin-echo 
single shot echo planar imaging (EPI) pulse sequence with the following scan 
parameters: TR/TE of  250/7ms; flip angle: 30º; number of repetitions: 150; slice 
thickness and interslice gap: 1.5mm and 0.1mm; number of slices: 6; FOV:  3.8cm and 
matrix size:  86x86. After an initial baseline period of 10s, a rapid bolus of Gd-DTPA 
was administered intravenously.  
ADC, CBF, CBV, and MTT maps were generated with a homemade software application 
(MatLab, R2007a), and tractography with MedINRIA software (MedINRIA Ver. 2.0.1, 
available free at http://www-sop.inria.fr/asclepios/software/MedINRIA/).  
ADC value was computed for each voxel using the exponential model according to the 
expression: Sb = S0e
−b*ADC, Sb: signal intensity versus the b factor and So: signal 
intensity versus b=0. Perfusion parameters were calculated based on the premise that 
∆R* is proportional to the contrast agent concentration according to the curve 
equation:   ∆R*= -K ln [S(t) / So (t)], where S is de intensity signal at time, So  baseline 
intensity signal and K a constant. The curve was fitted to a gamma variant function. 
ADC values of the central and peripheral lesion area of acute DWI were measured and 
the mean and standard error of the mean (SEM) calculated. The same measurement 
was done in the normal contralateral hemisphere in the same anatomic location as the 
lesion. The three regions of interests (ROI) are easy to identify on color ADC maps and 
were drawn manually on maps. The ROI were applied at all affected ADC slices in each 
rat with a maximum number of five slices. The mean ADC values of central and 
peripheral lesion areas were divided by the value in the contralateral normal 
hemisphere and expressed as a relative ADC (rADC) of the region. 
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As described above, MRI PWI was performed using bolus tracking and resulting data 
were used to obtain CBF, CBV and MTT maps. Here, we only used two ROI: ischemic 
lesion and the contralateral normal hemisphere, as the matrix size (86*x86) was 
smaller than in ADC maps, making it impossible to select the central and peripheral 
lesion areas. The mean CBF value of the ischemic region was divided by the value from 
the contralateral normal hemisphere as reference region and expressed as relative CBF 
(rCBF).  
We calculated PWI/DWI mismatch by the standard volumetric model (mismatch = 




Cell death was detected by TUNEL staining (biotin-dUTP nick end-labeling mediated by 
terminal deoxynucleotidyl transferase; TdT-FragEL DNA Fragmentation Detection Kit, 
Oncogene Research Products) following the methodology indicated by the 
manufacturer. Blind access to group code was employed in all microscopic 




Pro-oxidant enzyme, NADPH oxidase 4 (NOX-4) primary polyclonal antibody anti-Nox-4 
(1:1000, Abnova, Heidelberg, Germany) was incubated for one hour at room 
temperature. The slides were then incubated with a secondary antibody (donkey anti-
rabbit antibody diluted 1:50) conjugated with horseradish peroxidase (Chemicon 
International, Temecula, CA, USA) and incubated with 3',3'-diaminobenzidine 
(Invitrogen). 
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Immunofluorescence  
Serial coronal sections were cut at 10μm in a cryostat (Leica CM1950) and studied by 
immunofluorescence neural markers. Markers for neuronal nuclei (NeuN) (monoclonal 
antibody diluted 1:100, Millipore), astrocytes [glial fibrillary acid protein (GFAP) 
(monoclonal antibody diluted 1:400, Chemicon)], vascular growth [vascular endothelial 
growth factor (VEGF) marker (polyclonal antibody diluted 1:500, Millipore)], 
synaptogenesis [synaptophysin (monoclonal antibody diluted 1:200, Sigma - Aldrich)], 
Superoxide dismutase 2 (SOD-2) (polyclonal antibody diluted 1:150, Abcam®), and 
Heat shock protein 27 (HSP-27) (monoclonal antibody diluted 1:200, Abcam®), 
followed by goat anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 594 (1: 750, 
Molecular Probes, Invitrogen) were used.  
All sections were mounted with H-1200 VectaShield mounting medium for 
fluorescence with DAPI (ATOM). Samples were examined using a spectral confocal 
microscope Leica TCS SPE (Leica Microsystems, Heidelberg, Germany) and the confocal 
images were analyzed using Leica software LAS AF, version 2.0.1 build 2043. The 
images were acquired at confocal maximum projection. 
 
Western Blot  
Brain proteins levels were measured in the infarct zone of animals (n=4 per group) and 
its concentration was determined using a BCA protein assay kit (Pierce). Western-Blot 
for NADPH oxidase 4 (NOX-4)(polyclonal antibody 1:2000, Abnova), SOD-2 (polyclonal 
antibody diluted 1:5000, Abcam), HSP27 (monoclonal antibody diluted 1:1000, 
Abcam), GFAP (monoclonal antibody diluted 1:500, Millipore), VEGF (polyclonal 
antibody diluted 1:500, Millipore) and synaptophysin (monoclonal antibody diluted 
1:400, Sigma) were measured in all groups. The units were normalized based on Β-
actin levels (1:400, Sigma-Aldrich). To reduce methodological bias, at least three 





Statistical analysis  
Functional evaluation scores, lesion size, cell death, and protein levels are described as 
mean and standard error of the mean (SEM) and presented as box and whisker plots. 
Since data followed a non-normal distribution in the Shapiro-Wilk test, we selected 
non-parametric tests for data comparison between groups. The Mann–Whitney test 
was used to compare two samples and the Kruskal–Wallis test was employed to 
compare more than two samples in the same group or the same variable in more than 
two groups. Values of p<0.05 were considered significant at a 95% confidence level. 
We used SPSS 16 for Windows for statistical analysis.  
 
RESULTS 
Physiological parameters  
Glycemia was assessed immediately after starting the procedure and during surgery 
and was similar in all groups. Rectal temperature was significantly lower after 
induction of anesthesia in all groups (p<0.05) and maintained at 37±0.5ºC. Mean 
PaCO2 and PaO2 were not significantly different before and after surgical proceedings. 
  
Same lesion size and time after pMCAO: homogeneous versus heterogeneous ADC 
infarct pattern  
At 24 hours after pMCAO, lesion size measured by T2-weighted MRI did not differ 
between groups (heterogeneous vs. homogeneous: 28.99 ± 2.27 vs. 29.55 ±2.72, p= 
0.418). Sham animals showed no ischemic lesion (Figure 4.1B).  
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Better functional outcome in heterogeneous ADC pattern  
Functional assessment was performed before the procedure and at 24h. At baseline, 
Rogers Modified Scale was zero for all animals and the latency to fall in the Rotarod 
test was >120 seconds. Sham-operated animals did not show any functional deficit at 
24h. A better functional outcome was observed at 24h in animals with a 
heterogeneous ADC pattern when compared to animals with a homogeneous pattern 
regarding the latency to fall in the Rotarod test (118.37 ± 31.43 vs. 51.25 ± 30.87, p= 
0.032). No significant differences were observed in the Rogers test (3.43 ± 0.48 vs. 3.57 
± 0.41, p=0.158) (Figure 4.1C). 
 
Less cell death after pMCAO in heterogeneous ADC pattern  
Animals with a heterogeneous ADC pattern expressed significantly less TUNEL positive 
cells at 24h, in comparison to animals a homogeneous ADC pattern (56.25 ± 13.75 vs. 
170.5 ± 61.0, p=0.014) (Figure 4.2A). Sham operated rats did not show TUNEL positive 
cells.  
 
Brain protection associated markers:  homogeneous versus heterogeneous ADC 
pattern 
NOX-4 showed significantly lower expression levels in animals with heterogeneous 
intralesional ADC pattern when compared to homogeneous pattern (2.1 ± 0.367 vs. 
4.693 ± 1.31, p=0.0063) (Figure 4.2B above and Figure 4.2C). The levels of SOD2 at 24h 
were significantly higher in animals with a heterogeneous intralesional ADC type when 
compared to animals with a homogeneous pattern (4.84 ± 1.049 vs. 2.906 ± 0.368, p= 
0.0039) (Figure 4.2B middle and Figure 4.2C). At 24h, the group with a heterogeneous 
intralesional ADC pattern showed a decreased expression of GFAP  when compared to 
animals with a homogeneous pattern; however, the difference was not significant 




DWI: Apparent diffusion coefficients and tractographies - homogeneous versus 
heterogeneous ADC pattern infarct 
Mean relative apparent diffusion coefficients differed between the two different ADC 
patterns. Animals with a heterogeneous pattern showed the higher values and a wider 
variation (844.87 ± 155.402 vs. 537.33 ± 61.15, p= 0.0013). Furthermore, the lowest 
coefficient was observed in a homogeneous lesion and the highest value in a 
heterogeneous one. Additionally, the SEM of apparently diffusion coefficients was 
much larger in heterogeneous lesions (155.4 vs. 61.15) (Figure 4.3 A). DWI 
tractographies showed a more consistent preservation in the fiber reconstruction 
model of ischemic areas in the heterogeneous lesion type (Figure 4.3 B). We observed 
no heterogeneous patterns below an ADC of 600um2/s that in the present sample may 
be considered a cut-off value for irremiadetly lost brain tissue.   
 
Higher intralesional cerebral blood flow in heterogeneous ADC pattern  
CBF inside ischemic lesions differed between the two patterns. Animals with a 
heterogeneous pattern showed the higher values for CBF if compared to animals with 
homogeneous ADC patterns (79.66 ± 32.2 vs. 55.43 ± 16.0, p= 0.0026). The lowest 
value was observed in a homogeneous lesion (14 ml/100g/min) and the highest in a 
heterogeneous lesion (218 ml/100g/min) (examples are shown in Figure 4.3 C). 
 
Larger PWI/DWI mismatch in heterogeneous ADC pattern  
We calculated PWI/DWI mismatch by the standard volumetric model (mismatch = 
%PWI - %DWI volume), measured in each slice that showed the lesion. Then, we 
selected the slice that has the largest lesion size. The observed mismatch was higher in 
the heterogeneous type of pattern when compared to animals with homogeneous 
lesions (7.72 ± 1.94 vs. 2.35 ± 1.45, p=0.007) (examples are shown in in Figure 4.3 D)  
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DISCUSSION  
In the present study we used a rodent model of pMCAO and identified distinct 
intralesional patterns in MRI ADC maps that predicted a different functional outcome 
in lesions of similar size and the same time after ischemic induction. Intralesional 
heterogeneity was related to less expression of cell death and markers of brain tissue 
protection. Animals with heterogeneous patterns in ADC maps showed also a higher 
potential for recovery after acute ischemic infarction when compared to animals with 
the homogeneous type. When assessing PWI/DWI mismatch, homogeneous lesions 
showed a smaller mismatch, allegedly related to a lower probability of recovery of 
ischemic penumbra and a higher probability of progression to definitive infarct. 
(Kakuda et al., 2008; Ogata et al., 2011; Sobesky, 2012). 
In the clinical setting, it is known that acute lesions with the same interval after stroke 
onset and occurring in the same arterial territory do not always show a similar tissue 
fate in subacute imaging neither the same potential for functional recovery (Koyama et 
al., 2014; Malik et al., 2014). Reasons for this discrepancy include differences in 
vascular risk factors, age, preconditioning, and variability in collateral circulation and 
microcirculation response.  
Since futile reperfusion should be avoided in order to minimize the risks of reperfusion 
when they may outweigh the potential benefit, the topic of acute image patterns that 
might differentiate brain tissue fate after acute stroke is a subject of intense debate, 
moreover with the advent of more resources for reperfusion. The introduction of 
mismatch measurement as inclusion criteria for reperfusion in clinical trials included 
significant differences in the definition of mismatch and a somewhat arbitrary 
volumetric difference of 20% between PWI and DWI. Nevertheless, no validation was 
performed that would support this threshold as a tool for stratifying patients or take 
into account that mismatch could serve as a surrogate measure of penumbra (Barber, 
2013; Sobesky, 2012).  
Mismatch between the lesion volume in DWI (attributed to ischemic and irreversibly 
tissue dead) and PWI (decaying but not yet irreversibly lost) has been used to define 
| 145 
 
penumbra (where CBF is reduced and the tissue is at risk of infarction), but the time 
needed to process PWI limits its use in the clinical context. In the present study, we 
were able to show that interpretation of distinct intralesional MRI DWI ADC patterns in 
lesions of the same size might offer useful pre-treatment information without the 
need of using contrast and losing valuable time while processing PWI (Mishra et al., 
2010; Neumann-Haefelin et al., 1999). 
In the present study, we observed that animals with heterogeneous intralesional ADC 
patterns showed higher CBF with larger variations inside the ischemic lesion that will 
reduce the risk for definite infarction. This observation is further supported by the 
better functional outcome in animals with a heterogeneous ADC pattern. Additionally, 
tractographies showed a better preservation in the heterogeneous type. In the clinical 
setting, tractography has also been used to show structural integrity of the 
corticospinal tract and was related to recovery of motor impairment (Borich et al., 
2012; Park et al., 2013). 
In our experimental setting, it was possible to control for the variables lesion size and 
interval after ischemic induction, since the same experimental protocol was used in all 
animals and T2-weighted MRI confirmed lesion size and involved territory. No 
differences between heterogeneous and homogeneous groups were observed 
concerning infarct size. However, we were able to observe significant differences in 
intralesional apparent diffusion coefficients in ischemic lesions of the same size and 
arterial territory. It is known that DWI sequences better reflect anatomical structure of 
tissues (del Zoppo et al., 2011). Moreover, MRI is a bridge between basic science and 
clinical assessment by representing a high resolution anatomical delineation of disease 
at an ionic and molecular level (Barber, 2013). As the heterogeneous type showed 
higher diffusion coefficients that represent a surrogate measure of better anatomical 
tissue preservation, an increased possibility of avoiding definite infarction and 
reversion to well perfused brain tissue can be assumed. Our findings support an 
improved preservation of the intralesional region when ADC maps show a 
heterogeneous pattern in lesions of MCA territory.  
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It would be desirable to identify an ADC threshold that distinguishes heterogeneous 
from homogeneous ADC maps. In our study, no heterogeneous samples were 
observed below 600um2/s ADC. If confirmed in the clinical context, this observation 
may proove usefull in identifying patients with irreversible ischemia, without indication 
for thrombolysis.  
Animals with a heterogeneous pattern showed a better functional outcome measured 
by the latency to fall in Rotarod test. Also in the clinical setting, functional outcome 
after complete MCA occlusion is far from uniform. Several clinical studies 
demonstrated the variability of clinical recovery in patients with lesions of the same 
size and location (Honarmand et al., 2014; Lima et al., 2014). Several explanations for 
this diversity in functional outcome have been brought forward and include individual 
variability in collateral circulation, pre-conditioning, and microcirculation response 
after ischemic insult (Malik et al., 2014; Thompson et al., 2013). However, to our 
knowledge, the relation between heterogeneous patterns in ADC maps and functional 
outcome in the clinical setting has not yet been fully addressed.   
As outlined above, DWI is the MRI sequence that more consistently reflects ionic and 
molecular tissue changes since the effect in the Brownian  movement of water 
molecules is changed in the presence of abnormal anatomical features (Tsang et al., 
2011). Genomic studies demonstrated yet that there is gene expression associated 
with trophic factors and CNS development within the lesion core at 24h after pMCAO, 
suggesting the existence of surviving areas inside the ischemic core (Ramos-Cejudo et 
al., 2012). These findings support the argument that the central region of the ischemic 
territory is not inexorably dead or irreversibly damaged. In the present study, we could 
show differences in the expression of cell death related to different patterns in ADC 
maps with significantly less expression in the group with a heterogeneous pattern. 
Consequently, present imaging data emphasize previous findings of genetic expression 
inside the central areas of the infarct, and, the relation between ADC patterns and 
tissue preservation  requires further exploration.   
Oxidative stress causes tissue damage after acute brain ischemia with overexpression 
of ROS above physiological levels (Kleinschnitz et al., 2010; Moskowitz et al., 2010). In 
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the present study, we analyzed the expression of major ROS producing enzyme NOX-4 
in both groups of ADC patterns and observed significantly reduced expression of NOX-
4 in animals with a heterogeneous pattern in ADC maps. At 24h, we also found a 
higher expression of SOD2, a major scavenger of mitochondrial superoxide, in the 
group with a heterogeneous ADC pattern. SOD2 is synthesized after brain infarction 
and tissue levels were related to lesion size (Murakami et al., 1998). We also observed 
a smaller expression of GFAP in the group with a heterogeneous pattern, albeit not 
significant. After a brain lesion, astrocytes occupy the space that becomes empty after 
phagocytosis has taken place, in order to fill up the empty space and maintain tissue 
structure. Reactive gliosis is part of the healing process but massive gliosis is related 
with worse outcome (Suma et al., 2008). Consequently, the reduced expression of 
GFAP in animals with the heterogeneous pattern is possibly related to a reduced 
ischemic injury.   
Reperfusion of tissue that is no longer able to recover from oligemia to 
normoperfusion exposes stroke patients to risks and may  worsen prognosis instead of 
contributing to improved  functional outcome  (Barlinn et al., 2014; Yoo et al., 2014). 
The penumbra concept includes the premise that acute stroke treatment can avoid 
that part of the ischemic region progresses into infarction. The mismatch lesion 
volume has been used as a surrogate marker of ischemic penumbra and is defined as 
the PWI map that exceeds the isotopic DWI lesion. In clinical practice, PWI/DWI 
mismatch has been employed to evaluate tissue that may recover from acute ischemia 
in order to avoid futile reperfusion (Barlinn et al., 2014; Foley et al., 2010). Previous 
clinical studies based on MRI mismatch profiles assessed its usefulness in predicting 
the clinical response to early reperfusion after rt-PA administration in humans (Albers 
et al., 2006). Unfortunately, overall benefit of mismatch as inclusion criteria for 
reperfusion failed to prove its clinical relevance (Kakuda et al., 2008; Nagakane et al., 
2011).  
Although our study did not address early reperfusion, we observed a pre-treatment 
DWI MRI pattern that distinguishes between improved and impaired functional 
outcome. We found increased PWI/DWI mismatch in ischemic MCA lesions with a 
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heterogeneous pattern in ADC maps indicating a higher potential for reversibility in 
these animals. On the other hand, in animals with a homogeneous pattern, CBF was 
not only below the functional threshold but became as low as 6-15 ml/100g/min. 
Despite the variability that may exist in CBF thresholds in different brain locations, gray 
or white matter, or different age groups, levels as low as 6-15ml/100g/ min correspond 
to thresholds of biochemical biomarkers of protein synthesis inhibition, preference for 
aerobic glycolysis, neurotransmitter release, impaired energy metabolism and terminal 
depolarization with potassium influx. We also observed coherence in our data 
concerning functional outcome and biochemical markers (with less expression of cell 
death and less expression of ROS markers) favoring the group with a heterogeneous 
pattern in ADC maps. Possibly, homogeneous ADC pattern indicate irreversible brain 
damage where reperfusion might be futile or even dangerous. However, research in 
the clinical setting is necessary to confirm our experimental data and validate the 
usefulness of intralesional ADC patterns to predict outcome and identify patients that 
may benefit from reperfusion. Nonetheless, the results of the present study represent 
a promising starting point and may indicate a new tool in pre-treatment decisions in 
the acute stroke setting.  
 
Study limitations and potential bias  
As shown by our experimental data in a pMCAO model of ischemic stroke, the 
heterogeneity in the coefficients of apparent diffusion inside the ischemic lesion 
represents areas with a different potential for recovery. Nevertheless, there is 
significant variability in ADC values depending on the coil systems, imagers, or field 
strengths used for MR imaging that may have to be taken into account when analyzing 
data from different MRI equipments. We used relative ADC values because they are 
more suitable for evaluating diffusion abnormalities than absolute ADC values. 
Moreover, their use in the experimental setting facilitates translational application.   
We used a model of permanent MCAO with high reproducibility as confirmed by equal 
lesion size in both the heterogeneous and homogeneous group. However, our 
experimental model did not include vascular risk factors, older age or female sex.  
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Most importantly, we controlled for time after stroke onset and lesion size, but 
variability in preconditioning or individual variability in collateral circulation or 
intracranial pressure variations that may interfere with microcirculation are difficult to 
assess in an experimental model and may have impact on results.  
 
CONCLUSIONS  
Intralesional patterns of MRI ADC maps in an experimental model of ischemic stroke 
can be classified in heterogeneous and homogeneous patterns. Animals with the same 
infarct size and interval after ischemia but a heterogeneous intralesional ADC pattern 
showed a better functional outcome, a higher expression of markers of brain 
protection, and less expression of cell death. Animals with a homogeneous pattern  
showed a smaller PWI/DWI mismatch with lower probability of recovery from ischemic 
penumbra and an increased progression to definitive infarction. Applied to the clinical 
setting, early identification of tissue at increased risk of irreversible infarction through 
DWI ADC map patterns may assist in acute therapeutic decisions. 
 
  






Figure 4.1. LESION SIZE AND FUNCTIONAL OUTCOME OF TWO DIFFERENT 
INTRALESIONAL PATTERNS OF MRI ADC MAPS: HOMOGENEOUS AND 
HETEROGENEOUS. A. T2 sequence MRI and DWI ADC maps of intralesional 
homogenous (upper images and graphs) and heterogeneous patterns (lower images 
and graphs).  Heterogeneous and homogeneous showed the same infarct size (left 
images), but heterogeneous pattern showed an increased range of ADC coefficients 
(lower graphs)   
B. Lesion size: homogeneous pMCAO, heterogeneous pMCAO and sham groups. For 
the same interval after stroke induction, lesion size was the same in rats with pMCAO 
and different ADC patterns. 
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C. Functional outcome in homogeneous and heterogeneous ADC patterns: 
Maintenance time (sec) in Rotarod test is significantly superior in heterogeneous ADC 
patterns (left graph). No difference observed with Rotarod test (right graph).  
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Figure 4.2. EXPRESSION OF CELL DEATH AND IMMUNOHISTOCHEMICAL MARKERS AT 
24H AFTER PMCAO IN TWO DIFFERENT INTRALESIONAL ADC PATTERNS: 
HOMOGENEOUS AND HETEROGENEOUS. 
A. Expression of cell death by TUNEL: less expression in heterogeneous ADC pattern 
(right image and graph). 
B. Immunohistochemical markers and W/B: Upper images: less expression of NOX-4 in 
heterogeneous pattern (right image). Middle images: less expression of SOD-2 in 
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homogeneous type (left image and white bar in Figure 2 C). Lower images:  less 
expression of GFAP in heterogeneous patterns (right image, grey bar in Figure 2 C). 
C. Western-Blot of NOX-4, SOD-2 and GFAP 24h after pMCAO. Upper: W/B of NOX-4, 
SOD-2 and GFAP (image). Lower: W/B of NOX-4, SOD-2 and GFAP (graph). 
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Figure 4.3. DWI AND PWI MRI OF HOMOGENEOUS AND HETEROGENEOUS PATTERN.  
A. Mean relative apparent diffusion coefficients of homogeneous and heterogeneous 
patterns. Heterogeneous patterns show significantly increased mean ADC values (left 
graph) and clustering of rADC in two different patterns (Box and whisker plots of mean 
rADC, right graph).  
B. Tractography. Homogeneous pattern of intralesional ADC maps (upper image) 
showing more fiber disruption in MCA territory than heterogeneous pattern (lower 
image).  
C. Perfusion MRI after pMCAO: Homogeneous and heterogeneous patterns. 
Homogeneous pattern showed less intralesional CBF (left image and graph) than 
heterogeneous pattern (right image and graph).  
 D. PWI/DWI mismatch. Homogeneous ADC patterns (upper images) show less 
mismatch area when compared to heterogeneous type (lower images). 
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In the present study, we explored the effect of short-term exposure to H2S after acute 
ischemia in an animal model of pMCAO. We hypothesized that hydrogen sulfide 
exposure after acute ischemic stroke modulates ischemic lesion either by an early 
protective effect or by promoting post-ischemic repair. To address our hypothesis we 
exposed rats to H2S after pMCAO and measured functional outcome and infarct size in 
vivo and post-mortem. We identified underlying markers of cytoprotection and repair. 
Finally, we compared brain imaging with immunohistochemical data to look for 
premature imaging features of ischemic tissue damage that may relate to functional 
outcome.  
H2S exposure after pMCAO improved functional outcome and decreased infarct size 
and cell death. H2S may act very early in the ischemic process, since there were lower 
levels of acute injury-related markers at 24h without enhancement of repair-
associated markers for vasculogenesis, angiogenesis or synaptogenesis at day 14. 
Significant benefit is likely to occur before major tissue damage ensues and includes 
modulation of NOX-4, a major generator of reactive oxygen species (ROS) and 
endothelial dysfunction, as well as vasomodulation of intralesional microcirculation 
since intralesional CBF assessed by PWI MRI improved in rats exposed to H2S. Since H2S 
limits brain damage after ischemic stroke, hydrogen sulfide donors may play a role as 
new drugs in the context of acute ischemic stroke.  
 
A main goal in acute stroke treatment is reestablishing previous functional status or, if 
not possible, improve functional outcome. Therefore, endpoints in clinical and 
experimental stroke must provide prove of functional benefit. In the present study, we 
observed a better functional outcome in animals exposed to H2S, both at 24h and day 
14. This observation was in agreement with immunohistochemical data and in vivo 
imaging that showed improved intralesional tissue preservation and smaller lesion size 
in rats exposed to H2S.  
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One of the reasons for failure in proving clinical benefit in previous research regarding 
neuroprotectors in the setting of acute ischemia is linked to the exclusive focus on 
neuron protection. We still nominate brain protection as neuroprotection but recent 
focus of translational stroke research centers on the complexity of interactions in the 
the neurovascular unit and the relevance of collateral circulation and regulation of 
microcirculation broadening the multiplicity of mechanisms involved in regaining 
homeostasis after acute ischemia (Kulik et al., 2008; Terasaki et al., 2013). Also several 
previously identified potential neuroprotectors only interfere with isolated paths of 
the complex ischemic pathophysiology and do not achieve clinical efficacy (Ferro and 
Dávalos, 2006; Moskowitz et al., 2010). H2S possesses several mechanisms of action 
that intervene in the ischemic cascade. The role of H2S in the regulation of 
microvascular tone is well established. It also acts as a sensor of oxygen in normal and 
ischemic brain environment and interferes directly with mitochondrial energy 
mechanism and ROS production. It influences the cascades of apoptosis and necrosis 
through pleotropic mechanisms at different time points and pathways of the ischemic 
cascade (Fu et al., 2012; Luo et al., 2013; Majid et al., 2013; Olson, 2013). This diversity 
of mechanisms contributes to the higher potential of H2S as a candidate with 
substantial efficacy in improving outcome after experimental and clinical stroke.  
Another advantage of H2S derives from being a gas and thus be able to interfere with 
intracellular mechanism without the need of active membrane transportation 
(Bannenberg and Vieira, 2009). Moreover, in the labile cellular energetic balance, quick 
adjustment between energy production and needs may contribute to very early 
protection  before major tissue damage occurs(Szabó, 2007; Szabó et al., 2011).  
In experimental research, the use of in vivo imaging to measure infarct size has the 
advantage of repetitive measurements over time whereas histological techniques only 
can be carried out once in each animal. However, immunohistochemical techniques 
are more precise in identifying distinctive parameters of cell death. Consequently, 
brain imaging in acute stroke benefits from being correlated with histological markers 
and parameters for cell death (Zille et al., 2012).  
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Since ischemia ultimately provokes cell death, the reduction of infarct size and a 
diminished cell death burden after a potential therapeutic intervention possibly 
indicates protection (Ferrer and Planas, 2003). In the present study, the group exposed 
to H2S showed significantly less TUNEL-positive cells in the peri-infarct zone after 
pMCAO, indicative of less cell death, both at 24h and at day 14. As such, our results 
suggest strongly that H2S modulates cell death after acute ischemic injury. This finding 
is additionally supported by a diminished infarct size at day 14 in our post mortem 
data. 
The possibility of measuring in vivo the area of cell death defined as area of definitive 
necrosis was also approached. MRI DWI ADC maps, by measuring coefficients of 
attenuation, reflect preserved or destroyed tissue anatomy and may be used as a 
surrogate of maintenance of tissue structure in vivo (Rojas et al., 2006; Rosso et al., 
2009; Zille et al., 2012). We found a better anatomical preservation of ischemic tissue 
in MRI DWI ADC maps in rats exposed to H2S and an improved functional outcome was 
observed in functional motor scale and score. It is known from clinical studies that 
patient selection according to acute MRI profiles can differentiate subgroups of 
patients that benefit from early reperfusion from those that do not or those for whom 
reperfusion therapy can even be harmful (so called futile reperfusion) (Farr and 
Wegener, 2010). We measured perfusion through MRI PWI inside the ischemic lesion 
and found that CBF was higher in the treated group revealing improved tissue 
perfusion. Higher intralesional CBF was related to both better functional outcome and 
smaller infarct size in the treated group. 
We further observed a pattern of intralesional ADC that consistently discriminated 
between better and worse functional outcome (heterogeneous versus homogeneous), 
probably by differentiating ischemic tissue fate and its potential for rescue. Since 
images were obtained by DWI permitting faster image acquisition and processing if 
compared to PWI, our results regarding ADC patterns represent a translational 
potential for acute stroke treatment in the clinical context through timely 
identification of patients with potential for tissue recovery. Observed heterogeneities 
in ADC coefficients inside the ischemic territory possibly represent previously 
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described areas of "mini-cores and mini-penumbras", a concept that refers to a central 
zone of hypoperfused territory at risk of infarction that shows a variable pattern of 
penumbra evolution with a heterogeneity in molecular and microvascular response 
(del Zoppo et al., 2011). Characteristic ADC patterns with heterogeneous and 
homogeneous lesions in ADC maps may consequently represent areas with a different 
potential for recovery, independently of its localization in the center or in the 
periphery of the ischemic lesion.  
We compared  further ADC hetero- and homogeneities with mismatch extension and 
found a correlation between larger mismatch size and presence of heterogeneous 
patterns in ADC map as suggested in previous studies (Mishra et al., 2010; Ogata et al., 
2011; Sobesky, 2012).  
The presence of a heterogeneous coefficient in ADC maps in the treated group related 
to better outcome highlights the possibility that these heterogeneities could be used 
as a surrogate imaging marker for outcome in the acute pretreatment stroke setting. 
This image marker of favorable outcome may prove beneficial in clinical decision 
making since homogeneous low acute diffusion coefficients inside ischemic lesion 
showed to be predictive for adverse progression from ischemia to necrosis, a situation 
where thrombolysis is futile and potentially harmful (Hussein et al., 2010; Oppenheim 
et al., 2001).   
The hypothermic effect of H2S was described and associated with its beneficial effects 
in the context of stroke, especially in protocols that included prolonged exposure times 
(Joseph et al., 2012).  Nevertheless, hypothermia, when not externally induced, can be 
a consequence of decreased metabolism and not its cause (Szabó, 2007). H2S is known 
to hold temperature-independent properties including arteriolar vasodilatation by 
activation of ATP-sensitive K+ channels of the smooth muscle cell membrane. 
Furthermore, H2S is also able to contribute to the neutralization of excitocicity 
mediated by glutamate through increasing of glutathione in neurons by inducing 
astrocytes to incorporate more glutamate from the extracellular space (Leffler et al., 
2011). Notwithstanding, vasodilatation is exactly the opposite of what we would 
expect if H2S action would be exclusively related to hypothermia observed after 
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exposure (since external hypothermia induces vasoconstriction) (Faridar et al., 2011). 
Furthermore, H2S also protects neurons from secondary neuronal injury by its anti-
oxidant, anti-inflammatory and anti-apoptotic properties (Majid et al., 2013; Szabó et 
al., 2011).  
Despite all benefit and advances that thrombolysis added to the therapy of acute 
ischemic stroke, it is also known that recovery from ischemia is not only a matter of 
reestablishing blood flow inside the occluded artery. The contribution of collateral 
circulation and microcirculation are key determinants of final tissue irrigation and 
ultimate tissue fate of reestablished homeostasis or definite infarct (Kulik et al., 2008; 
Shuaib et al., 2011). H2S does not only interfere with tonus regulation of 
microcirculation via K+- ATPase but is also an oxygen sensor both in the ischemic and 
the healthy brain (Fu et al., 2012; Olson et al., 2013; Zhao et al., 2001). As such, H2S 
can potentially be used alone or in association with thrombolytic therapy.  
In the present study, we observed less expression of ROS associated enzyme NOX-4 
and less cell death together with a better intraregional perfusion and CBF in rats 
exposed to H2S. Therefore, our results suggest that the beneficial effect observed after 
short-term exposure to H2S might not be explained by the concomitant brief and mild 
hypothermia but more appropriately by other temperature-independent mechanisms. 
In our view, the induction of mild hypothermia lasting less than two hours after initial 
exposure, with a mean decrease in body temperature of merely 1.85ºC may represent 
an insufficient explanation for the observed benefit in the treated group. Our 
interpretation is underscored by the fact that we found effects of H2S action like less 
expression of cell death and acute markers of necrosis including ROS production 
enzymes as soon as 24h and as late as day 14. Consequently, hypothermia may be 
rather the consequence of H2S action than its cause. Furthermore, a decrease in body 
temperature of less than 2ºC as observed in the present experimental study would not 
require management inside highly selective and hardly available intensive care units 
beds, if our findings could be reproduced in clinical research and human stroke 
patients.  
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Previous studies of H2S in the context of acute stroke used very long exposure times 
which represents a largely inconvenient aspect if it comes to acute stroke 
management in patients (Joseph et al., 2012). On the contrary, we observed in the 
present study that a much shorter exposure time was effective in reducing infarct size 
and enhancing recovery.  
For many years, pretreatment predictors of good outcome have been looked for since 
they may be useful in clinical decision making together with current NIHSS and time 
elapsed since symptom onset. DWI MRI with ADC maps represents a technique that is 
able to differentiate tissue preservation or destruction in vivo by identifying distinctive 
apparent diffusion coefficients in the ischemic zone that depend on preservation of 
anatomical structure. We studied the hypothesis that different ADC patterns inside 
lesions in the same location, of the same size and with the same chronological 
evolution will reflect different fates regarding tissue ischemia and recovery. Our results 
showed that, although much less common in non-treated group, heterogeneities in 
ADC maps could still differentiate between more and less favorable outcome after 
experimental induction of acute ischemia. In summary, the presence of 
heterogeneities inside an ischemic lesion observed in MRI ADC maps predicts a better 
functional outcome in a pMCAO model of acute ischemic stroke. 
 
Study limitations 
We designed this study to fulfill the most recent recommendations for research in 
translational stroke.  
Because of its high reproducibility, we chose a model of permanent focal brain 
ischemia including craniotomy and permanent artery ligation combined with 
temporary common carotid artery occlusion during one hour. As all rodent models for 
acute ischemic stroke manifest failures regarding volume of infarct area, besides other 
pitfalls (Gerriets et al., 2004), we minimized bias by using MRI as confirmation tool of 
complete ischemic induction in the MCA territory and absence of hemorrhagic 
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transformation. We considered this confirmation crucial since we intended to compare 
lesion size between treated animals and controls.   
We randomized animals to groups and all procedures except surgery were performed 
in a blinded manner by using codes not known to observers to avoid bias regarding 
functional outcome, MRI image evaluation, and all other bench procedures. We gave 
detailed data on procedures to facilitate reproducibility. However, as the time window 
for administration of H2S was limited to 3h after induction of ischemic stroke, no 
conclusions regarding effects outside this interval can be drawn. Exposure dosage of 
H2S in the present study was the same for all animals and different dosages might 
produce distinct effects regarding outcome. Due to a limitation of study design and 
budget and due to the preliminary nature of our study, we were not able to include 
female and older animals or animals with co-morbidities in this study.  
In the setting of an experimental study using rodents, we only can assess clinical 
outcome by evaluation of motor skills, not permitting evaluation concerning other 
signs and symptoms of ischemic stroke. As we used MRI at 24h as a confirmation tool 
of successful pMCAO, no bias can be attributable to surgical failure. We do not report 
long-term results of H2S exposure as study design included comparison of in vivo and 
post mortem data in the acute setting at 24h and after day 14.  
 
Implications and future research 
Regarding future research, we already proposed a prospective observational clinical 
study to test if ADC heterogeneities inside the ischemic lesion in pre-treatment MRI 
represent a candidate for an imagiological pre-treatment marker of a favorable 
prognosis in acute stroke. After confirmation of the reproducibility of our data, we 
further propose a clinical trial with H2S donors that are already available in clinical 
medicine for other purposes like memantine or diclofenac. Primary outcome measure 
should include poststroke functional dependency and death.  
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In our pMCAO model of ischemic stroke, early exposure to hydrogen sulfide after focal 
brain ischemia improved functional outcome and decreased infarct size and cell death 
through processes that involve modulation of NOX-4, a major enzyme generator of 
reactive oxygen species. Regarding brain imaging, perfusion MRI in rats exposed to H2S 
revealed improved cerebral blood flow, while diffusion MRI showed spots of 
heterogeneity inside ischemic lesions in ADC maps, including central regions. H2S 
probably acts very early after administration, since lower levels of acute injury-related 
markers were present at 24h, without increase of repair-associated markers for 
vasculogenesis, angiogenesis or synaptogenesis at day 14. Significant benefit is likely to 
occur before major tissue damage has taken place. Since H2S donors exist already for 
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pattern in ADC maps showed better functional outcome in 
Rotarod test (p = 0.032), less expression of cell death (p = 
0.014) and NOX-4 (p = 0.0063), higher intralesional CBF (p = 
0.0026) and larger PWI/DWI mismatch (p = 0.007).  Conclu-
sions: In a rodent model for ischemic stroke, intralesional 
heterogeneity in ADC maps was related to better functional 
outcome in lesions of similar size and interval after pMCAO. 
DWI ADC maps may assist in the early identification of isch-
emic tissue with an increased potential for recovery as high-
er expression of acute protection markers, lower expression 
of cell death, increased PWI/DWI mismatch, and higher intra-
lesional CBF were present in animals with a heterogeneous 
ADC pattern.   © 2015 S. Karger AG, Basel 
 Introduction 
 After acute ischemia, the viable tissue that is at risk of 
infarction can be detected by perfusion-weighted imaging/
diffusion-weighted imaging (PWI/DWI) mismatch but 
 Key Words 
 Magnetic resonance imaging · MRI · ADC maps · Ischemic 
stroke · Stroke model · Functional outcome · Intralesional 
heterogeneity 
 Abstract 
 Background: After acute ischemia, the tissue that is at risk 
of infarction can be detected by perfusion-weighted imag-
ing/diffusion-weighted imaging (PWI/DWI) mismatch but 
the time that is needed to process PWI limits its use. As DWI 
is highly sensitive to acute ischemic tissue damage, we hy-
pothesized that different ADC patterns represent areas with 
a different potential for recovery.  Methods: In a model of 
permanent middle cerebral artery occlusion (pMCAO), 
Sprague-Dawley rats were randomly distributed to sham 
surgery and pMCAO. We further separated the pMCAO 
group according to intralesional ADC pattern (homoge-
neous or heterogeneous). At 24 h after ischemia induction, 
we analyzed lesion size, functional outcome, cell death ex-
pression, and brain protection markers including ROS en-
zyme NOX-4. MRI included DWI (ADC maps), DTI (tractogra-
phy), and PWI (CBF, CBV and MTT).  Results: The lesion size 
was similar in pMCAO rats. Animals with a heterogeneous 
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the time that is needed to process PWI limits its use in the 
acute clinical setting. However, acute ischemic stroke can 
produce different types of intralesional patterns in DWI 
 [1] . In ADC maps, those patterns can be either homoge-
neous or patchy and heterogeneous. Since DWI is highly 
sensitive to tissue damage, we hypothesized that these two 
patterns in ADC maps represent ischemic areas with a dif-
ferent potential for recovery after acute ischemia and con-
sequently predict functional outcome after acute ischemia. 
 In this study, we evaluated the correlation between dif-
ferent intralesional patterns in MRI ADC maps, function-
al outcome, and immunohistochemical markers of tissue 
damage to further confirm that different patterns are as-
sociated to brain tissue preservation despite the same in-
farct size and interval after permanent middle cerebral 
artery occlusion (pMCAO). 
 Material and Methods 
 Ethical Committee, Animal Rights 
 Procedures were carried out at the Cerebrovascular and Neu-
roscience Research Laboratory at La Paz University Hospital, and 
at the Animal Imaging Department (SIERMAC ® ), Universidad 
Autónoma de Madrid, Spain. Experiments were performed in 
compliance with the Ethical Committee for the Care and Use of 
Animals in Research rules following the International Guidelines 
for the Care and Use of Laboratory Animals (Royal Decree 
(RD)1201/2005 and European Directive 2010/63/UE). The exper-
iments were designed to use the smallest number of animals pos-
sible and to minimize their suffering in accordance with the ethical 
standards of the Helsinki Declaration of 1975. We included post-
surgery analgesia for all groups. All rats (sham and pMCAO) had 
a right cranial suture of the same dimension. Group allocation 
codes were used to keep observation blinded to group allocation 
while collecting functional data and performing molecular and 
histological procedures. 
 Subject Selection Criteria and Data Collection Tools 
 Adult male Sprague-Dawley rats, 10 to 12 weeks old, with an 
average body weight of 250 to 320 g (Charles River ® S.L., Barce-
lona, Spain), were housed with free access to standard rat chow 
and water. Room temperature was maintained at 21 ± 2   °   C, with 
a relative humidity of 45 ± 15% and a light/dark cycle of 12/12 h 
(7: 00–19: 00 h/19: 00–7: 00 h). Rats were randomly assigned to the 
following groups: sham surgery (craniotomy) and permanent 
middle cerebral artery occlusion (pMCAO). After 24 h, T2-weight-
ed MRI was performed in order to confirm complete MCAO and 
equal infarct size in animals submitted to pMCAO. Rats submitted 
to pMCAO were then further divided into 2 groups according to 
the result of the DWI MRI ADC maps: group 1 if heterogeneities 
were present inside the ischemic lesion in more than 2/3 of the 
ADC maps (subgroup ‘heterogeneous’), and group 2 if DWI 
showed a homogenous lesion in ADC maps (subgroup ‘homoge-
neous’). The number of rats submitted to surgery was progres-
sively increased until a minimum of 12 animals was reached in 
both groups. Three rats were excluded from the study because of 
incomplete ischemia in the MCA territory.
 We defined ADC patterns according to qualitative visual criteria: 
heterogeneous pattern if more than 2/3 of the ischemic area was 
 heterogeneous (patchy) and homogeneous pattern for the remain-
ing. Later on, in order to confirm this point, we designed a quantita-
tive method based on a histogram analysis categorization. Briefly, we 
delineated the lesion zone on each slice of ADC maps. Then, we ad-
justed the levels from 0 to 3,000 μm 2 /s (standard values of ADC maps 
from rat brain). All images visually considered homogeneous 
showed differences in ADC values (between minimum to maxi-
mum) below 300 μm 2 /s. All heterogeneous images showed differ-
ences above 300 μm 2 /s. This value was determinated as cut-off for 
this study using the pMCAO experimental model. Quantitative as-
sessment using the apparent diffusion coefficient showed that there 
were no heterogeneous patterns with an ADC value below 630. 
 Experimental Procedures 
 A surgical model of pMCAO was used as previously described 
elsewhere  [2] and physiological parameters were recorded 
throughout the procedure (online suppl. material; for all online 
suppl. material, see www.karger.com/doi/10.1159/000381727).
 Functional Evaluation Scales  
 Functional evaluation scales were performed before proce-
dures at baseline and at 24 h. All rats were evaluated using a variant 
of the Rogers scale and the Rotarod performance test TM (accelerat-
ing course of 4–40 rpm) as previously described  [3] .
 Magnetic Resonance Imaging  
 The extension of the ischemic lesions was analyzed using T2-
weighted MRI. We used diffusion-weighted imaging (DWI) in-
cluding apparent diffusion coefficient (ADC) maps and tractogra-
phy, as well as perfusion-weighted imaging (PWI) with determina-
tion of cerebral blood flow (CBF), cerebral blood volume (CBV), 
and mean transient time (MTT). Relative ADC values were calcu-
lated in comparison with the corresponding contralateral region 
(online  suppl. material). 
 Statistical Analysis  
 Functional evaluation scores, lesion size, cell death, and protein 
levels are described as the mean and standard error of the mean (SEM) 
and presented as box and whisker plots. Data were analyzed using 
the Student’s  t -test or the non-parametric Mann-Whitney test if data 
followed a non-normal distribution in the Shapiro-Wilk test. Values 
of p < 0.05 were considered significant at a 95% confidence level. 
 Results 
 Physiological Parameters 
 Glycemia was assessed immediately after starting the 
procedure and during surgery and it was found to have 
similar values in all groups. Rectal temperature was sig-
nificantly lower after induction of anesthesia in all groups 
(p < 0.05) and maintained at 37 ± 0.5  °  C. Mean PaCO 2 and 
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 Same Lesion Size and Time after pMCAO: 
Homogeneous versus Heterogeneous ADC Infarct 
Pattern  
 At 24 h after pMCAO, the lesion size measured by T2-
weighted MRI did not differ between groups (heteroge-
neous vs. homogeneous: 28.99 ± 2.27 vs. 29.55 ± 2.72, p = 
0.418). Sham animals showed no ischemic lesion ( fig. 1 a, b). 
 Better Functional Outcome in Heterogeneous ADC 
Pattern  
 Functional assessment was performed before the pro-
cedure and at 24 h. At baseline, Rogers modified scale was 
zero for all animals and the latency to fall in the Rotarod 
test was >120 s. Sham-operated animals did not show any 
functional deficit at 24 h. A better functional outcome was 
 Fig. 1. Lesion size and functional outcome in two different intral-
esional patterns of MRI ADC maps after permanent MCA occlu-
sion.  a T2 sequence MRI and DWI ADC maps of intralesional 
homogeneous (upper images and graphs) and heterogeneous pat-
terns (lower images and graphs). Heterogeneous and homoge-
neous showed the same infarct size (left images), but heteroge-
neous pattern showed an increased range of ADC coefficients 
(right).  b Lesion size: homogeneous pMCAO, heterogeneous 
 pMCAO and sham groups. For the same interval after stroke in-
duction, lesion size was the same in rats with pMCAO and differ-
ent ADC patterns.  c Functional outcome in homogeneous and het-
erogeneous ADC patterns: maintenance time (s) in Rotarod test is 
significantly superior in heterogeneous ADC patterns (left graph). 
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observed at 24 h in animals with a heterogeneous ADC 
pattern when compared to animals with a homogeneous 
pattern regarding the latency to fall in the Rotarod test 
(110.37 ± 31.43 vs. 51.25 ± 30.87, p = 0.032). No signifi-
cant differences were observed in the Rogers test (3.43 ± 
0.48 vs. 3.57 ± 0.41, p = 0.158) ( fig. 1 c).
 Less Cell Death Expression after pMCAO in 
Heterogeneous ADC Pattern  
 Animals with a heterogeneous ADC pattern expressed 
significantly less TUNEL positive cells at 24 h, when com-
pared to animals showing homogeneous ADC pattern 
(56.25 ± 13.75 vs. 170.5 ± 61.0, p = 0.014)  ( fig. 2 a). Sham-
operated rats did not show TUNEL positive cells. 
 Brain Protection Associated Markers: Homogeneous 
versus Heterogeneous ADC Pattern 
 NOX-4 showed a significantly lower expression in an-
imals with a heterogeneous intralesional ADC pattern 
when compared to homogeneous pattern (2.1 ± 0.367 vs. 
4.693 ± 1.31, p = 0.0063) ( fig. 2b , c). The levels of SOD2 
at 24 h were significantly higher in animals with a hetero-
geneous intralesional ADC type when compared to ani-
mals with a homogeneous pattern (4.84 ± 1.049 vs. 2.906   ± 
0.368, p = 0.0039) ( fig. 2 b middle, c). At 24 h, the group 
with a heterogeneous intralesional ADC pattern showed 
a decreased expression of GFAP when compared to ani-
mals with a homogeneous pattern; however, the differ-
ence was not significant (2.52 ± 0.53 vs. 4.04 ± 0.71, p = 
0.068) ( fig. 2 b below, c). 
 Apparent Diffusion Coefficients and Tractographies: 
Homogeneous versus Heterogeneous ADC Pattern  
 Apparent diffusion coefficients differed significantly 
between the two ADC patterns and animals with a het-
erogeneous pattern showed higher values (844.87 ± 
155.402 vs. 537.33 ± 61.15, p = 0.0013). Furthermore, the 
lowest coefficient was observed in a homogeneous lesion 
and the highest value in a heterogeneous lesion. No het-
erogeneous lesion type was observed below 630. Addi-
tionally, the SEM of apparently diffusion coefficients was 
much larger in heterogeneous lesions (155.4 vs. 61.15) 
( fig. 3a ). DWI tractographies showed also a more consis-
tent preservation in the fiber reconstruction model of 
ischemic areas in the heterogeneous lesion type ( fig. 3 b).
 Higher Intralesional Cerebral Blood Flow in 
Heterogeneous ADC Pattern  
 CBF inside ischemic lesions differed between the two 
patterns. Animals with a heterogeneous pattern showed 
the higher values for CBF if compared to animals with 
homogeneous ADC patterns (79.66 ± 32.2 vs. 55.43 ± 
16.0, p = 0.0026). The lowest value was observed in a ho-
mogeneous lesion (14 ml/100 g/min) and the highest in a 
heterogeneous lesion (218 ml/100 g/min) ( fig. 3 c).
 Larger PWI/DWI Mismatch in Heterogeneous ADC 
Pattern  
 We calculated the PWI/DWI mismatch using the stan-
dard volumetric model (mismatch = %PWI – %DWI vol-
ume) measured in each slice that showed the lesion and 
selected the slice that had the largest lesion size. The ob-
served mismatch was higher in the heterogeneous pattern 
when compared to animals with homogeneous lesions 
(7.72 ± 1.94 vs. 2.35 ± 1.45, p = 0.007) ( fig. 3 d).
 Discussion 
 We used a rodent model of pMCAO and identified 
distinct intralesional patterns in MRI ADC maps that 
were associated with different functional outcome in le-
sions of similar size and the same ischemic duration. An-
imals with heterogeneous patterns in ADC maps showed 
a better outcome after acute ischemic infarction when 
compared to animals with the homogeneous type. Intra-
lesional heterogeneity was also related to less expression 
of cell death and markers of brain tissue protection. When 
assessing PWI/DWI mismatch, heterogeneous lesions 
showed a larger mismatch, purportedly related to a high-
er probability of recovery of ischemic penumbra and 
without progression to definitive infarction  [4–6] .
 Clinical studies demonstrated inconsistency regarding 
prognosis in patients with lesions of the same size, arte-
rial territory and time after symptoms onset including 
complete MCA occlusion  [7–9] . Several explanations for 
this diversity in functional outcome have been brought 
forward and include individual variability in collateral 
circulation, preconditioning, and microcirculation re-
sponse after ischemic insult  [10, 11] . However, the rela-
tion between heterogeneous patterns in ADC maps and 
functional outcome has not yet been addressed in the 
clinical setting. In our experimental model, rats with the 
same lesion size, territory, and time after ischemic induc-
tion, showed also that kind of diversity, with the hetero-
geneous pattern of ADC maps presenting a better func-
tional outcome. Consequently, patterns of ADC maps in-
dicated different functional prognoses. As MRI DWI 
sequences better reflect anatomical tissue structure  [12] , 
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 Fig. 2. Cell death and immunohistochemical markers at 24 h after 
pMCAO in two different intralesional patterns of MRI ADC maps. 
 a Cell death evaluation by TUNEL: less cell death was observed in 
heterogeneous ADC pattern.  b Immunohistochemical of NOX-4, 
SOD-2 and GFAP markers at 24 h after pMCAO. Less expression 
of NOX-4 was observed in the animals showing heterogeneous 
pattern (upper images). Less expression of SOD-2 was observed in 
animals showing homogeneous pattern (middle images). Lower 
levels of GFAP were observed in animals with heterogeneous pat-
terns (lower images).  c Western blot quantification of NOX-4, 
SOD-2 and GFAP markers at 24 h after pMCAO.  
 Fig. 3. DWI and PWI MRI of homogeneous and heterogeneous 
ADC map patterns.  a Mean relative apparent diffusion coefficients 
of homogeneous and heterogeneous lesion type: clustering of 
rADC values in two different patterns, with no heterogeneous le-
sion type below 630. Heterogeneous lesions showed significantly 
increased mean rADC values.  b Tractography. Homogeneous pat-
tern of intralesional ADC maps (upper image) showing more fiber 
disruption in MCA territory than heterogeneous pattern (lower 
image).  c Perfusion MRI after pMCAO: Homogeneous and het-
erogeneous patterns. Homogeneous pattern showed less intrale-
sional CBF (left image and graph) than heterogeneous pattern 
(right image and graph).  d PWI/DWI mismatch. Homogeneous 
ADC patterns (upper images) showed less mismatch area when 
compared to heterogeneous type (lower images). 
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clinical assessment through high resolution anatomical 
delineation of disease at an ionic and molecular level  [13] . 
As our findings support improved preservation of the in-
tralesional region when ADC maps show a heteroge-
neous pattern in lesions of MCA territory and higher dif-
fusion coefficients that represent a surrogate measure of 
better anatomical tissue preservation, a reduced risk of 
definite infarction can be assumed.
 The introduction of mismatch measurement as inclu-
sion criteria for reperfusion in clinical trials included sig-
nificant differences in the definition of mismatch and a 
rather arbitrary volumetric difference of 20% between 
PWI and DWI that still lacks validation as a threshold for 
stratifying patients or as a surrogate measure of penum-
bra  [5, 13] . PWI also requires contrast administration and 
time-consuming processing, losing valuable time before 
reperfusion  [14, 15] . In this study, we were able to show 
that the interpretation of distinct intralesional MRI DWI 
ADC patterns in lesions of the same size might offer sim-
ilar pretreatment information. 
 We also observed that animals with heterogeneous in-
tralesional ADC patterns showed higher CBF with larger 
variations inside the ischemic lesion, along with enhanced 
functional outcome. Additionally, tractographies showed 
better fiber preservation in the heterogeneous type. In the 
clinical setting, tractography has also been used to show 
structural integrity of the corticospinal tract and was re-
lated to recovery  [16, 17] .
 As outlined earlier, DWI is the MRI sequence that 
more consistently reflects ionic and molecular tissue 
changes since the effect in the Brownian movement of 
water molecules is changed in the presence of abnormal 
anatomical features  [18] . In previous studies, our group 
described gene expression associated with trophic factors 
and CNS development within the lesion core at 24 h after 
pMCAO, suggesting the existence of surviving areas in-
side the ischemic core  [19] . Our findings support the ar-
gument that the central region of the ischemic territory is 
not inexorably dead or irreversibly damaged. In this 
study, we could show differences in the expression of cell 
death related to different patterns in ADC maps with sig-
nificantly less expression in the group with a heteroge-
neous pattern. The present data further emphasize our 
previous findings and show additionally a relation be-
tween ADC patterns and tissue preservation that requires 
further exploration. 
 Oxidative stress causes tissue damage after acute brain 
ischemia with overexpression of ROS above physiological 
levels  [20, 21] . We analyzed the expression of major ROS 
producing enzyme NOX-4 in both groups of ADC pat-
terns and observed significantly reduced expression of 
NOX-4 in the heterogeneous pattern. We also found a 
higher expression of SOD2, a major scavenger of mito-
chondrial superoxide, in the group with a heterogeneous 
ADC pattern. SOD2 is synthesized after brain infarction 
and tissue levels are generally related to lesion size. How-
ever, since we compare lesions with equal size, higher ex-
pression of SOD2, together with less expression of ROS 
producing enzyme NOX-4, is indicative of less use of 
SOD2 for neutralization of mitochondrial superoxide 
 [22] and, consequently, less oxidative stress and definite 
brain lesion in the heterogeneous type. Additionally, we 
observed a smaller expression of GFAP in the group with 
a heterogeneous pattern, albeit not significant. Since after 
an acute brain lesion, astrocytes occupy the empty space 
left by phagocytosis in order to maintain tissue structure, 
reactive gliosis is part of the healing process being massive 
gliosis related to worse outcome  [23] . Consequently, the 
reduced expression of GFAP in animals with the hetero-
geneous pattern may indicate a reduced ischemic injury. 
 Although not addressing early reperfusion directly, we 
observed a DWI MRI pattern that distinguishes function-
al outcome. We observed increased PWI/DWI mismatch 
in ischemic MCA lesions with a heterogeneous pattern 
indicating a higher potential for reversibility in these an-
imals. On the other hand, in animals with a homogeneous 
pattern, CBF was reduced and eventually it reached a val-
ue as low as 6–15 ml/100 g/min. Despite the variability in 
CBF thresholds in different brain locations or age groups, 
levels as low as 6–15 ml/100 g/min correspond to thresh-
olds of biochemical biomarkers of protein synthesis inhi-
bition, preference for aerobic glycolysis, neurotransmit-
ter release, impaired energy metabolism and terminal de-
polarization with potassium influx. We also observed 
coherence in our data concerning functional outcome 
and biochemical markers (with less expression of cell 
death and less expression of ROS markers) favoring the 
group with a heterogeneous pattern. Possibly, the homo-
geneous ADC pattern indicates irreversible brain damage 
where reperfusion might be futile or even dangerous. 
However, research in the clinical setting is necessary to 
confirm our experimental data and validate the useful-
ness of intralesional ADC patterns to predict outcome 
and identify patients that may benefit from reperfusion. 
 Finally, it would be desirable to identify a quantitative 
threshold that easily distinguishes heterogeneous from 
homogeneous patterns and consequently subjects with a 
high potential for recovery from subjects with an in-
creased risk for irreversible infarction. In our study, no 
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only a single homogeneous sample showed an ADC value 
above this threshold (643). If confirmed in the clinical 
context, the determination of a similar threshold may 
prove useful in identifying patients with irreversible isch-
emia without indication for thrombolysis. In this context, 
the results of this study represent a promising tool in pre-
treatment decisions in the acute stroke setting. 
 Study Limitations and Potential Bias  
 As shown by our experimental data in a pMCAO mod-
el of ischemic stroke, the heterogeneity in the coefficients 
of apparent diffusion inside the ischemic lesion represents 
areas with a different potential for recovery. Nevertheless, 
there is significant variability in ADC values depending on 
MRI apparatus, coil systems, imagers, or employed field 
strengths that should be taken into account when analyz-
ing data from different MRI equipment. We used relative 
ADC values because they are more suitable for evaluating 
diffusion abnormalities than absolute values. 
 We used a model of permanent MCAO with high re-
producibility confirmed by equal lesion size in both the 
heterogeneous and homogeneous groups and interval af-
ter stroke onset was controlled for. However, our experi-
mental model did not include vascular risk factors, older 
age, or the female gender. Also, variability in precondi-
tioning, individual variability in collateral circulation, or 
intracranial pressure variations that may interfere with 
microcirculation are difficult to assess in an experimental 
model and may have impact on results. 
 Conclusions 
 Intralesional patterns of MRI ADC maps in an experi-
mental model of ischemic stroke can be categorized in 
heterogeneous and homogeneous patterns. Animals with 
the same infarct size and interval after ischemia but a het-
erogeneous intralesional ADC pattern showed better 
functional outcome, higher expression of brain protec-
tion markers, and less expression of cell death. Animals 
with a homogeneous pattern showed a smaller PWI/DWI 
mismatch, indicating a reduced potential for recovery 
from ischemic penumbra and an increased risk for pro-
gression to definitive infarction. Applied to the clinical 
setting, early identification of tissue fate after ischemic 
stroke through DWI ADC map patterns may assist in 
acute therapeutic decisions.
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Background: Hydrogen sulfide (H2S) induces hypometabolism through mechanisms that 
include a dramatic reduction in oxygen consumption, local vasoregulation, and inhibition 
of cell death. Prolonged exposure to H2S after experimental ischemic stroke modulates 
injury through induction of severe hypothermia but the mechanisms and effects of 
reduced exposure times remain to be further characterized.  
Methods:  In the present study, we used Sprague-Dawley rats in a model of permanent 
middle cerebral artery occlusion (pMCAO) and compared functional outcome, in vivo 
and post-mortem lesion size, diffusion and perfusion Magnetic Resonance Imaging 
(MRI), cell death, brain protection and repair-associated markers after short-term 
exposure to H2S.  
Results: We observed an improved functional outcome (24h and 14d, P<0.05), 
diminished infarct size (14d, P<0.01) and cell death (24h and 14d, P<0.05) in animals 
exposed to H2S. Perfusion MRI revealed higher intralesional cerebral blood flow 
(P<0.05) while diffusion MRI showed intralesional heterogeneity compared to controls 
(P<0.05). In treated animals, expression of NOX-4 was lower at 24h and 14d, HSP-27 
was lower at 24h, and SOD-2 and GFAP were lower at 14d (P<0.05).  
Conclusions: Observed improvements in functional outcome, infarct size and cell death 
included processes involving modulation of reactive oxygen species and reduction of 
acute injury-related markers, without enhancement of repair-associated markers for 
vasculogenesis, angiogenesis, and synaptogenesis. Thus, H2S possibly acts before the 
onset of irreversible ischemia and limits brain damage after stroke. In the future, H2S 
donors may play a role in the context of acute stroke management in humans.  





































































There are exceptions in nature to the rule that lack of cerebral blood flow during a 
prolonged period inexorably leads to ischemia and irreversible brain damage. Two 
examples are cardiac arrest from extreme cold and hibernation. In both cases, survival 
is possible without permanent neurological damage despite of very little or no cerebral 
blood flow at all [1,2]. These examples show that severe brain damage may be 
prevented even in the absence of cerebral blood flow during long periods. The induction 
of a “hibernation-like” state in mice using the inorganic gas hydrogen sulfide (H2S) 
suggested its potential in the context of acute ischemia [3,4]. 
H2S is endogenously produced in different organs including the brain [5] and regulates 
oxygen consumption by competing with O2 in binding to cytochrome C oxidase at the 
mitochondrial electron transport chain [3]. Data about the potential benefit of H2S in the 
context of acute ischemic stroke is modest and conflicting. First reports showed no 
functional benefit [6], others demonstrated improvement in functional outcome and 
lesion size [7]. Data from ischemic heart and kidney experimental models showed 
protection after acute ischemia [8,9].  
We hypothesized that inducing a reversible hypometabolic state after acute cerebral 
ischemia through administration of H2S could limit acute ischemic brain damage. We 
investigated the effects of short-term H2S exposure after permanent middle cerebral 
artery occlusion (pMCAO) by analyzing the functional outcome, infarct size, and 
markers of cytoprotection or repair. We completed the study with in vivo brain imaging 




































































by Magnetic Resonance Imaging (MRI) as compared to post-mortem 
immunohistochemical data.  
 
MATERIALS AND METHODS  
Experiments were designed to minimize animal suffering in compliance with the 
ARRIVE criteria and our medical school’s Ethical Committee for the Care and Use of 
Animals in Research (EU directives 86/609/CEE and 2003/65/CE). Researchers were 
blinded to group allocation after randomization. Male 8 - 12 week old Sprague-Dawley 
rats (250 to 320g) (Charles River©, Spain) were randomly assigned to 3 groups:  sham 
(craniotomy, n=13), control (craniotomy + pMCAO, n=23) and treated (craniotomy + 
pMCAO + exposure to 40 ppm H2S, n=28). Rats were anesthetized with Sevoflurane 
(CAM 2.5±0.3 volume %). We performed a small craniotomy above the rhinal fissure 
over the branch of the right middle cerebral artery (MCA), exposing MCA and 
permanently ligated it with a 9-0 silk suture before its bifurcation. Then, both common 
carotid arteries were temporarily occluded for 60min with a 6-0 silk suture lace as 
previously described [10,11].  Scar size and location were equal for all groups, animal 
cages had no information about group allocation, and codes were used in post mortem 
samples, in order to maintain blinded data collection and analysis. Body temperature 
and glycemia were measured throughout procedures. Rats were sacrificed at 24h and 
14d after surgery. 
  





































































Treated animals were exposed during 24 min to H2S, 3 hours after acute ischemia, 
breathing a mixture of atmosphere with H2S [Gasin medical bottles, 40 ppm H2S in 
nitrogen (N2: 99.9%)] inside a closed box (9.5 x 20 x 10 cm = Volume 1,900 cm
3). 
Control and sham animals breathed normal atmosphere in the same temperature and 
humidity conditions. We used rectal temperature before and after exposure as an 
indirect measure of induction of hypometabolism. 
Ischemic lesion size          
Lesion size was evaluated in vivo at 24h and 14d using T2-weighted sequence MRI and 
post mortem hematoxylin/eosin (H&E) stains, as previously described [10,11].  
Magnetic Resonance Imaging  
The extension of ischemic lesions was analyzed non-invasively after 24h (group 
sacrificed at 24h) and twice, after 24h and 14d (group sacrificed at 14d), using T2-
weighted images. Observers were blinded to allocation groups. After contrast 
adjustment, the contours of the hemispheres were traced manually on each slice. Data 
analysis was performed using Image J software from NIH Image, slice-by-slice 
contouring at lesion site and in the contralateral hemisphere in the same location. Only 
lesions larger than 2mm x 2mm x 2mm were analyzed to minimize partial volume 
effects. We used JPG® region of interest (ROI) to measure infarct size. To correct for 
brain edema effect, lesion size was determined by an indirect method: infarct area = 
area of the intact contralateral hemisphere – area of the intact ipsilateral hemisphere. 




































































Lesion size was expressed as percentage of total ipsilateral hemisphere. Exclusion 
criteria were no measurable lesion on MRI, except for the sham group (n=3). T2-
weighted MRI at 24h was used as confirmation tool for successful ischemic lesion 
induction.  
Diffusion-weighted imaging (DWI) was obtained with 3 different directions defined by 
read, phase, and slice encoding gradients, using a multishot spin-echo echo planar 
imaging (EPI) sequence. We used the following acquisition conditions: diffusion gradient 
duration: 3ms, diffusion gradient separation: 18ms, TR: 3000ms, TE: 35ms, FOV: 
3.5cm, section thickness of 1.5mm with a 0.1mm gap, 5 axial slices, 3 b values with b 
as measure of diffusion weighting (100, 400 and 1000 s/mm2), acquisition matrix = 128 
× 128 corresponding to an in-plane resolution of 273 × 273 μm2. The apparent diffusion 
coefficient (ADC) was computed for each voxel using the exponential model according 
to the expression: Sb = S0e
−b*ADC, being Sb the signal intensity versus the b factor and S0 
the signal intensity versus b=0. 
MRI images were acquired on a 7 Tesla/16 cm Bruker Avance III system (Bruker 
Medical Gmbh, Ettlingen, Germany) at the MR Imaging Facility (SIERMAC, CSIC/UAM,  
Madrid). Anesthesia was induced with isoflurane. Rats were monitored during MRI with 
a Biotrig physiological monitor (Bruker) depicting on-line the respiratory rate.  
Hematoxylin/eosin stains 
Lesion size was estimated with H&E staining which reveals an ischemic area as a well-
defined pale region. Lesion size was expressed as the percentage of brain tissue 
affected by ischemia in the right hemisphere as evaluated on 10-μm-thick sections. 




































































Brains were sectioned at the optic chiasm and at the infundibular stalk. The resultant 
brain block from between these two cuts was placed in 4% paraformaldehyde for 24 h 
and 30% sacarose PBS buffer for 3 days. Optimal cutting temperature (OCT) 
embedded samples were coronally sectioned in 10-μm-thick slices. A digitized image 
was made of these slices (Epson Perfection 1260 scanner, Suwa, Nagano, Japan) and 
used to automatically measure the ischemic area (Image Pro plus 4.0, Media 
Cybernetics, Rockville, MD, USA) [11]. 
Functional evaluation scales  
Functional evaluation was performed using Rotarod and Rogers modified test, by a 
blinded observer at baseline, 24h and at 14d after surgery. The latency to fall from a 
rotator cylinder (accelerating at 4-40 rpm) was recorded. Motor function by Rogers test 
was scored: 0, no deficit; 1, failure to extend contralateral forepaw fully; 2, decreased 
grip of the contralateral forelimb while tail gently pulled; 3, spontaneous movement in all 
directions, contralateral circling only if pulled by the tail; 4, circling or walking to the right; 
5, walks only when stimulated; 6, unresponsive to stimulation; and 7, dead [10]. 
Cell death 
Cell death was assessed by TUNEL staining (biotin-dUTP nick end-labeling mediated 
by terminal deoxynucleotidyl transferase; TdT-FragEL DNA Fragmentation Detection 
Kit, Oncogene Research Products) following manufacturer’s instructions. The number of 
positive cells was counted using a 40× objective and image analysis software (Image-




































































Pro Plus 4.1®, Media Cybernetics). We maintained blind access to group allocation and 
samples were independently counted by two of the authors. 
Immunohistochemistry, immunofluorescence and western blot 
Immunohistochemistry 
NOX-4: Pro-oxidant enzyme, NADPH oxidase 4 (NOX-4) primary polyclonal antibody 
anti-Nox-4 (1:1000, Abnova, Heidelberg, Germany) was incubated for one hour at room 
temperature. The slides were then incubated with a secondary antibody (donkey anti-
rabbit antibody diluted 1:50) conjugated with horseradish peroxidase (Chemicon 
International, Temecula, CA, USA) and incubated with 3',3'-diaminobenzidine 
(Invitrogen). 
Immunofluorescence  
Serial coronal sections were cut at 10μm in a cryostat (Leica CM1950) and studied by 
immunofluorescence neural markers. Markers for neuronal nuclei (NeuN) (monoclonal 
antibody diluted 1:100, Millipore), astrocytes [glial fibrillary acid protein (GFAP) 
(monoclonal antibody diluted 1:400, Chemicon)], vascular growth [vascular endothelial 
growth factor (VEGF) marker (polyclonal antibody diluted 1:500, Millipore)], 
synaptogenesis [synaptophysin (monoclonal antibody diluted 1:200, Sigma - Aldrich)], 
superoxide dismutase 2 (SOD-2) (polyclonal antibody diluted 1:150, Abcam®), and heat 
shock protein 27 (HSP-27) (monoclonal antibody diluted 1:200, Abcam®), followed by 
goat anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 594 (1: 750, Molecular 
Probes, Invitrogen) were used.  




































































All sections were mounted with H-1200 VectaShield mounting medium for fluorescence 
with DAPI (ATOM). Samples were examined using a spectral confocal microscope 
Leica TCS SPE (Leica Microsystems, Heidelberg, Germany) and the confocal images 
were analyzed using Leica software LAS AF, version 2.0.1 build 2043. The images were 
acquired at confocal maximum projection. 
Western Blot  
Brain proteins levels were measured in the infarct zone of animals (n=4 per group) and 
its concentration was determined using a BCA protein assay kit (Pierce). Western-Blot 
for NADPH oxidase 4 (NOX-4) (polyclonal antibody 1:2000, Abnova), SOD-2 (polyclonal 
antibody diluted 1:5000, Abcam), HSP27 (monoclonal antibody diluted 1:1000, Abcam), 
GFAP (monoclonal antibody diluted 1:500, Millipore), VEGF (polyclonal antibody diluted 
1:500, Millipore) and synaptophysin (monoclonal antibody diluted 1:400, Sigma) were 
measured in all groups. The units were normalized based on Β-actin levels (1:400, 
Sigma-Aldrich). To reduce methodological bias, at least three Western blots were 
performed for each animal.  
Statistical analysis  
Quantitative data is shown as mean ± standard error of the mean (SEM) presented as 
box and whiskers plot. As data followed a non-normal distribution in the Shapiro-Wilk 
test, the Mann–Whitney test was used to compare two samples and the Kruskal–Wallis 
test to compare more than two samples (SPSS 16 for Windows®). Values of p<0.05 
were considered significant at a 95% confidence level. Power analysis showed that with 
non-parametric testing randomization of at least 18 animals to each group (exposed or 




































































control) would yield an effect size d of 1.0 with a power of 0.80 (beta-value 0.20) and an 




Functional outcome after exposure to hydrogen sulfide  
We measured functional outcome before procedure, at 24h and 14d. At baseline, 
Rogers Modified Scale was zero for all animals and the latency to fall in the Rotarod test 
was >120 seconds. The sham-operated group showed no functional deficit at 24h or 
14d. A better functional outcome was observed at 24h in animals exposed to H2S 
compared to control group regarding Rogers Modified Scale (1.73 ± 0.23 vs. 3.29 ± 
0.18, P=0.001) and Rotarod test (65 ± 5.97, vs. 37 ± 7.14, P=0.03). At 14d, the 
functional benefit observed in treated animals was sustained in both tests: Rogers 
Modified Scale (1.18±0.17 vs. 1.82± 0.20, P=0.03), and Rotarod (55.25±5.17 vs. 
31.5±7.79, P=0.04) (Figure 1A). 
Infarct size after exposure to hydrogen sulfide  
At 24 hours after pMCAO, lesion size measured by T2-weighted MRI did not differ 
significantly between treated and control groups (9.69±1.67 vs. 15.45±1.06, P=0.054). 
However, H&E stains showed a reduced infarct size in the treated group (6.69±1.38 vs. 
23.20±3.05, P=0.008). At day 14, T2-weighted MRI and H&E showed smaller infarct size 
in treated compared to control rats (6.13±0.62 vs. 11.56±0.4, P=0.0004 and 4.94±0.92 




































































vs. 11.63±1.99, P=0.002, respectively). Sham operated rats showed no cerebral lesion. 
The largest lesion was observed in the control group (Figure 1B). 
MRI heterogeneities in ischemic territory after exposure to hydrogen sulfide 
In treated rats (rats exposed to H2S), we observed heterogeneities inside the ischemic 
MCA territory on MRI ADC maps at 24h (Figure 2D upper right image and graph). 
These heterogeneities were observed inside the ischemic territory, including central and 
peripheral areas, presenting some central areas a higher diffusion coefficient than 
peripheral ones.  In animals treated with H2S, the relative ADC (rADC) coefficients were 
similar in central and peripheral areas (Figure 2D lower left images and graph). Finally, 
using perfusion MRI, the differential CBF between the lesion side and contralateral 
hemisphere was lower in treated rats (P<0.05) (Figure 2D, lower right image and right 
graph).  
Cell death after exposure to hydrogen sulfide  
Treated rats showed significantly less TUNEL positive cells, both at 24h (367.5 ± 78.03 
vs. 901.25 ± 217.45 P=0.047) and 14d (42.7 ± 7.76 vs. 53.71 ± 6.75 P=0.04) (Figure 
2A, Figure 3A) in comparison to controls. No sham operated rats showed TUNEL 
positive cells.  
  




































































Exposure to hydrogen sulfide does not increase brain repair but enhances 
markers associated with brain protection  
At day 14, the group treated with H2S showed no increase in expression of VEGF (0.75 
± 0.22 vs. 0.79 ± 0.18 P=0.88) or synaptophysin (1.40 ± 0.39 vs.1.29 ± 0.30 p=0.50) 
compared to control group (Figure 3B and C).  GFAP showed significantly lower levels 
at day 14 in treated animals compared to control (0.36 ± 0.16 vs. 0.77 ± 0.43, P=0.027). 
The levels of SOD2 at day 14 were lower than in the control group (0.66 ± 0.06 vs. 1.07 
± 0.14, P=0.05) (Figure 3B and C), but not at 24h (0.788±0.13 vs. 0.90±0.3 P=0.11) 
(Figure 2B and C). The levels of NOX-4 were lower in treated rats compared to the 
control group at 24h (0.50 ± 0.12 vs. 1.11 ± 0.28 P=0.03) (Figure 2A and C) and day 14 
(0.47 ± 0.21 vs. 1.40 ± 0.46 P=0.049) (Figure 3A and C). HSP-27 levels were lower at 
24h in treated rats compared to control animals (0.41 ± 0.12 vs. 0.81 ± 0.11 P=0.49) but 
not at day 14 (0.84 ± 0, 51 vs. 1,056 ±0, 55 P= 0.24) (Figure 2B and C, Figure 3B and 
C).  
Physiological parameters 
Glycemia was assessed immediately after starting the surgical procedure and during 
surgery in all animals and was similar in all groups. Body temperature was significantly 
lower after induction of anesthesia in all groups (P<0.001). After an exposure time to 
H2S of 24 minutes, body temperature decreased by 1.85 ºC (mean) but quickly 
recovered after animals started to breathe normal atmosphere again; no difference in 
body temperature was observed at 2 hours after exposure (Figure 4).  
  





































































We report on the role of short-term exposure to H2S in acute ischemic brain damage. 
Our results show that exposure to hydrogen sulfide after pMCAO improves functional 
outcome and decreases infarct size and cell death. The longitudinal study suggests that 
H2S may act very early in the ischemic process, since there were lower levels of acute 
injury-related markers at 24h without enhancement of repair-associated markers for 
vasculogenesis, angiogenesis or synaptogenesis at day 14. Significant benefit is likely 
to occur before major tissue damage develops, including modulation of NOX-4, a major 
generator of reactive oxygen species (ROS) and mediator of endothelial dysfunction. 
A main goal of acute stroke treatment is the improvement of functional outcome. In the 
present study, a better functional outcome in animals exposed to H2S was observed at 
24h and day 14. A similar benefit in functional outcome has been reported in studies 
that used  H2S in an ischemia-reperfusion model [12] and global brain [13], cardiac or 
kidney ischemia [14,15]. In our model, functional benefit from H2S exposure was not 
limited to short term but sustained until day 14. Immunohistochemical and in vivo 
imaging data support this observation showing improved brain tissue preservation and 
smaller lesion size.  
Previous data using a H2S donor (NaHS) in an ischemic electrocauterization model did 
not show reduction in lesion size after NaHS [6]. Later, smaller infarct sizes were 
reported using longer H2S exposure times, higher doses [7]
 or reversible MCAO models 
[12]. Our data show that lower dose and shorter exposure (40 ppm, during 24 min) are 
able to decrease infarct size after pMCAO. Despite of smaller infarcts at day 14 both in 




































































vivo and post mortem, at 24h differences between infarct sizes assessed by T2-
weighted MRI were not significant, possibly due to acute post ischemic brain edema 
that increases lesion volume. However, H&E staining at 24h showed smaller lesion size 
in treated rats.  
Interestingly, MRI ADC maps at 24h in treated rats revealed heterogeneity, with spotty 
areas inside ischemic lesion and higher ADC coefficients, both in central and peripheral 
areas. We previously described gene expression associated with CNS development 
and trophic factors within lesion core at 24h after pMCAO, suggesting the presence of 
surviving areas within the ischemic core [16]. These heterogeneities, revealing different 
rates of water diffusion and underlying brain tissue integrity,  may represent previously 
described "mini-cores and mini-penumbras" [17]. As heterogeneity in ADC maps 
corresponded to better functional outcome as well as smaller lesions and better 
ischemic tissue preservation in treated rats, prognostic relevance of ADC 
heterogeneities may deserve further research in a translational context.   
Hypothermia, when not induced from external sources, is the result of hypometabolism 
and not the cause of metabolic changes. H2S modulation in the context of acute stroke 
has been associated with induction of hypothermia, especially in protocols that included 
prolonged exposure times [7]. In our study, after an exposure time of 24 minutes, a 
mean decrease of 1.85ºC in body temperature was observed. Body temperature fully 
recovered in less than 120 min (Figure 4). Consequently, hypothermia appears to be a 
limited side effect of hypometabolism induced by H2S and other mechanisms must be 
involved since the effects of H2S administration were observed until day 14. In the 




































































present study, a shorter exposure time than previously reported was effective with a 
minor effect on body temperature. This observation represents an important finding in a 
translational context since minor changes in body temperature will not require patient 
management in high-dependency or intensive care units. 
Previous in vitro studies have shown that the use of D-cysteine (a biosynthetic pathway 
for H2S production) was associated with attenuation of ischemia-reperfusion injury in the 
kidney [15]. Also in a murine primary cortical neuron preparation ischemic neuronal 
death was prevented using a H2S-releasing NMDA receptor antagonist [18].
 
Additionally, rats pre-treated with diallyl sulfide showed a significant decrease in TUNEL 
positive cell count [12]. Our study confirmed that markers for cell death depict 
significantly less expression in treated animals.  
HSP27 is a stress-related protein known to be differentially expressed after stroke. We 
previously showed in a genomic study that several chaperones including HSP27 were 
upregulated at 24h, both in the core and peri-infarct areas [16]. Others reported that 
neuronal expression of another HSP (HSP70) was associated with ischemic penumbra 
and core, using a reporter mice model [19]. Interestingly, a study with reperfusion in 
cardiac ischemia showed that HSP27 expression was lower in H2S-treated pigs [20]. In 
the present study, we observed less expression of HSP27 at 24h after pMCAO in rats 
exposed to H2S, associated with tissue preservation, reflecting an additional indication 
of a possible protective role for H2S. 
It is known that oxidative stress causes tissue damage in the context of acute brain 
ischemia with ROS expressed above physiological levels [21,22]. ROS downregulation 




































































after exposure to H2S was reported in ischemia-reperfusion models, after hemorrhagic 
shock [23], and during lung transplantation [24]. NOX-4 is a major source of oxidative 
stress in ischemic stroke [21]. In our study, NOX-4 levels were lower at 24h and day 14 
in treated rats. Thus, H2S may modulate early ROS expression. GFAP levels were  
lower in rats exposed to H2S, suggesting that early protection may be related to 
preservation of tissue structure and less glial scar, since we did not find increased levels 
of repair-associated markers implicated in synaptogenesis, vasculogenesis or 
angiogenesis at day 14.  
Study limitations 
We designed this study to fulfill the recommendations for research in translational 
stroke. Animals were randomized and all procedures except surgery were performed in 
a blinded manner to avoid observational bias regarding functional outcome, MRI image 
evaluation, and in-bench procedures, by using codes not known to observers. Detailed 
data is shown to facilitate reproducibility. 
Dosage of H2S in the present study was the same in all animals and different dosages 
might produce distinct effects on outcome. Due to budget limitations and the preliminary 
nature of our study, we did not include female or older animals or animals with co-
morbidities in this study. In the setting of an experimental study using rodents, clinical 
outcome was limited to assessment of motor skills. We used MRI at 24h as a 
confirmation tool for successful pMCAO to avoid bias in results that could be attributable 
to surgical failure. No conclusions regarding long-term results of H2S exposure should 




































































be drawn as the study design focused on comparison of in vivo and post mortem data in 
the acute setting at 24h and after 14d.  
 
CONCLUSIONS 
In our pMCAO model of ischemic stroke, early exposure to hydrogen sulfide after focal 
brain ischemia improved functional outcome and decreased infarct size and cell death 
through processes that involve modulation of NOX-4, a major enzyme generator of 
reactive oxygen species. Regarding brain imaging, perfusion MRI in rats exposed to 
H2S revealed improved cerebral blood flow, while diffusion MRI showed spots of 
heterogeneity inside ischemic lesions in ADC maps, including central regions. H2S 
probably acts very early after administration, since lower levels of acute injury-related 
markers were present at 24h, without enhancement of repair-associated markers for 
vasculogenesis, angiogenesis or synaptogenesis at day 14. Significant benefit is likely 
to occur before major tissue damage has taken place. In the future, H2S donors may 
play a role in the context of acute stroke management in humans. 
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Figure 1. Rats exposed to H2S after stroke show better functional outcome and smaller 
lesion size. A. Functional outcome. Rats exposed to H2S had significantly lower score 
in Rogers scale (left) at 24h (***P<0.001) and at 14d (*P<0.05) (left graph) and more 
latency to fall from the Rotarod at 24h (*P<0.05) and at 14d (*P<0.05) (right graph). B. 
Infarct size. At 14d, rats exposed to H2S had significantly smaller ischemic lesion size, 
both in MRI (T2 weighted sequence) (left graph) (***P<0.001) and H&E stain (right 
graph) (**P<0.01). At 24h, MRI showed a lower but non-significant difference in lesion 
size, whereas H&E showed a significantly smaller ischemic lesion after H2S exposure 
(**P<0.01).    
Figure 2.  Rats sacrificed at 24h. At 24h rats exposed to H2S after stroke show lower 
expression of cell death and ROS producing enzyme NOX-4 with higher intralesional 
perfusion. A. Rats exposed to H2S show lower levels of cell death (*P<0.05) and NOX-4 
(*P<0.05). B. Rats exposed to H2S show lower levels of heat shock protein 27 (HSP 27) 
(*P<0.05) and no differences in superoxide dismutase-2 (SOD-2) levels. C. Western-
blot of NOX-4, HSP27 and SOD2 at 24h. D. MRI with DWI and PWI. Rats exposed to 
H2S showed intralesional heterogeneities in ADC maps (right upper image and graph) 
whereas control rats showed homogeneous ischemic lesions (left upper image and 
graph). ADC maps in rats exposed to H2S showed islands of ADC diffusion coefficient in 
central lesion area, similar to ADC observed in peripheral areas (left lower images and 
graph). For quantification, three manually designed Regions of Interest (ROIs) were 
considered on ADC maps: ROI 1, ischemic central lesion area; ROI 2, peripheral lesion 
area; ROI 3, contralateral hemisphere. Animals exposed to H2S showed similar 
differential ADC coefficients (rADC) in central and peripheral lesion areas and 




































































intralesional CBF was improved. The difference between intralesional and contralateral 
hemisphere CBF (ΔCBF) was significantly smaller in comparison to controls (*P<0.05) 
(right lower image and graph).  
Figure 3. Rats sacrificed at 14d. At day 14, rats exposed to H2S expressed less cell 
death and ROS producing enzyme NOX-4, without detectable enhancement of repair 
mechanisms including angiogenesis, vasculogenesis or synaptogenesis. A. Cell death 
(*P<0.05) and NOX-4 levels (*P<0.05) were significantly lower in rats exposed to H2S B. 
Significant lower levels of SOD2 (*P<0.05) and GFAP (*P<0.05) in rats exposed to H2S 
with no differences in HSP27, VEGF or synaptophysin. C. Western-blot of NOX4, 
SOD2, GFAP, HSP27, VEGF and synaptophysin. 
Figure 4. Body temperature. Rats exposed to H2S (lower graph) and controls (upper 
graph). No difference in body temperature was observed 2h after exposure to hydrogen 
sulfide. Axis legend: Body temperature. Before: rectal temperature in rats before starting 
surgery; After surgery: rectal temperature after surgery, before entering the box with 
atmosphere or enriched with 40 ppm H2S; Out of Box: Rectal temperature after getting 
out of the box, 24 minutes later; 1h after and 2h after: rectal temperature one and two 
hours after exposure to H2S. All rats showed significant differences in rectal 
temperature before and after surgery (***P<0.001). Rats exposed to H2S showed a 
significant decrease in body temperature after exposition (***P<0.001) until one hour 
(*P<0.05). No difference in rectal temperature was observed 2h after exposure. 
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